|  |  |
| --- | --- |
| European Parliament2019-2024 |  |

<Commission>{ENVI}Committee on the Environment, Public Health and Food Safety</Commission>

<RefProc>2020/0321</RefProc><RefTypeProc>(COD)</RefTypeProc>

<Date>{28/04/2021}28.4.2021</Date>

<TypeAM>AMENDMENTS</TypeAM>

<RangeAM>112 - 737</RangeAM>

<TitreType>Draft report</TitreType>

<Rapporteur>Nicolás González Casares</Rapporteur>

<DocRefPE>(PE680.818v01-00)</DocRefPE>

<Titre>A reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices</Titre>

<DocAmend>Proposal for a regulation</DocAmend>

<DocRef>(COM(2020)0725 – C9-0365/2020 – 2020/0321(COD))</DocRef>

AM\_Com\_LegReport

<RepeatBlock-Amend><Amend>Amendment <NumAm>112</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (1) Pursuant to Articles 9 and 168 of the Treaty on the Functioning of the European Union (‘TFEU’) and Article 35 of the Charter of Fundamental Rights of the European Union the Union is to ensure a high level of human health protection in the definition and implementation of all Union policies and activities. | (1) Pursuant to Articles 9 and 168 of the Treaty on the Functioning of the European Union (‘TFEU’) and Article 35 of the Charter of Fundamental Rights of the European Union the Union is to ensure a high level of human health protection in the definition and implementation of all Union policies and activities***, within the strict limit defined by those two articles***. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>113</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 1 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(1a)*** ***The COVID-19 pandemic has highlighted risks to human health posed by over-exploitation of wildlife and other natural resources and accelerated loss of biodiversity. As health of humans, animals and the environment are inextricably linked and similar medicines and medical devices are used for humans and animals, it is crucial to take the ‘One Health’ approach to address current and emerging crises. This is paramount as the majority (72%) of emerging diseases of humans, including COVID-19, influenza and HIV/AIDS, are caused by zoonotic pathogens.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>114</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (2) The unprecedented experience of the COVID-19 pandemic has demonstrated ***that*** the Union ***should*** be more effective in managing the availability of medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public health. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States. | (2) The unprecedented experience of the COVID-19 pandemic has ***shown the difficulties of Member States to cope with a cross-border or global health emergency, and has therefore*** demonstrated ***the need to strengthen the competences of*** the Union ***in order to*** be more effective***, efficient and expeditious*** in managing the availability of medicinal products and medical devices***, in asserting supply chains of medicinal products and medical devices,*** and in developing medical countermeasures to address the threats posed to public health***. The unprecedented experience of the COVID-19 pandemic has also underlined the risks to human health posed by zoonotic spill-overs triggered by global biodiversity loss and wildlife over-exploitation***. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>115</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (2) The ***unprecedented*** experience of the COVID-19 pandemic has demonstrated that the Union should be more effective in managing the availability of medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public health. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States. | (2) The ***unprecedent*** experience of the COVID-19 pandemic has demonstrated that the Union should be more effective in managing the availability of medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public ***health in a harmonised way between authorities, industry and other stakeholders of the pharmaceuticals supply chain. The Union needs to give a higher priority to health, to have health systems ready to provide state of the art care, and to be prepared to cope with epidemics and other unforeseeable health threats in line with the International*** Health. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>116</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (2) The unprecedented experience of the COVID-19 pandemic has demonstrated that the Union should be more effective in managing the availability of medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public health. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States. | (2) The unprecedented experience of the COVID-19 pandemic has demonstrated that the Union should be more effective in managing the availability of medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public health ***in a coordinated way between public authorities, industry and other entities of the pharmaceuticals' manufacturing, distribution and provision chains. A two-way dialogue between authorities and all the industry stakeholders is key and should be ensured to prevent and better manage medicines shortage***. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>117</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (2) The unprecedented experience of the COVID-19 pandemic has demonstrated that the Union should be more effective in managing the availability of medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public health. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States. | (2) The unprecedented experience of the COVID-19 pandemic has demonstrated that***, by strengthening its capacity and improving cooperation and coordination between the EU Member States,*** the Union should be more effective in managing the availability of medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public health. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States ***and by the lack of cooperation and coordination between the latter***. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>118</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (2) The unprecedented experience of the COVID-19 pandemic has demonstrated that the Union should be more effective in managing the availability of medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public health. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States. | (2) The unprecedented experience of the COVID-19 pandemic has demonstrated that the Union should be more effective in managing the availability of medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public health***, but it has also demonstrated the need for closer cooperation and faster exchanges of information between Members States and the European institutions on the measures implemented***. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>119</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Nils Torvalds, Susana Solís Pérez, Andreas Glück, Jan Huitema, Ondřej Knotek, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (2) The unprecedented experience of the COVID-19 pandemic has demonstrated that the Union should be more effective in managing the availability of medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public health. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States. | (2) The unprecedented experience of the COVID-19 pandemic has demonstrated that the Union should be more effective in managing the availability of medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public health ***from an early stage and in coordination with the national authorities, the industry and other entities of the pharmaceutical supply chain***. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>120</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (2) The unprecedented experience of the COVID-19 pandemic has demonstrated that the Union should be more effective in managing the availability of medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public health. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States. | (2) The unprecedented experience of the COVID-19 pandemic has demonstrated that***, due to the significant risks posed by emerging zoonoses,*** the Union should be more effective in managing the availability of ***human or veterinary*** medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public health. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>121</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (2) The unprecedented experience of the COVID-19 pandemic has demonstrated that the Union should be more effective in managing the availability of medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public health. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, and also by the limited degree of Union preparedness in case of a public health emergency impacting a majority of Member States. | (2) The unprecedented experience of the COVID-19 pandemic has demonstrated that the Union should be more effective in managing the availability of medicinal products and medical devices and in developing medical countermeasures to address the threats posed to public health. The Union’s ability to do so has been severely impeded by the absence of a clearly defined legal framework for managing its response to the pandemic, ***insufficient mandates of its health agencies*** and also by the limited degree of Union ***and Member States*** preparedness in case of a public health emergency impacting a majority of Member States. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>122</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(2a)*** ***As experienced during the COVID-19 crisis, regulatory capacity to adapt and activate exceptional measures to facilitate Marketing Authorisations for emergency medicines and medical devices is key for an effective and coordinated response to health emergencies at Union level. This capacity should be applied even beyond crisis situations, for example applying the Rolling Review procedures to critical medicinal products, covering procedures for changes in suppliers of APIs or for the designation of new manufacturing sites, leading to prevention and better mitigation of medicines shortage, in coherent and consistent coordination with Member States, avoiding fragmentation of the internal market and inefficient outcomes. The National Agencies should align their regulatory capacity to the EMA enhanced one, in terms of reduced times, efficiency and flexibility to prevent shortages and effectively respond to patients' clinical needs.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>123</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(2a)*** ***The COVID-19 crisis has shown that coordination and dialogue between European, national and regional authorities, industry, entities involved in the pharmaceutical supply chain, healthcare professionals and patients’ associations at European level are vital for countering health threats and should continue after the current health crisis ends so that the shortage of one-off and recurrent medicinal products can be tackled effectively. Ongoing dialogue between all such stakeholders should be assured.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>124</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(2a)*** ***The coronavirus pandemic has demonstrated that a pan-European coordination and dialogue among authorities, industry and relevant supply chain actors, is needed to fight against health threats, and should be continued beyond health crisis to tackle medicines shortage. A two-way communication between regulatory authorities and industry actors should be guaranteed to better mitigate and prevent medicines shortage.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>125</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(2a)*** ***It is therefore necessary that the Union be a full-fledged complementary component of European health systems, providing a guarantee or a last-resource stakeholder in case of serious cross-border health threats. For this reason, the know-how, expertise and capabilities of Union agencies should be strengthened accordingly.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>126</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(2b)*** ***Capitalizing on all pragmatic efforts made during the covid19 crisis, it is important to continue to allow regulatory flexibilities for Marketing Authorisations Holders even beyond crisis situations, for example covering procedures for changes in suppliers of APIs, the designation of new manufacturing sites, faster import authorisations, leading to better mitigation of medicines shortage. It is however crucial that those flexibilities are followed and applied in a coherent way by Member States avoiding fragmentation of the internal market and inefficient outcomes.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>127</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2 c (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(2c)*** ***The root causes of medicines shortage should be assessed and tackled in the context of a strategy on medicines shortage. Root causes include economic causes, increasing regulatory burden, unforeseen surges in demand, supply chain interdependencies and manufacturing and quality challenges.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>128</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 2 d (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(2d)*** ***The combination of cost containment measures, lack of market predictability, combined with an onerous and rigid regulatory framework are challenging sustainable and equitable access to medicines, especially for very old inexpensive essential drugs, as well as the competitiveness of the European pharmaceutical industry.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>129</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (3) The often complex supply chains of medicinal products and medical devices, national export restrictions and bans, border closures impeding the free movement of those goods, ***and***uncertainty related to their supply and demand in the context of the COVID-19 pandemic have led to significant impediments to the smooth functioning of the single market and to addressing the serious threats to public health across the Union. | (3) ***Disruptions to*** the often complex supply chains of medicinal products and medical devices, national export restrictions and bans, border closures impeding the free movement of those goods, uncertainty related to their supply and demand in the context of the COVID-19 pandemic***, and the lack of production in Europe of certain essential medicinal products or chemical active ingredients*** have led to significant impediments to the smooth functioning of the single market and to addressing the serious threats to public health across the Union. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>130</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (3) The often complex supply chains of medicinal products and medical devices, national export restrictions and bans, border closures impeding the free movement of those goods, and uncertainty related to their supply and demand in the context of the COVID-19 pandemic have led to significant impediments to the smooth functioning of the single market and to addressing the serious threats to public health across the Union. | (3) The often complex supply chains of medicinal products and medical devices, national export restrictions and bans, border closures impeding the free movement of those goods, and uncertainty related to their supply and demand in the context of the COVID-19 pandemic have led to significant impediments to the smooth functioning of the single market and to addressing the serious threats to public health across the Union***, with dire consequences for its citizens***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>131</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 3 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(3a)*** ***The COVID-19 crisis has revealed the complexity of the supply of raw materials and highlighted a highly fragmented production chain and complex distribution networks, which are factors that the manufacturers and their management controllers are struggling to deal with and which require real collaboration between states, as well as a clear stance by the EMA.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>132</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 3 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(3b)*** ***The essential free movement of goods should be possible with revised border management.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>133</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, Jan Huitema, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (4) ***Dealing with*** the issue of shortages of medicinal products has been a long-standing priority for the Member States and European Parliament as illustrated by several reports from the European Parliament11 as well as discussions under recent Presidencies of the Council of the European Union. | (4) The issue of shortages of medicinal products has been a long-standing ***and insufficiently addressed*** priority for the Member States and European Parliament as illustrated by several reports from the European Parliament11 as well as discussions under recent Presidencies of the Council of the European Union. |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 11 European Parliament resolution of 17 September 2020 on the shortage of medicines – how to address an emerging problem (2020/2071(INI)) | 11 European Parliament resolution of 17 September 2020 on the shortage of medicines – how to address an emerging problem (2020/2071(INI)) |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>134</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (4) Dealing with the issue of shortages of medicinal products has been a long-standing ***priority*** for the Member States and European Parliament as illustrated by several reports from the European Parliament11 as well as discussions under recent Presidencies of the Council of the European Union. | (4) Dealing with the issue of shortages of medicinal products has been a long-standing ***but unresolved problem*** for the Member States and European Parliament as illustrated by several reports from the European Parliament11 as well as discussions under recent Presidencies of the Council of the European Union. |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 11 European Parliament resolution of 17 September 2020 on the shortage of medicines – how to address an emerging problem (2020/2071(INI)) | 11 European Parliament resolution of 17 September 2020 on the shortage of medicines – how to address an emerging problem (2020/2071(INI)) |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>135</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (4) Dealing with the issue of shortages of medicinal products has been a long-standing priority for the Member States and European Parliament as illustrated by several reports from the European Parliament11 as well as discussions under recent Presidencies of the Council of the European Union. | *(Does not affect English version.)*  |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |   |
| 11 European Parliament resolution of 17 September 2020 on the shortage of medicines – how to address an emerging problem (2020/2071(INI)) |   |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>136</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 4 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(4a)*** ***The long-standing issue of shortages of medicinal products within the Union has become significantly worse in recent years, and increased global demand exacerbated by the COVID-19 pandemic has led to further shortages, weakening the health systems of the Member States and posing significant risks to health and patient care, particularly in terms of disease progression or worsening of symptoms, longer delays or interruptions in care or treatment, longer periods of hospitalisation, increased exposure to fake medicinal products, medication errors or adverse reactions caused by substitutes for missing medicinal products, avoidable transmission of infectious diseases, significant psychological distress and increased costs for the healthcare systems.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>137</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 4 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(4a)*** ***The COVID-19 pandemic has clearly illustrated that human health is linked to animal health and the environment, and that action to tackle health threats should take account of all three dimensions.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>138</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (5) The COVID-19 pandemic has exacerbated the problem of shortages for certain medicinal products considered as critical in addressing the pandemic, and has highlighted the structural limitations in the Union’s ability to rapidly and effectively react to such challenges during public health crises. | (5) The COVID-19 pandemic has exacerbated the problem of shortages for certain medicinal products considered as critical in addressing the pandemic, and has highlighted the structural limitations in the Union’s ***and Member States'***ability to rapidly and effectively react to such challenges during public health crises. ***Effective communication among Member States about both anticipated and actual shortages and available stocks is essential. To ensure such information exchange, the Single Point of Contact Network (SPOC) should become an established monitoring system.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>139</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (5) The COVID-19 pandemic has exacerbated the problem of shortages for certain medicinal products considered as critical in addressing the pandemic, and has highlighted the structural limitations in the Union’s ability to rapidly and effectively react to such challenges during public health crises. | (5) The COVID-19 pandemic has exacerbated the ***existing*** problem of shortages for certain medicinal products considered as ***essential and***critical in addressing the pandemic, and has highlighted ***the Union’s dependence on third countries such as India or China, particularly in terms of the production of chemical active ingredients, the lack of coordination and cooperation between Member States,*** the structural limitations in the Union’s ability to rapidly and effectively react to such challenges during public health crises***, and the need to support and strengthen the Union’s industrial fabric through appropriate policies***. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>140</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (5) The COVID-19 pandemic has exacerbated the problem of shortages for certain medicinal products considered as critical in addressing the pandemic, and has highlighted the structural limitations in the Union’s ability to rapidly and effectively react to such challenges during public health crises. | (5) The COVID-19 pandemic has exacerbated the problem of shortages for certain medicinal products considered as critical in addressing the pandemic, and has highlighted the structural limitations in the Union’s ability to rapidly and effectively react to such challenges during public health crises ***and the need for a more active and extended involvement of the European institutions addressing the health of the European citizens***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>141</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (5) The COVID-19 pandemic has exacerbated the problem of shortages for certain medicinal products considered as critical in addressing the pandemic, and has highlighted the structural limitations in the Union’s ability to rapidly and effectively react to such challenges during public health crises***.*** | (5) The COVID-19 pandemic has exacerbated the ***already existing*** problem of shortages for certain medicinal products considered as critical in addressing the pandemic, and has highlighted the structural limitations in the Union’s ability to rapidly and effectively react to such challenges during public health crises***, also due to the lack of implementation of sustainable economic, regulatory and industrial policy reforms needed*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>142</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (5) The COVID-19 pandemic has exacerbated the problem of shortages for certain medicinal products considered as critical in addressing the pandemic, and has highlighted the structural limitations in the Union’s ability to rapidly and effectively react ***to such*** challenges during public health crises***.*** | (5) The COVID-19 pandemic has exacerbated the problem of shortages for certain medicinal products***, devices and services*** considered as critical in addressing the pandemic, and has highlighted the structural limitations in the Union’s ability to rapidly***, efficiently*** and effectively react ***to such*** challenges during public health crises |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>143</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 5 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(5a)*** ***In order to tackle the Union’s dependence on third countries as well as production uncertainties and supply disruptions, emphasis must be placed on the importance of diversifying supplies and contracting practices for pharmaceutical products and on the need to offer prompt guidance to Member States, especially on the best way to apply the most economically advantageous tender criteria, without being confined to just the lowest price criterion. Investments in the manufacture of active ingredients and medicinal end products in the EU should also be retained as a criterion, as well as the number and location of production sites, the reliability of supply, the reinvestment of profits into R&D and the application of social, environmental, ethical and quality standards.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>144</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 5 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(5a)*** ***It is therefore necessary that the Agency assist the Commission in assessing the supply chain resilience of these products and devices in order to achieve a sufficient strategic autonomy of the Union in health products and devices. Ensuring supply chain resilience across the Union is not a primordial mission of the Agency, yet the European Medicines Agency (EMA) should provide data, knowledge, and skills, to the Commission and the ECDC in order to ensure supply chain resilience in Europe. Supply chain resilience is part of the four working groups of the COVID–19 taskforce of the EMA, alongside the therapeutic response, business continuity and impact, and human resources.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>145</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Nils Torvalds, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 6</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (6) The rapid evolution of COVID-19 and the spread of the virus led to a sharp increase in demand for medical devices such as ventilators, surgical masks, and COVID-19 test kits while disruption of production or limited capacity to rapidly increase production and the complexity and global nature of the supply chain for medical devices, led to a negative impact on supply. Those issues resulted in new entities being involved in the production of those products, which subsequently resulted in bottlenecks in conformity assessment, as well as the prevalence of non-compliant, unsafe, and in some cases counterfeit products. It is therefore appropriate to establish long-term structures within an appropriate Union body to ensure monitoring of shortages of medical devices resulting from a public health emergency. | (6) The rapid evolution of COVID-19 and the spread of the virus led to a sharp increase in demand for medical devices such as ventilators, surgical masks, and COVID-19 test kits while disruption of production or limited capacity to rapidly increase production and the complexity and global nature of the supply chain for medical devices, led to a negative impact on supply ***and placed Member States in competition with each other to respond to the legitimate needs of their citizens, contributing to uncoordinated actions at national levels such as national hoarding and stockpiling***. Those issues ***further*** resulted in new entities being involved in the ***rushed*** production of those products, which subsequently resulted in bottlenecks in conformity assessment, as well as the prevalence of non-compliant, unsafe, and in some cases counterfeit products. It is therefore appropriate to establish long-term structures within an appropriate Union body to ensure monitoring of shortages of medical devices resulting from a public health emergency***, as well as increased and early dialogue with the industry to prevent and mitigate these shortages***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>146</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 6</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (6) The rapid evolution of COVID-19 and the spread of the virus led to a sharp increase in demand for medical devices such as ventilators, surgical masks, and COVID-19 test kits while disruption of production or limited capacity to rapidly increase production and the complexity and global nature of the supply chain for medical devices, led to a negative impact on supply. Those issues resulted in new entities being involved in the production of those products, which subsequently resulted in bottlenecks in conformity assessment, as well as the prevalence of non-compliant, unsafe, and in some cases counterfeit products. It is therefore appropriate to establish long-term structures within an appropriate Union body ***to*** ensure monitoring of shortages of medical devices resulting from a public health emergency. | (6) The rapid evolution of COVID-19 and the spread of the virus led to a sharp increase in demand for medical devices such as ventilators, surgical masks, and COVID-19 test kits while disruption of production or limited capacity to rapidly increase production and the complexity and global nature of the supply chain for medical devices, led to a negative impact on supply. Those issues resulted in new entities being involved in the production of those products, which subsequently resulted in bottlenecks in conformity assessment, as well as the prevalence of non-compliant, unsafe, and in some cases counterfeit products. It is therefore appropriate to establish long-term structures within an appropriate Union body ***that will*** ensure monitoring of shortages of medical devices resulting from a public health emergency ***and to propose measures that can be agreed and implemented jointly across Europe***. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>147</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 6</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (6) The rapid evolution of COVID-19 and the spread of the virus led to a sharp increase in demand for medical devices such as ventilators, surgical masks, and COVID-19 test kits while disruption of production or limited capacity to rapidly increase production and the complexity and global nature of the supply chain for medical devices, led to a negative impact on supply. Those issues resulted in new entities being involved in the production of those products, which subsequently resulted in bottlenecks in conformity assessment, as well as the prevalence of non-compliant, unsafe, and in some cases counterfeit products. It is therefore appropriate to establish long-term structures within an appropriate Union body to ensure monitoring of shortages of medical devices resulting from a public health emergency. | (6) The rapid evolution of COVID-19 and the spread of the virus led to a sharp increase in demand for medical devices such as ventilators, surgical masks, and COVID-19 test kits while disruption of production or limited capacity to rapidly increase production and the complexity and global nature of the supply chain for medical devices, led to a negative impact on supply. Those issues resulted in new entities being involved in the production of those products, which subsequently resulted in bottlenecks in conformity assessment, as well as the prevalence of non-compliant, unsafe, and in some cases counterfeit products. It is therefore appropriate to establish long-term structures within an appropriate Union body to ensure monitoring of shortages of medical devices resulting from a public health emergency. ***These structures should, among other obligations, assess supply chain resilience and reliance.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>148</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 6</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (6) The rapid evolution of COVID-19 and the spread of the virus led to a sharp increase in demand for medical devices such as ventilators, surgical masks, and COVID-19 test kits while disruption of production or limited capacity to rapidly increase production and the complexity and global nature of the supply chain for medical devices, led to a negative impact on supply. Those issues resulted in new entities being involved in the production of those products, which subsequently resulted in bottlenecks in conformity assessment, as well as the prevalence of non-compliant, unsafe, and in some cases counterfeit products. It is therefore appropriate to establish long-term structures within an appropriate Union body to ensure monitoring of shortages of medical devices resulting from a public health emergency. | (6) The rapid evolution of COVID-19 and the spread of the virus led to a sharp increase in demand for medical devices such as ventilators, surgical masks, and COVID-19 test kits while disruption of production or limited capacity to rapidly increase production and the complexity and global nature of the supply chain for medical devices, led to a negative impact on supply ***and stock shortages***. Those issues resulted in new entities being involved in the production of those products, which subsequently resulted in bottlenecks in conformity assessment, as well as the prevalence of non-compliant, unsafe, and in some cases counterfeit products. It is therefore appropriate to establish long-term structures within an appropriate Union body to ensure monitoring of shortages of medical devices resulting from a public health emergency ***and the necessary coordination within the Union***. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>149</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 6</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (6) The rapid evolution of COVID-19 and the spread of the virus led to a sharp increase in demand for medical devices such as ventilators, surgical masks, and COVID-19 test kits while disruption of production or limited capacity to rapidly increase production and the complexity and global nature of the supply chain for medical devices, led to a negative impact on supply. Those issues resulted in new entities being involved in the production of those products, which subsequently resulted in bottlenecks in conformity assessment, as well as the prevalence of non-compliant, unsafe, and in some cases counterfeit products. It is therefore appropriate to establish long-term structures within an appropriate Union body to ensure monitoring of shortages of medical devices resulting from a public health emergency. | (6) The rapid evolution of COVID-19 and the spread of the virus led to a sharp increase in demand for medical devices such as ventilators, surgical masks, and COVID-19 test kits while disruption of production or limited capacity to rapidly increase production and the complexity and global nature of the supply chain for medical devices, led to a negative impact on supply. Those issues resulted in new entities being involved in the production of those products, which subsequently resulted in bottlenecks in conformity assessment, as well as the prevalence of ***over-priced,***non-compliant, unsafe, and in some cases counterfeit products. It is therefore appropriate to establish long-term structures within an appropriate Union body to ensure monitoring of shortages of medical devices resulting from a public health emergency. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>150</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(6a)*** ***During the first stages of the COVID-19 pandemic, uncoordinated actions at national level, such as national hoarding and stockpiling, undermined industry ability to deliver equitable supply in all markets. This represents a lesson learned to avoid in any future crisis situations and highlights the urgent need for a more solid and effective coordination at Union level.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>151</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(6a)*** ***The Covid-19 pandemic has shown the need for increased cooperation of the European Medicines Agency with Member States and the pharmaceutical industry in order to improve the capacity of the Union and Member States to combat future health emergencies or serious events.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>152</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 7</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (7) Uncertainty of supply and demand and the risk of shortages of essential medicinal products and medical devices during a public health emergency like the COVID-19 pandemic can trigger export restrictions amongst Member States and other national protective measures, which can seriously impact the functioning of the internal market. Furthermore, shortages of medicinal products can result in serious risks to the health of patients in the Union due to their lack of availability, which can cause, medication errors, increased duration of hospital stays, and adverse reactions caused by the administration of unsuitable products used as a substitute for unavailable ones. With respect to medical devices, shortages can lead to a lack of diagnostic resources with negative consequences for public health measures, a lack of treatment or deterioration of the disease and may also prevent health professionals from adequately carrying out their tasks. Those shortages can also have a significant impact on controlling the spread of a given pathogen caused by, for example, an insufficient supply of COVID-19 test kits. It is therefore important to address the question of shortages ***and to*** reinforce and formalise monitoring of critical medicinal products and medical devices. | (7) Uncertainty of supply and demand and the risk of shortages of essential medicinal products and medical devices during a public health emergency like the COVID-19 pandemic can trigger export restrictions ***or bans*** amongst Member States and other national protective measures***, such as inappropriate stockpiling***, which can seriously impact the functioning of the internal market. Furthermore, shortages of medicinal products can result in serious risks to the health of patients in the Union due to their lack of availability, which can cause, medication errors, increased duration of hospital stays, and adverse reactions caused by the administration of unsuitable products used as a substitute for unavailable ones. With respect to medical devices, shortages can lead to a lack of diagnostic resources with negative consequences for public health measures, a lack of treatment or deterioration of the disease and may also prevent health professionals from adequately carrying out their tasks. Those shortages can also have a significant impact on controlling the spread of a given pathogen caused by, for example, an insufficient supply of COVID-19 test kits ***or suitable PPE such as masks, gloves and protective clothing***. It is therefore important to address the question of shortages***,*** reinforce and formalise monitoring of critical medicinal products and medical devices***, and improve coordination within the Union***. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>153</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Jan Huitema</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 7</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (7) Uncertainty of supply and demand and the risk of shortages of essential medicinal products and medical devices during a public health emergency like the COVID-19 pandemic can trigger export restrictions amongst Member States and other national protective measures, which can seriously impact the functioning of the internal market. Furthermore, shortages of medicinal products can result in serious risks to the health of patients in the Union due to their lack of availability, which can cause, medication errors, increased duration of hospital stays, and adverse reactions caused by the administration of unsuitable products used as a substitute for unavailable ones. With respect to medical devices, shortages can lead to a lack of diagnostic resources with negative consequences for public health measures, a lack of treatment or deterioration of the disease and may also prevent health professionals from adequately carrying out their tasks. Those shortages can also have a significant impact on controlling the spread of a given pathogen caused by, for example, an insufficient supply of COVID-19 test kits. It is therefore important to address the question of shortages and to reinforce and formalise monitoring of critical medicinal products and medical devices. | (7) Uncertainty of supply and demand and the risk of shortages of essential medicinal products and medical devices during a public health emergency like the COVID-19 pandemic can trigger export restrictions amongst Member States and other national protective measures, which can seriously impact the functioning of the internal market. Furthermore, shortages of medicinal products can result in serious risks to the health of patients in the Union due to their lack of availability, which can cause, medication errors, increased duration of hospital stays, and adverse reactions caused by the administration of unsuitable products used as a substitute for unavailable ones. With respect to medical devices, shortages can lead to a lack of diagnostic resources with negative consequences for public health measures, a lack of treatment or deterioration of the disease and may also prevent health professionals from adequately carrying out their tasks. Those shortages can also have a significant impact on controlling the spread of a given pathogen caused by, for example, an insufficient supply of COVID-19 test kits. It is therefore important to address the question of shortages and to reinforce and formalise monitoring of critical medicinal products and medical devices ***in the most efficient way and so as to avoid creating unnecessary burdens for stakeholders which may strain resources and cause additional delays***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>154</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 7</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (7) Uncertainty of supply and demand and the risk of shortages of essential medicinal products and medical devices during a public health emergency like the COVID-19 pandemic can trigger export restrictions amongst Member States and other national protective measures, which can seriously impact the functioning of the internal market. Furthermore, shortages of medicinal products can result in serious risks to the health of patients in the Union due to their lack of availability, which can cause, medication errors, increased duration of hospital stays, and adverse reactions caused by the administration of unsuitable products used as a substitute for unavailable ones. With respect to medical devices, shortages can lead to a lack of diagnostic resources with negative consequences for public health measures, a lack of treatment or deterioration of the disease and may also prevent health professionals from adequately carrying out their tasks. Those shortages can also have a significant impact on controlling the spread of a given pathogen caused by, for example, an insufficient supply of COVID-19 test kits. It is therefore important to address the question of shortages and to reinforce and formalise monitoring of critical medicinal products and medical devices. | (7) Uncertainty of supply and demand and the risk of shortages of essential medicinal products and medical devices during a public health emergency like the COVID-19 pandemic can trigger export restrictions amongst Member States and other national protective measures, which can seriously impact the functioning of the internal market. Furthermore, shortages of medicinal products can result in serious risks to the health of patients in the Union due to their lack of availability, which can cause, medication errors, increased duration of hospital stays, and adverse reactions caused by the administration of unsuitable products used as a substitute for unavailable ones. With respect to medical devices, shortages can lead to a lack of diagnostic resources with negative consequences for public health measures, a lack of treatment or deterioration of the disease and may also prevent health professionals from adequately carrying out their tasks. Those shortages can also have a significant impact on controlling the spread of a given pathogen caused by, for example, an insufficient supply of COVID-19 test kits. It is therefore important to address the question of shortages and to reinforce and formalise monitoring of critical ***human and veterinary*** medicinal products and medical devices. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>155</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 7</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (7) Uncertainty of supply and demand and the risk of shortages of essential medicinal products and medical devices during a public health emergency like the COVID-19 pandemic can trigger export restrictions amongst Member States and other national protective measures, which can seriously impact the functioning of the internal market. Furthermore, shortages of medicinal products can result in serious risks to the health of patients in the Union due to their lack of availability, which can cause, medication errors, increased duration of hospital stays, and adverse reactions caused by the administration of unsuitable products used as a substitute for unavailable ones. With respect to medical devices, shortages can lead to a lack of diagnostic resources with negative consequences for public health measures, a lack of treatment or deterioration of the disease and may also prevent health professionals from adequately carrying out their tasks. Those shortages can also have a significant impact on controlling the spread of a given pathogen caused by, for example, an insufficient supply of COVID-19 test kits. It is therefore important to address the question of shortages and to reinforce and formalise monitoring of critical medicinal products and medical devices. | (7) Uncertainty of supply and demand and the risk of shortages of essential medicinal products and medical devices during a public health emergency like the COVID-19 pandemic can trigger export restrictions amongst Member States and other national protective measures, which can seriously impact the functioning of the internal market. Furthermore, shortages of medicinal products can result in serious risks to the health of patients in the Union due to their lack of availability, which can cause ***fatalities***, medication errors, increased duration of hospital stays, and adverse reactions caused by the administration of unsuitable products used as a substitute for unavailable ones. With respect to medical devices, shortages can lead to a lack of diagnostic resources with negative consequences for public health measures, a lack of treatment or deterioration of the disease and may also prevent health professionals from adequately carrying out their tasks. Those shortages can also have a significant impact on controlling the spread of a given pathogen caused by, for example, an insufficient supply of COVID-19 test kits. It is therefore important to address the question of shortages and to reinforce and formalise monitoring of critical medicinal products and medical devices. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>156</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 8</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (8) Safe and efficacious medicinal products that treat, prevent or diagnose diseases which cause public health emergencies, should be developed and made available within the Union as soon as possible during such emergencies. The COVID-19 pandemic has also highlighted sub-optimal coordination and decision-making as regards multinational clinical trials, and Union-level advice on the use of medicinal products in national compassionate use programmes or outside of their authorised indications in the Union, causing delays in the adoption of research outcomes and in the development and availability of new or repurposed medicines. | (8) Safe and efficacious medicinal products that treat, prevent or diagnose diseases which cause public health emergencies, should be developed***, if necessary*** ***through joint undertakings by public authorities, the private sector and academia,*** and made available within the Union as soon as possible during such emergencies. The COVID-19 pandemic has also highlighted sub-optimal coordination and decision-making as regards multinational clinical trials, and Union-level advice on the use of medicinal products in national compassionate use programmes or outside of their authorised indications in the Union, causing delays in the adoption of research outcomes and in the development and availability of new or repurposed medicines. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>157</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 8 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(8a)*** ***Experience with clinical trials during the Covid-19 pandemic revealed a tremendous amount of duplication of investigations on the same interventions, many small trials, under-representation of important population subgroups, based on gender, age, ethnicity or medical comorbidities, and a lack of collaboration, posing a risk of research waste. To improve the clinical research agenda, international regulators pointed out the need for robust evidence on quality, efficacy and safety of medicinal products. The main way to obtain reliable evidence is through co-ordinated, well-designed, well-powered large randomised controlled trials. Clinical trial results and data should be made public.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>158</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 8 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(8a)*** ***Experience with clinical trials during the Covid-19 pandemic revealed a tremendous amount of duplication of investigations on the same interventions, many small trials, underrepresentation of important population groups and a lack of collaboration putting a risk of research waste. To improve the clinical research agenda, international regulators pointed out the need for robust evidence on quality, efficacy and safety of medicinal products. The main way to obtain reliable evidence is through co-ordinated, well-designed, well powered large randomised controlled trials. Clinical trial results and data should be made public.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>159</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 8 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(8b)*** ***To accelerate, facilitate and coordinate the launch and development of clinical trials in Europe, the Agency should make full use of existing networks, including the Heads of Medicines Agencies (HMA), the Clinical Trials Facilitation and Coordination Group (CTFG), and the European Clinical Research Infrastructure Network (ECRIN).*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>160</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 8 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(8b)*** ***To speed up, facilitate and coordinate the development and launch of clinical trials in Europe, the Agency should make full use of existing networks like the Heads of Medicines Agencies (HMA), the Clinical Trials Facilitation and Coordination Group (CTFG), and the European Clinical Research Infrastructure Network (ECRIN).*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>161</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 9</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (9) During the COVID-19 pandemic ad hoc solutions, including contingent arrangements between the Commission, the European Medicines Agency (‘the Agency’), marketing authorisation holders, manufacturers and Member States, had to be found to achieve the objective of making available safe and efficacious medicinal products to treat COVID-19 or prevent its spread, and to facilitate and speed up the development and marketing authorisation of treatments and vaccines. | (9) During the COVID-19 pandemic ad hoc solutions, including contingent arrangements between the Commission, the European Medicines Agency (‘the Agency’), marketing authorisation holders, manufacturers and Member States, had to be found to achieve the objective of making available safe and efficacious medicinal products to treat COVID-19 or prevent its spread, and to facilitate and speed up the development and marketing authorisation of treatments and vaccines. ***These ad-hoc solutions should be taken into account as well as all the lessons learned during the pandemic in order to better use the Agency’s potential to face future outbreaks.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>162</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 9</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (9) During the COVID-19 pandemic ad hoc solutions, including contingent arrangements between the Commission, the European Medicines Agency (‘the Agency’), marketing authorisation holders, manufacturers and Member States, had to be found to achieve the objective of making available safe and efficacious medicinal products to treat COVID-19 or prevent its spread, and to facilitate and speed up the development and marketing authorisation of treatments and vaccines. | (9) During the COVID-19 pandemic ad hoc solutions, including contingent arrangements between the Commission, the European Medicines Agency (‘the Agency’), marketing authorisation holders, manufacturers ***or other entities in the pharmaceutical supply chain*** and Member States, had to be found to achieve the objective of making available safe and efficacious medicinal products to treat COVID-19 or prevent its spread, and to facilitate and speed up the development and marketing authorisation of treatments and vaccines. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>163</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 9</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (9) During the COVID-19 pandemic ad hoc solutions, including contingent arrangements between the Commission, the European Medicines Agency (‘the Agency’), marketing authorisation holders, manufacturers and Member States, had to be found to achieve the objective of making available safe and efficacious medicinal products to treat COVID-19 or prevent its spread, and to facilitate and speed up the development and marketing authorisation of treatments and vaccines. | (9) During the COVID-19 pandemic ad hoc solutions, including contingent arrangements between the Commission, the European Medicines Agency (‘the Agency’), marketing authorisation holders, manufacturers***, other entities of the pharmaceutical supply chain*** and Member States, had to be found to achieve the objective of making available safe and efficacious medicinal products to treat COVID-19 or prevent its spread, and to facilitate and speed up the development and marketing authorisation of treatments and vaccines. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>164</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 9</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (9) During the COVID-19 pandemic ad hoc solutions, including contingent arrangements between the Commission, the European Medicines Agency (‘the Agency’), marketing authorisation holders, manufacturers and Member States, had to be found to achieve the objective of making available safe and efficacious medicinal products to treat COVID-19 or prevent its spread, and to facilitate and speed up the development and marketing authorisation of treatments and vaccines. | (9) During the COVID-19 pandemic ad hoc solutions, including contingent arrangements between the Commission, the European Medicines Agency (‘the Agency’), marketing authorisation holders, manufacturers and Member States, had to be found to achieve the objective of making available ***to the Member States*** safe and efficacious medicinal products to treat COVID-19 or prevent its spread, and to facilitate and speed up the development and marketing authorisation of treatments and vaccines. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>165</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 9 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(9a)*** ***In order to facilitate the supply of medicinal products during the COVID-19 pandemic, marketing authorisation holders were granted regulatory flexibility in relation to, for example, existing procedures for changing suppliers of active ingredients, designation of new production sites and faster processing of import permits, so that shortages of medicinal products could be addressed. Those solutions should remain in place to assist with future situations and those flexibilities should be applied consistently across the Member States to prevent fragmentation of the internal market and ineffective outcomes.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>166</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 10</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (10) In order to ensure a better functioning of the internal market of those products and contribute to a high level of human health protection, it is therefore appropriate to approximate the rules on monitoring of shortages of medicinal products and medical devices, and to facilitate the research and development of medicinal products, which may have the potential to treat, prevent, or diagnose diseases that cause public health crises. | (10) In order to ensure a better functioning of the internal market of those products and contribute to a high level of human health protection, it is therefore appropriate to approximate the rules on monitoring of shortages of medicinal products and medical devices, and to facilitate the research and development of medicinal products, which may have the potential to treat, prevent, or diagnose diseases that cause public health crises. ***The Union's actions should be consistent with the WHO’s One Health approach, as well as with the Health in All Policies principle, recognising the interconnections between human and animal health and the environment and the cross-sectoral character of health policies.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>167</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Jan Huitema</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 10</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (10) In order to ensure a better functioning of the internal market of those products and contribute to a high level of human health protection, it is therefore appropriate to approximate the rules on monitoring of shortages of medicinal products and medical devices, and to facilitate the research and development of medicinal products, which may have the potential to treat, prevent, or diagnose diseases that cause public health crises. | (10) In order to ensure a better functioning of the internal market of those products and contribute to a high level of human health protection, it is therefore appropriate to approximate the rules on monitoring of shortages of medicinal products and medical devices, and to facilitate the research and development of medicinal products, which may have the potential to treat, prevent, or diagnose diseases that cause public health crises***, with a view to strategically complement the efforts of the Commission and other existing Agencies to that end, as well as that of future key agencies such as the proposed European Health Emergency Preparedness and Response Authority (HERA)***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>168</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 10</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (10) In order to ensure a better functioning of the internal market of those products and contribute to a high level of human health protection, it is therefore appropriate to approximate the rules on monitoring of shortages of medicinal products and medical devices, and to facilitate the research and development of medicinal products, which may have the potential to treat, prevent, or diagnose diseases that cause public health crises. | (10) In order to ensure a better functioning of ***the internal*** market of those products and contribute to a high level of human health protection, it is therefore appropriate to approximate the rules on monitoring of shortages of medicinal products and medical devices, and ***to facilitate*** the research and development of medicinal products, which may have the potential to treat, prevent, or diagnose diseases that cause public health crises. ***Requirements could be defined in close cooperation between authorities, industry and relevant entities of the pharmaceutical supply chain.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>169</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 10</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (10) In order to ensure a better functioning of the internal market of those products and contribute to a high level of human health protection, it is therefore appropriate to approximate the rules on monitoring of shortages of medicinal products and medical devices, and to facilitate the research and development of medicinal products, which may have the potential to treat, prevent, or diagnose diseases that cause public health crises. | (10) In order to ensure a better functioning of the internal market of those products and contribute to a high level of human health protection, it is therefore appropriate to approximate ***and better coordinate*** the rules on monitoring of shortages of medicinal products and medical devices, and***, through increased support for research and innovation,*** to facilitate the research and development of medicinal products, which may have the potential to treat, prevent, or diagnose diseases that cause public health crises. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>170</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 10</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (10) In order to ensure a better functioning of the internal market of those products and contribute to a high level of human health protection, it is therefore appropriate to approximate the rules on monitoring of shortages of medicinal products and medical devices, and to facilitate the research and development of medicinal products, which may have the potential to treat, prevent, or diagnose diseases that cause public health crises. | (10) In order to ensure a better functioning of the internal market of those products and contribute to a high level of human health protection, it is therefore appropriate to approximate the rules on monitoring of shortages of medicinal products and medical devices, and to facilitate the research and development of ***human and veterinary*** medicinal products, which may have the potential to treat, prevent, or diagnose diseases that cause public health crises. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>171</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 10 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(10a)*** ***In order to ensure a better functioning of the internal market of those products and contribute to a high level of human health protection, it is therefore appropriate to facilitate the research and development of human and veterinary medicinal products, which may have the potential to treat, prevent, or diagnose diseases that cause serious public health events, including emerging zoonoses that particularly stem from human and animal environmental changes.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>172</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 10 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(10a)*** ***In order to ensure effective health systems, stress tests should be introduced to assess the resilience of health systems in emergencies with a view to providing an effective means of countering shortages in the event of pandemics and identifying structural risk factors that create shortages.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>173</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 11</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (11) This Regulation aims to ensure the smooth functioning of the internal market as regards medicinal products and medical devices, with a high level of human health protection being fundamental in those aims. Moreover, this Regulation aims to ensure the quality, safety and efficacy of medicinal products with the potential to address public health emergencies. Both objectives are being pursued simultaneously and are inseparably linked whilst one not being secondary to the other. As regards Article 114 TFEU, this Regulation establishes a framework for the monitoring and reporting on shortages of medicinal products and medical devices during public health crises. As regards Article 168(4)(c) TFEU, this Regulation provides for a strengthened Union framework ensuring the quality and safety of medicinal products and medical devices. | (11) This Regulation aims to ensure the smooth functioning of the internal market as regards ***human and veterinary*** medicinal products and medical devices, with a high level of human health protection being fundamental in those aims. Moreover, this Regulation aims to ensure the quality, safety and efficacy of medicinal products with the potential to address public health emergencies. Both objectives are being pursued simultaneously and are inseparably linked whilst one not being secondary to the other. As regards Article 114 TFEU, this Regulation establishes a framework for the monitoring and reporting on shortages of ***human and veterinary*** medicinal products and medical devices during public health crises. As regards Article 168(4)(c) TFEU, this Regulation provides for a strengthened Union framework ensuring the quality and safety of medicinal products and medical devices. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>174</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 11</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (11) This Regulation aims to ensure the smooth functioning of the internal market as regards medicinal products and medical devices, ***with*** a high level of human health protection being fundamental in those aims. Moreover, this Regulation aims to ensure the quality, safety and efficacy of medicinal products with the potential to address public health emergencies. Both objectives are being pursued simultaneously and are inseparably linked whilst one not being secondary to the other. As regards Article 114 TFEU, this Regulation establishes a framework for the monitoring and reporting on shortages of medicinal products and medical devices during public health crises. As regards Article 168(4)(c) TFEU, this Regulation provides for a strengthened Union framework ensuring the quality and safety of medicinal products and medical devices. | (11) This Regulation aims to ensure the smooth functioning of the internal market as regards medicinal products and medical devices, ***as well as*** a high level of human health protection being fundamental in those aims. Moreover, this Regulation aims to ensure the quality, safety and efficacy of medicinal products with the potential to address public health emergencies. Both objectives are being pursued simultaneously and are inseparably linked whilst one not being secondary to the other. As regards Article 114 TFEU, this Regulation establishes a framework for the monitoring and reporting on shortages of medicinal products and medical devices during public health crises. As regards Article 168(4)(c) TFEU, this Regulation provides for a strengthened Union framework ensuring the quality and safety of medicinal products and medical devices. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>175</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 11 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(11a)*** ***This Regulation aims at establishing a pan-European coordination and information system to tackle all medicines shortage which is in place and functional also under normal circumstances to be able to better manage a crisis. In this respect, this regulation sets the basis for the creation of an harmonised pan-European interoperable and digitalized shortages reporting and notification system, interconnecting national reporting systems, with data collected in digital and harmonised fields, and based on a common definition, covering both Centralised and National Marketing Authorisations. The knowledge of digital reporting systems used already in some Member States should be used as best practices to develop a pan-European harmonized system.*** |
|  | ***Such harmonized and digital system should be supported by a two-way communication between industry and authorities as a prerequisite to pro-actively address medicines shortage and to use the two-months reporting lead time to try to avoid them. The combination of such information and communication systems would provide the transparency needed to take actions to prevent and mitigate cross border shortages, ultimately ensuring that public health is not impacted and patients access their medicines with no disruption. It would also enable coordination and solidarity, increase efficiency, better visibility and predictability during crisis situations, speed-up the decision-making process, while avoiding duplications of efforts, red tapes and miss communication.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>176</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 11 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(11a)*** ***This Regulation establishes a framework to address the problem of shortages during public health emergencies and major events. However, shortages of medicinal products and medical devices are a persistent problem that has been increasingly affecting health and lives of EU citizens for decades. Therefore, this Regulation should be a first step towards improving the EU response to this long-lasting issue. The Commission should subsequently propose the expansion of this framework to ensure that the issue of shortages is broadly and permanently tackled in the upcoming revision of Regulation (EC) 726/2004 and Directive 2001/83/EC.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>177</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 11 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(11a)*** ***This Regulation aims at establishing the foundations of a European Union of Health coordination and early-warning digitalized interoperable system, to monitor and report medicines shortage, based on shared definitions and procedures, in order to be prepared and better react during a crisis. The existing best practices of digital reporting systems at national level should be shared and taken into account after a common evaluation.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>178</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 12</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (12) In order to improve crisis preparedness and management for medicinal products and medical devices and increase resilience and solidarity across the Union, the procedures and the respective roles and obligations of different concerned entities involved should be clarified. The framework should build on the ad hoc solutions identified so far in the response to the COVID-19 pandemic. | (12) In order to improve crisis preparedness and management for medicinal products and medical devices and increase resilience and solidarity across the Union, the procedures and the respective roles and obligations of different concerned entities involved should be clarified. The framework should build on the ad hoc solutions identified so far in the response to the COVID-19 pandemic ***that have proven effective and operative and that can provide foundational protocols on which to build upon***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>179</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Nils Torvalds, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 12</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (12) In order to improve crisis preparedness and management for medicinal products and medical devices and increase resilience and solidarity across the Union, the procedures and the respective roles and obligations of different concerned entities involved should be clarified. The framework should build on the ad hoc solutions identified so far in the response to the COVID-19 pandemic. | (12) In order to improve crisis preparedness and management for medicinal products and medical devices and increase resilience and solidarity across the Union, the procedures and the respective roles and obligations of different concerned entities involved should be clarified. The framework should build on the ad hoc solutions identified so far in the response to the COVID-19 pandemic***, while remaining flexible enough to tackle any future health crisis in the most efficient way to the benefit of public health and patients***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>180</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 12</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (12) In order to improve crisis preparedness and management for medicinal products and medical devices and increase resilience and solidarity across the Union, the procedures and the respective roles and obligations of different concerned entities involved should be clarified. The framework should build on the ad hoc solutions identified so far in the response to the COVID-19 pandemic. | (12) In order to improve crisis preparedness and management for ***human and veterinary*** medicinal products and medical devices and increase resilience and solidarity across the Union, the procedures and the respective roles and obligations of different concerned entities involved should be clarified. The framework should build on the ad hoc solutions identified so far in the response to the COVID-19 pandemic. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>181</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 13</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (13) A harmonised system of monitoring of shortages of medicinal products and medical devices should be established, which will facilitate appropriate access ***to*** critical medicinal products and medical devices during public health emergencies and major events, which may have a serious impact on public health. That system should be complemented with improved structures to ensure appropriate management of public health crises and coordinate and provide advice on the research and development of medicinal products which may have the potential to address public health emergencies. In order to facilitate the monitoring and reporting on potential or actual shortages of medicinal products and medical devices, the Agency should be able to ask and obtain information and data from the concerned marketing authorisation holders, manufacturers and Member States through designated points of contact. | (13) A harmonised system***, based on common data fields,*** of monitoring of shortages of medicinal products***, personal protective equipment*** and medical devices should be established, which will facilitate appropriate access ***for relevant national and Union authorities on markets situations for*** critical medicinal products and medical devices during public health emergencies and major events, which may have a serious impact on public health. That system should be complemented with improved ***telematics*** structures to ensure appropriate management of public health crises and coordinate and provide advice on the research and development of medicinal products which may have the potential to address public health emergencies. In order to facilitate the monitoring and reporting on potential or actual shortages of medicinal products and medical devices, ***as well as to avoid duplications of the information submitted, the system should be interoperable with the national shortages reporting system,*** the Agency should be able to ask and obtain ***additional any*** information and data ***– not already in the system -*** from the concerned marketing authorisation holders, manufacturers and Member States ***who should all have the obligation to provide complete information and data*** through designated points of contact ***(iSPOC and SPOC)***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>182</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 13</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (13) A harmonised system of monitoring of shortages of medicinal products and medical devices should be established, which will facilitate appropriate access to critical medicinal products and medical devices during public health emergencies and major events, which may have a serious impact on public health. That system should be complemented with improved structures to ensure appropriate management of public health crises and coordinate and provide advice on the research and development of medicinal products which may have the potential to address public health emergencies. In order to facilitate the monitoring and reporting on potential or actual shortages of medicinal products and medical devices, the Agency should be able to ask and obtain information and data from the concerned marketing authorisation holders, manufacturers and Member States through designated points of contact. | (13) A harmonised system of monitoring of shortages of medicinal products and medical devices should be established, which will facilitate appropriate access to critical medicinal products and medical devices during public health emergencies and ***access to critical medicinal products, devices and applications in*** major events, which may have a serious impact on public health. That system should be complemented with improved structures to ensure appropriate management of public health crises and coordinate and provide advice on the research***, innovation*** and development of medicinal products which may have the potential to address public health emergencies. In order to facilitate the monitoring and reporting on potential or actual shortages of medicinal products and medical devices, the Agency should be able to ask ***demand*** and obtain information and data from the concerned marketing authorisation holders, manufacturers and Member States through designated points of contact. ***Should any of the aforementioned stakeholders not give information to the Agency in the time lapse established by the Agency, the Commission should assist the Agency in obtaining such information, with the prospect of an eventual sanction, which should also be duly made available to the public.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>183</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 13</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (13) A harmonised system of monitoring of shortages of medicinal products and medical devices should be established, which will facilitate appropriate access to critical medicinal products and medical devices during public health emergencies and major events, which may have a serious impact on public health. That system should be complemented with improved structures to ensure appropriate management of public health crises and coordinate and provide advice on the research and development of medicinal products which may have the potential to ***address*** public health emergencies. In order to facilitate the monitoring and reporting on potential or actual shortages of medicinal products and medical devices, the Agency should be able to ask and obtain information and data from the concerned marketing authorisation holders, manufacturers and Member States through designated points of contact. | (13) A harmonised system of monitoring of shortages of medicinal products and medical devices should be established, which will facilitate appropriate access to critical medicinal products and medical devices during public health emergencies and major events, which may have a serious impact on public health. That system should be complemented with improved structures to ensure appropriate management of public health crises and coordinate and provide advice on the research and development of medicinal products which may have the potential to ***mitigate*** public health emergencies. In order to facilitate the monitoring and reporting on potential or actual shortages of medicinal products and medical devices, the Agency should be able to ask and obtain information and data from the concerned marketing authorisation holders, manufacturers***, wholesalers*** and Member States through designated points of contact. ***The Agency should also establish a system for the exchange of information on the availability of medicines and medical devices with healthcare professionals, in particular medical doctors and community and hospital pharmacists, consumers and patients facilitated through national medicines agencies.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>184</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 13</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (13) A harmonised system ***of monitoring*** of shortages of medicinal products and medical devices should be established, which will facilitate appropriate access to critical medicinal products and medical devices during public health emergencies and major events, which may have a serious impact on public health. That system should be complemented with improved structures to ensure appropriate management of public health crises and coordinate and provide advice on the research and development of medicinal products which may have the potential to address public health emergencies. In order to facilitate the monitoring and reporting on potential or actual shortages of medicinal products and medical devices, the Agency should be able to ***ask and obtain*** information and data from the concerned marketing authorisation holders, manufacturers and Member States ***through designated points of contact***. | (13) A harmonised ***European Union of Health digitalized and interoperable early-warning*** system of shortages of medicinal products and medical devices should be established, which will facilitate appropriate access to critical medicinal products and medical devices during public health emergencies and major events, which may have a serious impact on public health. That system should be complemented with improved structures to ensure appropriate management of public health crises and coordinate and provide advice on the research and development of medicinal products which may have the potential to address public health emergencies. In order to facilitate the monitoring and reporting on potential or actual shortages of medicinal products and medical devices, the Agency should be able to ***access*** information and data from the concerned marketing authorisation holders, manufacturers***, relevant entities of the pharmaceuticals' supply chain*** and Member States***' national agencies, directly via the uploaded information at national level available in the European Union of Health early-warning, interoperable and digitalized system, avoiding duplications of reporting requirements at different levels***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>185</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 13</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (13) A harmonised system of monitoring of shortages of medicinal products and medical devices should be established, which will facilitate appropriate access to critical medicinal products and medical devices during public health emergencies and major events, which may have a serious impact on public health. That system should be complemented with improved structures to ensure appropriate management of public health crises and coordinate and provide advice on the research and development of medicinal products which may have the potential to address public health emergencies. In order to facilitate the monitoring and reporting on potential or actual shortages of medicinal products and medical devices, the Agency should be able to ask and obtain information and data from the concerned marketing authorisation holders, manufacturers and Member States through designated points of contact. | (13) A harmonised system of monitoring of shortages of medicinal products and medical devices should be established, which will facilitate appropriate access to critical medicinal products and medical devices during public health emergencies and major events, which may have a serious impact on public health. That system should be complemented with improved structures to ensure appropriate management of public health crises and coordinate and provide advice on the research and development of medicinal products which may have the potential to address public health emergencies. In order to facilitate the monitoring and reporting on potential or actual shortages of ***human or veterinary*** medicinal products and medical devices, the Agency should be able to ask and obtain information and data from the concerned marketing authorisation holders, manufacturers and Member States through designated points of contact. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>186</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 13 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(13a)*** ***However, in order to facilitate the prevention, monitoring and reporting of shortages of medicinal products, it would be necessary for the Union and Member States to set up an electronic platform capable of determining the volume of stocks and detecting, predicting and preventing shortages of medicinal products. To facilitate the development of such a system, lessons could be learnt from projects such as CISMED, funded by the Union through Horizon Europe. The platform should provide the national competent authorities with real-time access to unmet demands from wholesale distributors, community pharmacies and hospital pharmacies, providing accurate data in order to understand the functioning of the supply chain and anticipate potential shortages of medicinal products. The platform should also act as the sole portal for marketing authorisation holders and wholesale distributors to provide the information required during major events and public health emergencies once fully implemented, with a view to increase efficiency, predictability during crises, and speed-up the decision making process while avoiding duplication of efforts and unjustified burden on all stakeholders. In order to facilitate the coordination role of the Agency, Member States' supply monitoring platforms should be interoperable and replicate their information in a Union database managed by the Agency. To accelerate the implementation of the system at Union and national level, its development and implementation should be supported by Union funding from, inter alia, the EU4Health Programme or the Recovery and Resilience Facility established by Regulation (EU) 2021/241 of the European Parliament and of the Council***1a***.*** |
|  | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
|  | 1a ***1a Regulation (EU) 2021/241 of the European Parliament and of the Council of 12 February 2021 establishing the Recovery and Resilience Facility (OJ L 57, 18.2.2021, p. 17).*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

While supporting the Rapporteur's proposal for a streamlined and single platform to monitor, detect, predict and prevent shortages of medicinal products so as to be immediately operational in preparation for or during a health crisis, the tracking and tracing system appears too costly, burdensome for pharmacies, hospitals and self-dispensing doctors. We therefore propose to amend his proposal to rely on volumes of stocks throughout the supply chain rather than a tracking-and-tracing system of each individual product..

</Amend>

<Amend>Amendment <NumAm>187</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 13 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(13a)*** ***In order to ensure that Member State strategies, particularly in terms of stock management, are correctly implemented and coordinated, the Agency should become the regulatory authority responsible for preventing shortages of medicinal products within the Union, not only during crises but also in normal times, and its mandate and resources should also be strengthened.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>188</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 13 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(13a)*** ***The Agency, together with the Commission, should also do its upmost to counterbalance smear campaigns and disinformation on medicines, medical products, devices or applications, in order to ensure proper information to the public.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>189</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 15</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (15) With respect to medicinal products, an executive steering group should be established within the Agency to ensure a robust response to major events and to coordinate urgent actions within the Union in relation to the management of issues relating to the supply of medicinal products. The Steering Group should establish ***lists*** of critical medicinal products to ensure monitoring of those products and it should be able to provide advice on the necessary action to take to safeguard the quality, safety, and efficacy of medicinal products and ensure a high level of human health protection. | (15) With respect to medicinal products, an executive steering group should be established within the Agency to ensure a robust response to major events and to coordinate urgent actions within the Union in relation to the management of issues relating to the supply of medicinal products. The Steering Group should establish ***a European list*** of ***essential and*** critical medicinal products***, in cooperation with all stakeholders,*** to ensure monitoring of those products and it should be able to provide advice on the necessary action to take to safeguard the quality, safety, and efficacy of medicinal products and ensure a high level of human health protection ***as well as adequate supplies***. ***Priorities should be established for the different types of medicinal product by drawing a distinction in particular between ‘medicinal products of major therapeutic interest’ (MITMs), i.e. medicines for which an interruption of treatment is likely to jeopardise the vital prognosis of patients in the short or medium term or significantly diminishes the patient’s chances with regard to the progressive potential of the disease, or for which there are no suitable therapeutic alternatives available in sufficient quantity, and ‘medicinal products of health and strategic importance’ (MISSs), for which the interruption of treatment causes an immediate threat to the patient’s life.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>190</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 15</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (15) With respect to medicinal products, an executive steering group should be established within the Agency to ensure a robust response to major events and to coordinate urgent actions within the Union in relation to the management of issues relating to the supply of medicinal products. The Steering Group should establish lists of critical medicinal products to ensure monitoring of those products and it should be able to provide advice on the necessary action to take to safeguard the quality, safety, and efficacy of medicinal products and ensure a high level of human health protection. | (15) With respect to medicinal products, an executive steering group should be established within the Agency to ensure a robust response to major events and to coordinate urgent actions within the Union in relation to the management of issues relating to the supply of medicinal products. The Steering Group should establish lists of critical medicinal products to ensure monitoring of those products and it should be able to provide advice ***and recommendations*** on the necessary action to take to safeguard the quality, safety, and efficacy of medicinal products and ensure a high level of human health protection.***The Steering Group should take into account and integrate in its works the outcomes of the ongoing discussions in the context of the European Commission Structured Dialogue on manufacturing and supply chain among institutions, national authorities and stakeholders, in order to achieve the best results in preventing and responding to shortage of medicines.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>191</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 15</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (15) With respect to medicinal products, an executive steering group should be established within the Agency to ensure a robust response to major events and to coordinate urgent actions within the Union in relation to the management of issues relating to the supply of medicinal products. The Steering Group should establish lists of critical medicinal products to ensure monitoring of those products and it should be able to provide advice on the necessary action to take to safeguard the quality, safety, and efficacy of medicinal products and ensure a high level of human health protection. | (15) With respect to medicinal products, an executive steering group should be established within the Agency to ensure a robust response to major events and to coordinate urgent actions within the Union in relation to the management of issues relating to the supply of medicinal products. The Steering Group should establish ***a single pan-European*** lists of critical medicinal products***, in close cooperation with industry,*** to ensure monitoring of those products and it should be able to provide advice on the necessary action to take to safeguard the quality, safety, and efficacy of medicinal products and ensure a high level of human health protection ***during public health emergencies and major events***. ***Such a list should take into account and integrate the outcomes of the ongoing discussions in the context of the EC structured dialogue on manufacturing and supply chain among institutions, national authorities and stakeholders, in order to avoid duplications of work and contradicting results*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>192</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 15</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (15) With respect to medicinal products, an executive steering group should be established within the Agency to ensure a robust response to major events and to coordinate urgent actions within the Union in relation to the management of issues relating to the supply of medicinal products. The Steering Group should establish lists of critical medicinal products to ensure monitoring of those products and it should be able to provide advice on the necessary action to take to safeguard the quality, safety, and efficacy of medicinal products and ensure a high level of human health protection. | (15) With respect to medicinal products, an executive steering group should be established within the Agency to ensure a robust response to major events and to coordinate urgent actions within the Union in relation to the management of issues relating to the supply of medicinal products. The Steering Group should establish lists of critical medicinal products to ensure monitoring of those products and it should be able to provide advice on the necessary action to take to safeguard the quality, safety, and efficacy of medicinal products and ensure a high level of human health protection. ***The World Health Organization Model List of Essential Medicines for adults and for children is the best base for the identification of critical medicinal products at Union level.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>193</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Nils Torvalds, María Soraya Rodríguez Ramos, Martin Hojsík, Andreas Glück, Susana Solís Pérez</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 15</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (15) With respect to medicinal products, an executive steering group should be established within the Agency to ensure a robust response to major events and to coordinate urgent actions within the Union in relation to the management of issues relating to the supply of medicinal products. The Steering Group should establish lists of critical medicinal products to ensure monitoring of those products and it should be able to provide advice on the necessary action to take to safeguard the quality, safety, and efficacy of medicinal products and ensure a high level of human health protection. | (15) With respect to medicinal products, an executive steering group should be established within the Agency to ensure a robust response to major events and to coordinate urgent actions within the Union in relation to the management of issues relating to the supply of medicinal products. The Steering Group should establish ***single European*** lists of critical medicinal products ***in consultation with the industry and healthcare professionals,*** to ensure monitoring of those products and it should be able to provide advice on the necessary action to take to safeguard the quality, safety, and efficacy of medicinal products and ensure a high level of human health protection. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>194</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 15</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (15) With respect to medicinal products, an executive steering group should be established within the Agency to ensure a robust response to major events and to coordinate urgent actions within the Union in relation to the management of issues relating to the supply of medicinal products. The Steering Group should establish lists of critical medicinal products to ensure monitoring of those products and it should be able to provide advice on the necessary action to take to safeguard the quality, safety, and efficacy of medicinal products and ensure a high level of human health protection. | (15) With respect to medicinal products, an executive steering group should be established within the Agency to ensure a robust response to major events and to coordinate urgent actions within the Union in relation to the management of issues relating to the supply of medicinal products. The Steering Group should establish lists of critical ***human and veterinary*** medicinal products to ensure monitoring of those products and it should be able to provide advice on the necessary action to take to safeguard the quality, safety, and efficacy of ***those*** medicinal products and ensure a high level of human health protection. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>195</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 16</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (16) The Executive Steering Group on Shortages and Safety of Medicinal Products should benefit from the Agency’s extensive scientific expertise as regards the evaluation and supervision of medicinal products and should further develop the Agency’s leading role in coordinating and supporting the response to shortages during the COVID-19 pandemic. | (16) The Executive Steering Group on Shortages and Safety of ***Human and Veterinary*** Medicinal Products should benefit from the Agency’s extensive scientific expertise as regards the evaluation and supervision of medicinal products and should further develop the Agency’s leading role in coordinating and supporting the response to shortages during the COVID-19 pandemic. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>196</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 16 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(16a)*** ***In order to facilitate the prevention, monitoring and reporting of shortages of medicinal products, devices and applications, the Agency and the Commission should establish an electronic platform to track and follow medicinal products, devices and applications throughout the supply chain. This platform should also be a one-stop shop for marketing authorisation holders and wholesale distributors to provide required information during major health events. This platform should use the distributed ledger technology (DLT) and include data from national and regional competent authorities. The platform should, among other duties, determine the volume of stock, the capabilities of all stakeholders linked in the supply chain or chains, the actual, current and foreseeable level of demand. This platform should also obtain, record and share information.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>197</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 16 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(16b)*** ***Finally, this platform should also be linked to the Health data space and managed by the Agency and the Commission.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>198</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 17</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (17) In order to ensure that safe, high quality, and efficacious medicinal products, which have the potential to address public health emergencies, can be developed and made available within the Union as soon as possible during public health emergencies, an emergency task force should be established within the Agency to provide advice on such medicinal products. The Emergency Task Force should provide advice free of charge on scientific questions related to the development of treatments and vaccines and on clinical trial protocols, to those organisations involved in their development, such as marketing authorisation holders, clinical trial sponsors, public health bodies, and academia, irrespective of their exact role in the development of such medicinal products. | (17) In order to ensure that safe, high quality, and efficacious medicinal products, which have the potential to address public health emergencies, can be developed and made available within the Union as soon as possible during public health emergencies, an emergency task force should be established within the Agency to provide advice on such medicinal products. The Emergency Task Force should provide advice free of charge on scientific questions related to the development of treatments and vaccines and on clinical trial protocols, to those organisations involved in their development, such as marketing authorisation holders, clinical trial sponsors, public health bodies, and academia, irrespective of their exact role in the development of such medicinal products.***The lessons learned during the COVID pandemic should be taken into account in order to better use the Agency’s potential to face future health crises.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>199</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 17</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (17) In order to ensure that safe, high quality, and efficacious medicinal products, which have the potential to address public health emergencies, can be developed and made available within the Union as soon as possible during public health emergencies, an emergency task force should be established within the Agency to provide advice on such medicinal products. The Emergency Task Force should provide advice free of charge on scientific questions related to the development of treatments and vaccines and on clinical trial protocols, to those organisations involved in their development, such as marketing authorisation holders, clinical trial sponsors, public health bodies, and academia, irrespective of their exact role in the development of such medicinal products. | (17) In order to ensure that safe, high quality, and efficacious medicinal products, which have the potential to address public health emergencies, can be developed and made available within the Union as soon as possible during public health emergencies, an emergency task force should be established within the Agency to provide advice on such medicinal products. The Emergency Task Force should provide advice free of charge on scientific questions related to the development of treatments and vaccines and on clinical trial protocols, ***as well as existing minimum stock levels needed to manage the crisis adequately,*** to those organisations involved in their development, such as marketing authorisation holders, clinical trial sponsors, public health bodies, and academia, irrespective of their exact role in the development of such medicinal products. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>200</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 17</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (17) In order to ensure that safe, high quality, and efficacious medicinal products, which have the potential to address public health emergencies, can be developed and made available within the Union as soon as possible during public health emergencies, an emergency task force should be established within the Agency to provide advice on such medicinal products. The Emergency Task Force should provide advice free of charge on scientific questions related to the development of treatments and vaccines and on clinical trial protocols, to those organisations involved in their development, such as marketing authorisation holders, clinical trial sponsors, public health bodies, and academia, irrespective of their exact role in the development of such medicinal products. | (17) In order to ensure that safe, high quality, and efficacious ***human and veterinary*** medicinal products, which have the potential to address public health emergencies, can be developed and made available within the Union as soon as possible during public health emergencies, an emergency task force should be established within the Agency to provide advice on such medicinal products. The Emergency Task Force should provide advice free of charge on scientific questions related to the development of treatments and vaccines and on clinical trial protocols, to those organisations involved in their development, such as marketing authorisation holders, clinical trial sponsors, public health bodies, and academia, irrespective of their exact role in the development of such medicinal products. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>201</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 18</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (18) The work of the Emergency Task Force should be separate from the work of the scientific committees of the Agency and should be carried out without prejudice to the scientific assessments of those committees. The Emergency Task Force should provide recommendations with regard to the use of medicinal products in the fight against the disease that is responsible for the public health crisis. The Committee for Medicinal Products for Human Use should be able to use those recommendations when preparing scientific opinions on compassionate or other early use of a medicinal product prior to marketing authorisation. | (18) The work of the Emergency Task Force should be separate from the work of the scientific committees of the Agency and should be carried out without prejudice to the scientific assessments of those committees***, although communication between these two bodies should be guaranteed***. The Emergency Task Force should provide recommendations with regard to the use of medicinal products in the fight against the disease that is responsible for the public health crisis. The Committee for Medicinal Products for Human Use should be able to use those recommendations when preparing scientific opinions on compassionate or other early use of a medicinal product prior to marketing authorisation. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>202</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 18</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (18) The work of the Emergency Task Force should be separate from the work of the scientific committees of the Agency and should be carried out without prejudice to the scientific assessments of those committees. The Emergency Task Force should provide recommendations with regard to the use of medicinal products in the fight ***against the disease that is responsible for*** the public health crisis. The Committee for Medicinal Products for Human Use should be able to use those recommendations when preparing scientific opinions on compassionate or other early use of a medicinal product prior to marketing authorisation. | (18) The work of the Emergency Task Force should be separate from the work of the scientific committees of the Agency and should be carried out without prejudice to the scientific assessments of those committees. The Emergency Task Force should provide recommendations with regard to the use of medicinal products in the fight ***to overcome*** the public health crisis. The Committee for Medicinal Products for Human Use should be able to use those recommendations when preparing scientific opinions on compassionate or other early use of a medicinal product prior to marketing authorisation. |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Not every health crisis is resulted from a disease. For example, extreme heat waves can also lead to health crises.

</Amend>

<Amend>Amendment <NumAm>203</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 19</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (19) The establishment of the Emergency Task Force should build on the support provided by the Agency during the COVID-19 pandemic, notably as regards scientific advice on clinical trials design and product development as well as the ‘rolling’ review i.e. on an on-going basis, of emerging evidence to allow a more efficient assessment of medicinal products including vaccines during public health emergencies. | (19) The establishment of the Emergency Task Force should build on the support provided by the Agency during the COVID-19 pandemic, notably as regards scientific advice on clinical trials design and product development as well as the ‘rolling’ review i.e. on an on-going basis, of emerging evidence to allow a more efficient assessment of medicinal products including vaccines during public health emergencies ***while guaranteeing a high level of human health protection***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>204</NumAm>

<RepeatBlock-By><Members>Simona Baldassarre, Silvia Sardone, Marco Dreosto, Joëlle Mélin, Gianantonio Da Re, Lucia Vuolo</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 19 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(19a)*** ***In order to ensure the full application of Article 35 of Regulation (EU) no.536/2014 of the European Parliament and of the Council*** 1a***, with regard to emergency clinical trials on subjects unable to provide informed consent, a special independent monitoring committee for emergency clinical trials is setup, in order to avoid the duplication of similar studies that could harm the human dignity and to ensure closer pharmacovigilance due to the particularity of the trial in question.*** |
|  | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
|  | 1a ***Regulation (EU) no 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Official Journal of the European Union L 158/1, p. 34. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg\_2014\_536/reg\_2014\_536\_en.pdf***  |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>205</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 20</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (20) Individual research entities may agree together, or with another party, to act as a sponsor in order to prepare one harmonised Union-wide clinical trial protocol, yet experience during the COVID-19 pandemic has shown that initiatives to set up large multinational trials struggle to materialise due to the lack of a single entity that can undertake all the responsibilities and activities of a sponsor within the Union, while interacting with multiple Member States. It is therefore appropriate for the Agency to identify and facilitate such initiatives by giving advice on the possibilities to act as a sponsor or, where applicable, to define respective responsibilities as co-sponsors in accordance with Article 72 of Regulation (EU) 536/2014. Such an approach would strengthen the research environment in the Union, and promote harmonisation and avoid subsequent delays in integrating the results of research to a marketing authorisation. A Union sponsor could benefit from Union research funding available at the time of the public health emergency as well as existing clinical trial networks to facilitate the development, application, submission, and running of the trial. This may be particularly valuable for trials established by Union or international public health or research organisations. | (20) Individual research entities may agree together, or with another party, to act as a sponsor in order to prepare one harmonised Union-wide clinical trial protocol, yet experience during the COVID-19 pandemic has shown that initiatives to set up large multinational trials struggle to materialise due to the lack of a single entity that can undertake all the responsibilities and activities of a sponsor within the Union, while interacting with multiple Member States. It is therefore appropriate for the Agency to identify and facilitate such initiatives by giving advice on the possibilities to act as a sponsor or, where applicable, to define respective responsibilities as co-sponsors in accordance with Article 72 of Regulation (EU) 536/2014 ***and coordinate the development of clinical trial protocols. The Emergency Task Force should define the most clinically relevant performance targets for vaccines and treatments to be measured in clinical trials, so that they can meet the criteria for effective public health interventions***. Such an approach would strengthen the research environment in the Union, and promote harmonisation and avoid subsequent delays in integrating the results of research to a marketing authorisation. A Union sponsor could benefit from Union research funding available at the time of the public health emergency as well as existing clinical trial networks to facilitate the development, application, submission, and running of the trial. This may be particularly valuable for trials established by Union or international public health or research organisations. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>206</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 20 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(20a)*** ***The Emergency Task Force should build on the trial networks to ensure that adequate data on new medicinal products, devices and applications, and it could build also upon the HERA Incubator, presented by Communication of 17 February 2021 “HERA Incubator: Anticipating together the threat of COVID-19 variants” [COM(2021) 78 final].*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>207</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 21</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (21) With respect to medical devices, an executive steering group on medical devices should be established to coordinate urgent actions within the Union in relation to the management of supply and demand issues of medical devices, and to establish a list of critical devices in the case of a public health emergency. | (21) With respect to medical devices, an executive steering group on medical devices should be established to coordinate urgent actions within the Union in relation to the management of supply and demand issues of medical devices, and to establish a list of critical devices in the case of a public health emergency. ***The executive steering group on medical devices should be managed by the Commission and the Agency.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>208</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 21</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (21) With respect to medical devices, an executive steering group on medical devices should be established to coordinate urgent actions within the Union in relation to the management of supply and demand issues of medical devices, and to establish a list of critical devices in the case of a public health emergency. | (21) With respect to medical devices, an executive steering group on medical devices should be established to coordinate urgent actions within the Union in relation to the management of supply and demand issues of medical devices, and to establish a list of critical devices ***and minimum stock levels required*** in the case of a public health emergency. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>209</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 24</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (24) Given the Agency’s long-standing and proven record of expertise in the field of medicinal products and considering the Agency’s experience from working with a multitude of groups of experts, it is appropriate to establish the appropriate structures within the Agency to monitor potential shortages of medical devices in the context of a public health emergency and to provide the Agency with a mandate to host the expert panels on medical devices. This would allow for long-term sustainability for the functioning of the panels and provide clear synergies with related crisis preparedness work for medicinal products. Those structures would in no way change the regulatory system or the decision-making procedures in the area of medical devices already in place in the Union, which should remain clearly distinct from the one for medicinal products. | (24) Given the Agency’s long-standing and proven record of expertise in the field of medicinal products and considering the Agency’s experience from working with a multitude of groups of experts, it is appropriate to establish the appropriate structures within the Agency to monitor potential shortages of medical devices in the context of a public health emergency and to provide the Agency with a mandate to host the expert panels on medical devices. ***In this regard, all national and, eventually, Union entities engaged in stockpiling of medical devices, should report their stocks to the Agency.*** This would allow for long-term sustainability for the functioning of the panels and provide clear synergies with related crisis preparedness work for medicinal products. Those structures would in no way change the regulatory system or the decision-making procedures in the area of medical devices already in place in the Union, which should remain clearly distinct from the one for medicinal products. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>210</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 25</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (25) In order to facilitate the work and the exchange of information under this Regulation, provision should be made for the establishment and management of IT infrastructures and synergies with other existing IT systems or systems under development, including the EUDAMED IT platform for medical devices. ***That work should also be facilitated by, where appropriate, emerging digital technologies such as computational models and simulations for clinical trials, as well as data from the EU Space Programme such as the Galileo geolocation services, and Copernicus earth observation data.*** | (25) In order to facilitate the work and the exchange of information under this Regulation, provision should be made for the establishment and management of IT infrastructures and synergies with other existing IT systems or systems ***under development***, including ***use of the European Medicines Verification System (set up in the context of the Falsified Medicines FMD) data for preventing medicines shortages in an epidemiological crisis by enabling national regulators to assess the availability of products versus what has been consumed or parallel exported in their market, as well as the Substance, product, organisation and referential (SPOR) master management for human medicines and*** the EUDAMED IT platform for medical devices. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>211</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 25</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (25) In order to facilitate the work and the exchange of information under this Regulation, provision should be made for the establishment and management of IT infrastructures and synergies with other existing IT systems or systems under development, including the EUDAMED IT platform for medical devices. That work should also be facilitated by, where appropriate, emerging digital technologies such as computational models and simulations for clinical trials, as well as data from the EU Space Programme such as the Galileo geolocation services, and Copernicus earth observation data. | (25) In order to facilitate the work and the exchange of information under this Regulation, provision should be made for the establishment and management of IT infrastructures and synergies with other existing IT systems or systems under development, including ***the*** ***use of the European Medicines Verification System (set up in the context of the Falsified Medicines FMD) data for mapping consumption for human medicines and preventing medicines shortages, and of the Substance, product, organisation and referential (SPOR) master management for human medicines and*** the EUDAMED IT platform for medical devices. That work should also be facilitated by, where appropriate, emerging digital technologies such as computational models and simulations for clinical trials, as well as data from the EU Space Programme such as the Galileo geolocation services, and Copernicus earth observation data. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>212</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 25</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (25) In order to facilitate the work and the exchange of information under this Regulation, provision should be made for the establishment and management of IT infrastructures and synergies with other existing IT systems or systems under development, including the EUDAMED IT platform for medical devices. That work should also be facilitated by, where appropriate, emerging digital technologies such as computational models and simulations for clinical trials, as well as data from the EU Space Programme such as the Galileo geolocation services, and Copernicus earth observation data. | (25) In order to facilitate the work and the exchange of information under this Regulation, provision should be made for the establishment and management of IT infrastructures and synergies with other existing IT systems or systems under development, including the EUDAMED IT platform for medical devices***, alongside enhanced protection of data infrastructure and dissemination from possible cyberattacks***. That work should also be facilitated by, where appropriate, emerging digital technologies such as computational models and simulations for clinical trials, as well as data from the EU Space Programme such as the Galileo geolocation services, and Copernicus earth observation data. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>213</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 25</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (25) In order to facilitate the work and the exchange of information under this Regulation, provision should be made for the establishment and management of IT infrastructures and synergies with other existing IT systems or systems under development, including the EUDAMED IT platform for medical devices. That work should also be facilitated by, where appropriate, emerging digital technologies such as computational models and simulations for clinical trials, as well as data from the EU Space Programme such as the Galileo geolocation services, and Copernicus earth observation data. | (25) In order to facilitate the work and the exchange of information under this Regulation, provision should be made for the establishment and management of IT infrastructures and synergies with other existing IT systems or systems under development, including ***SPOR data management for human medicines and*** the EUDAMED IT platform for medical devices. That work should also be facilitated by, where appropriate, emerging digital technologies such as computational models and simulations for clinical trials, as well as data from the EU Space Programme such as the Galileo geolocation services, and Copernicus earth observation data. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>214</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 26</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (26) Rapid access and exchange of health data, including real world data i.e. health data generated outside of clinical studies, is essential to ensure effective management of public health emergencies and other major events. This Regulation should allow the Agency to use and facilitate such exchange and be part of the establishment and operation of the European Health Data Space infrastructure. | (26) Rapid access and exchange of health data, including real world data i.e. health data generated outside of clinical studies, is essential to ensure effective management of public health emergencies and other major events. This Regulation should allow the Agency to use and facilitate such exchange and be part of the establishment and operation of the European Health Data Space ***interoperable***infrastructure***, taking advantage of all the potential of the supercomputing, the Artificial Intelligence and the Big Data science to develop predicting models and take better and more timely-effective decisions, without compromising the privacy rights***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>215</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 26</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (26) Rapid access and exchange of health data, including real world data i.e. health data generated outside of clinical studies, is essential to ensure effective management of public health emergencies and other major events. This Regulation should allow the Agency to use and facilitate such exchange and be part of the establishment and operation of the European Health Data Space infrastructure. | (26) Rapid access and exchange of health data, including real world data i.e. health data generated outside of clinical studies, is essential to ensure effective management of public health emergencies and other major events. This Regulation should allow the Agency to use and facilitate such exchange and be part of the establishment and operation of the European Health Data Space infrastructure***,*** ***but with clear rules on controlling access to the data (users with access, data retention period) and ensuring adequate protection of the data***. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>216</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 26 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(26a)*** ***Due to the sensitive nature of health data, the Agency should safeguard and guarantee its processing operations respect the data protection principles of lawfulness, fairness, transparency, purpose limitation, data minimisation, accuracy, storage limitation, integrity and confidentiality. The Agency should strictly respect the principles of data protection as defined in Article 27 of Regulation (EU)2018/1725 EUDPR, while also determining appropriate technical and organisational security measures in accordance with Article 33 EUDPR.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>217</NumAm>

<RepeatBlock-By><Members>Petar Vitanov</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 26 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(26a)*** ***Where it is necessary for the purposes of this Regulation to process personal data, this should be done in accordance with Union law on the protection of personal data. Any processing of personal data based on this Regulation should take place in accordance with Regulations (EU)2016/679 and (EU) 2018/1725.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>218</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 26 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(26a)*** ***In order to facilitate the reliable exchange of medicinal product information in a robust and consistent manner, identification of human medicinal products will be based on ISO IDMP standards.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>219</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 26 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(26b)*** ***Where processing of personal data is not necessary to perform the activities of the Agency, measures should be put in place to ensure use of anonymous data in line with the principle of data minimisation. Where anonymisation would not allow to achieve the specific purpose of the processing, the data should be pseudonymised. Where it is necessary for the purposes of this Regulation to process personal data, this should be carried out in accordance with Union law on the protection of personal data. Any processing of personal data based on this Regulation shall take place in accordance with Regulation 2018/1725 (EUDPR).*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>220</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 26 c (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(26c)*** ***It is imperative to have in place robust transparency measures and standards regarding the Agency’s regulatory activities on medicinal products and medical devices falling under the scope of this Regulation. These measures should include timely publication of all relevant information on approved products and clinical data, including full clinical trial protocols. The Agency should apply high degree of transparency on the membership, recommendations, opinions and decisions of the newly established Steering Groups and the Emergency Task Force. Members of the Steering Groups and the Emergency Task Force should have no financial or other interests in the pharmaceutical or medical device industry which could affect their impartiality.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>221</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 26 d (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(26d)*** ***Credibility of the Agency and public trust in its decisions relies on a high degree of transparency. Therefore, proactive engagement of adequate communication tools with the general public should be foreseen. In addition, strengthened and accelerated transparency standards and measures regarding the Agency’s working bodies and clinical data assessed for the evaluation and surveillance of medicinal products and medical devices are paramount to gain and upheld public trust. This Regulation establishes a framework for these strengthened transparency standards and measures, based on the EMA’s efforts, standards and measures put in place during the Covid-19 pandemic.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>222</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 27</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (27) During a public health emergency or in relation to a major event, the Agency should ensure cooperation with the European Centre for Disease Prevention and Control and other Union Agencies as appropriate. Such cooperation should include data sharing, including data on epidemiological forecasting, regular communication at an executive level, and invitations to representatives of the European Centre for Disease Prevention and Control and other Union Agencies to attend meetings of the Emergency Task Force, the Medicines Steering Group, and the Medical Devices Steering Group, as appropriate. | (27) During a public health emergency or in relation to a major event, the Agency should ensure cooperation with the European Centre for Disease Prevention ***– which should provide forecasts in a timely manner to relevant actor of the pharmaceutical supply chain -*** and Control and other Union Agencies as appropriate. Such cooperation should include data sharing, including data on epidemiological forecasting, regular communication at an executive level, and invitations to representatives of the European Centre for Disease Prevention and Control and other Union Agencies to attend meetings of the Emergency Task Force, the Medicines Steering Group, and the Medical Devices Steering Group, as appropriate. ***Regular two-way communication and exchange of information between regulators, industry and pertinent stakeholders of the pharmaceutical supply chain shall also be guaranteed to kick off prompt debates about estimated potential drug shortages in the market by way of sharing expected supply constraints which authorities become aware of via the notification process, allowing better coordination, interactions and proper response when required*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>223</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Nils Torvalds, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Jan Huitema</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 27</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (27) During a public health emergency or in relation to a major event, the Agency should ensure cooperation with the European Centre for Disease Prevention and Control and other Union Agencies as appropriate. Such cooperation should include data sharing, including data on epidemiological forecasting, regular communication at an executive level, and invitations to representatives of the European Centre for Disease Prevention and Control and other Union Agencies to attend meetings of the Emergency Task Force, the Medicines Steering Group, and the Medical Devices Steering Group, as appropriate. | (27) During a public health emergency or in relation to a major event, the Agency should ensure cooperation with the European Centre for Disease Prevention and Control and other Union Agencies as appropriate. Such cooperation should include data sharing, including data on epidemiological forecasting, regular communication at an executive level, and invitations to representatives of the European Centre for Disease Prevention and Control and other Union Agencies to attend meetings of the Emergency Task Force, the Medicines Steering Group, and the Medical Devices Steering Group, as appropriate. ***This cooperation should also include strategic discussions with relevant entities of the Union in a position to boost the research and development of appropriate solutions and technologies to mitigate the effects of the public health emergency or major event, or prevent future similar public health emergencies or major events, such as the proposed European Health Emergency Preparedness and Response Authority (HERA).*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>224</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 27</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (27) During a public health emergency or in relation to a major event, the Agency should ensure cooperation with the European Centre for Disease Prevention and Control and other Union Agencies as appropriate. Such cooperation should include data sharing, including data on epidemiological forecasting, regular communication at an executive level, and invitations to representatives of the European Centre for Disease Prevention and Control and other Union Agencies to attend meetings of the Emergency Task Force, the Medicines Steering Group, and the Medical Devices Steering Group, as appropriate. | (27) During a ***temporary*** public health emergency or in relation to a major event, the Agency should ensure cooperation with the European Centre for Disease Prevention and Control and other Union Agencies as appropriate. Such cooperation should include data sharing, including data on epidemiological forecasting, regular communication at an executive level, and invitations to representatives of the European Centre for Disease Prevention and Control and other Union Agencies to attend meetings of the Emergency Task Force, the Medicines Steering Group, and the Medical Devices Steering Group, as appropriate. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>225</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 27 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(27a)*** ***Public trust relies on full transparency. Pro-active engagement with adequate communication tools with the general public should be foreseen. Strengthened and accelerated transparency standards and measures regarding the Agency working bodies and clinical data assessed for the evaluation and surveillance of medicinal products and medical devices are paramount to gain and upheld public trust. The EMA has put in place strengthened and accelerated transparency standards and measures during the Covid-19 pandemic. This Regulation establishes a framework for these strengthened transparency standards and measures.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>226</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Jan Huitema</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 27 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(27a)*** ***During a public health emergency or in relation to a major event, the Agency should enable regular exchanges of information with the industry, relevant entities of the pharmaceutical supply chain, representatives of healthcare professionals, patients and consumers, to guarantee early discussions on potential drug shortages in the market and supply constraints, so as to allow better coordination and synergies to mitigate and respond to the public health emergency or major event.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>227</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Jan Huitema, Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 29</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (29) In order to ensure that sufficient resources are available for the work provided for under this Regulation, expenditure of the Agency should be covered by the contribution from the Union to the Agency’s revenue. | (29) In order to ensure that sufficient resources***, including appropriate staffing and adequate expertise,*** are available for the work provided for under this Regulation, expenditure of the Agency should be covered by the contribution from the Union to the Agency’s revenue. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>228</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 29 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(29a)*** ***The Commission retains the right to adjust the Agency's proposed resources and staffing allocation following the upcoming publication of the legislative proposal to establish a European Biomedical Research and Development Agency (BARDA) / European Health Emergency Preparedness and Response Authority (HERA).*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>229</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 31 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(31a)*** ***National Competent Authorities (NCAs) should establish a reliable and harmonised pan-European interoperable and digital reporting system for shortages and preventing duplication of shortages reporting. The standardized reporting requirements for information on clearly defined shortages should be agreed, giving priority to critical products with high potential impact. For this the NCAs should establish a uniform harmonized pan-European interoperable and digital NCAs reporting system consisting of harmonised and common data fields and interoperable with other systems like Substance, product, organisation and referential (SPOR) master management, EMA systems and Industry Single Point of Contact (iSPOC) and operating in a digital environment and having and effective alert system to discriminate between national and/or pan-European shortages.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>230</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 31 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(31a)*** ***National Competent Authorities (NCAs) should establish a reliable and harmonised pan-European interoperable and digital reporting system for shortages and preventing duplication of shortages reporting. The standardized reporting requirements for information on clearly defined shortages should be agreed, giving priority to critical products with high potential impact. For this the NCAs should establish a uniform harmonized pan-European interoperable and digital NCAs reporting system consisting of harmonised and common data fields and interoperable with other systems like Substance, product, organisation and referential (SPOR) master management, EMA systems and Industry Single Point of Contact (iSPOC) and operating in a digital environment and having and effective alert system to discriminate between national and/or pan-European shortages.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>231</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 31 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(31a)*** ***In the specific case of the COVID-19 epidemic, the shortage of adjuvant treatments for the disease had a variety of causes, ranging from production difficulties in third countries to logistical or production difficulties, whilst the shortage of vaccines was due to a rarer cause, namely an unexpectedly high and rising demand.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>232</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 31 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(31a)*** ***It is important to acknowledge the role of the pharmaceutical industry during the COVID-19 crisis and the fact that the industry demonstrated its resilience, through continuous manufacturing, avoiding any major disruption of supply to patients throughout the COVID-19 crisis.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>233</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 31 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(31b)*** ***In order to facilitate the reliable exchange of information on medicinal products in a robust and consistent manner, identification of human medicinal products should be based on the standards of the International Organization for Standardization (ISO) for the identification of medicinal products (IDMP).*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>234</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 31 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(31b)*** ***Shortages consist of different and complex root causes which still need to be further mapped, understood and analysed together with all different stakeholders to be capable of addressing all the different root causes.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>235</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 31 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(31b)*** ***The establishment of an interoperable electronic platform between Member States and the Union is necessary for the prevention, monitoring and reporting of shortages of medicines and medical devices.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>236</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 31 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(31b)*** ***It is important to take into account, in the assessment of potential health emergencies, the contribution of zoonoses and the role of veterinary services where they are involved.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>237</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 31 c (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(31c)*** ***Shortages consist of different and complex root causes which still need to be further mapped, understood and analysed together with all different stakeholders to be capable of addressing all the different root causes. A better understanding of the root causes and drivers of shortages should include identification of bottle necks in the supply chain via the European Medicines Verification System (set up in the context of the Falsified Medicines Directive) could readily be used for this purpose.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>238</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 31 c (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(31c)*** ***It is important to acknowledge the role of the pharmaceutical industry during the Covid-19 crisis and the fact that industry demonstrated resilience, through continued manufacturing, avoiding any major supply disruption for patients during the whole Covid-19 crisis.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>239</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 31 d (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(31d)*** ***Shortages consist of different and complex root causes which still need to be further mapped, understood and analysed together with all different stakeholders to be capable of addressing all the different root causes. A better understanding of the root causes and drivers of shortages should include identification of bottlenecks in the supply chain via the European Medicines Verification System (setup in the context of the Falsified Medicines Directive) could readily be used for this purpose.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>240</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Recital 31 e (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(31e)*** ***During Covid-19 the regulatory flexibility allowed by the Commission has proven to be a tool for industry to prevent shortages. Such regulatory flexibilities, such as electronic product information (e-leaflet), should also be feasible outside of a crisis to help manufacturers to prevent shortages.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>241</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) prepare for and manage the impact of major events on medicinal products for human use and of public health emergencies on medicinal products for human use and on medical devices; | (a) prepare for and manage the impact of major events on medicinal products for human ***and veterinary*** use and of public health emergencies on medicinal products for human ***and veterinary*** use and on medical devices; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>242</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) prepare for ***and*** manage the impact of major events on medicinal products for human use and of public health emergencies on medicinal products for human use and on medical devices; | (a) ***prevent,*** prepare for***,*** manage ***and coordinate at European level*** the impact of major events on medicinal products for human use and of public health emergencies on medicinal products for human use and on medical devices; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>243</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) prepare for and manage the impact of major events on medicinal products for human use and of public health emergencies on medicinal products for human use and on medical devices; | (a) prepare for***, coordinate*** and manage ***at European level*** the impact of major events on medicinal products for human use and of public health emergencies on medicinal products for human use and on medical devices; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>244</NumAm>

<RepeatBlock-By><Members>Traian Băsescu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) prepare for and manage the impact of major events on medicinal products for human use and of public health emergencies on medicinal products for human use and on medical devices; | (a) prepare for and manage the impact of major events ***in order to limit urgently that impact*** on medicinal products for human use and of public health emergencies on medicinal products for human use and on medical devices; |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>245</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) prepare ***for*** and manage the impact of major events on medicinal products for human use and of public health emergencies on medicinal products for human use and on medical devices; | (a) prepare and manage***(at a pan-European level)*** the impact of major events on medicinal products for human use and of public health emergencies on medicinal products for human use and on medical devices; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>246</NumAm>

<RepeatBlock-By><Members>Sara Cerdas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) prepare for and manage the impact of major events on medicinal products for human use and of public health emergencies on medicinal products for human use and on medical devices; | (a) ***prevent,*** prepare for and manage the impact of major events on medicinal products for human use and of public health emergencies on medicinal products for human use and on medical devices; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>247</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point a – point i (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***i)*** ***Set up the relevant harmonised pan-European interoperable and digitalized infrastructure and information systems in place and functional also under normal circumstances to monitor and report on shortages, as a basis to better manage crisis situations;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>248</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point a a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(aa)*** ***Set up the European Union of Health digitalized and interoperable early-warning system of shortages of medicinal products and medical devices, interconnecting national reporting systems, with common definitions and data collection procedures, as a basis to better prevent, manage and coordinate health emergencies at Union level;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>249</NumAm>

<RepeatBlock-By><Members>Traian Băsescu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) monitor and report on shortages of medicinal products for human use and medical devices; | (b) monitor and report on shortages of medicinal products for human use and medical devices***, and adopt all adequate and necessary measures to ensure that shortages of essential medicinal products can be avoided and patients have access to safe medicinal products and treatments at accessible prices***; |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>250</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) monitor and report on shortages of medicinal products for human use and medical devices; | (b) ***prevent,*** monitor and report on shortages of medicinal products for human use and medical devices; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>251</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) monitor and report on shortages of medicinal products for human use and medical devices; | (b) monitor and report ***to prevent*** on shortages of medicinal products for human use and medical devices; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>252</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) monitor and report on shortages of medicinal products for human use and medical devices; | (b) ***prevent,*** monitor and report on shortages of medicinal products for human use and medical devices; |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

A proactive policy of anticipation and prevention of manufacturing disruptions should be streamlined rather than a reactive policy based on monitoring and reporting of shortages exposing European citizens to possible negative consequences.

</Amend>

<Amend>Amendment <NumAm>253</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) monitor and report on shortages of medicinal products for human use and medical devices; | (b) ***prevent,*** monitor and report on shortages of medicinal products for human use and medical devices; |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

A proactive policy of anticipation and prevention of manufacturing disruptions should be streamlined rather than a reactive policy based on monitoring and reporting of shortages exposing European citizens to possible negative consequences.

</Amend>

<Amend>Amendment <NumAm>254</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point b a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(ba)*** ***set up an interoperable and digital database at Union level to track, monitor, report and share information on shortages of medicinal products, devices and applications;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>255</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 1 – paragraph 1 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) provide advice on medicinal products for human use with the potential to address public health emergencies; | (c) provide advice on medicinal products for human ***and veterinary*** use with the potential to address public health emergencies; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>256</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) ‘public health emergency’ means a public health emergency at Union level recognised by the European Commission in accordance with Article 23(1) of Regulation (EU) 2020/[…]17 ; | (a) ‘public health emergency’ means a public health emergency at Union level recognised by the European Commission in accordance with Article 23(1) of Regulation (EU) 2020/[…]17 ***and the Agency will define upfront the actual criteria to capture the drivers of such and emergency in Article 3***; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 17 [insert reference to the Regulation of the European Parliament and of the Council on serious cross-border threats to health and repealing Decision No 1082/2013/EU] OJ C […], […], p. […]. | 17 [insert reference to the Regulation of the European Parliament and of the Council on serious cross-border threats to health and repealing Decision No 1082/2013/EU] OJ C […], […], p. […]. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>257</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) ‘public health emergency’ means a public health emergency at Union level recognised by the European Commission in accordance with Article 23(1) of Regulation (EU) 2020/[…]17 ***;*** | (a) ‘public health emergency’ means a public health emergency at Union level recognised by the European Commission in accordance with Article 23(1) of Regulation (EU)2020/[…] ***and the Agency will define upfront the actual criteria to capture the drivers of such an emergency in Article 3.*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |  |
| 17 [insert reference to the Regulation of the European Parliament and of the Council on serious cross-border threats to health and repealing Decision No 1082/2013/EU] OJ C […], […], p. […]. |  |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>258</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) ‘public health emergency’ means a public health emergency at Union level recognised by the European Commission in accordance with Article 23(1) of Regulation (EU) 2020/[…]17; | (a) ‘public health emergency’ means a ***temporary*** public health emergency at Union level recognised by the European Commission in accordance with Article 23(1) of Regulation (EU) 2020/[…]17; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 17 [insert reference to the Regulation of the European Parliament and of the Council on serious cross-border threats to health and repealing Decision No 1082/2013/EU] OJ C […], […], p. […]. | 17 [insert reference to the Regulation of the European Parliament and of the Council on serious cross-border threats to health and repealing Decision No 1082/2013/EU] OJ C […], […], p. […]. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>259</NumAm>

<RepeatBlock-By><Members>Traian Băsescu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) ‘public health emergency’ means a public health emergency at Union level ***recognised*** by the European Commission in accordance with Article 23(1) of Regulation (EU) 2020/[…]17; | (a) ‘public health emergency’ means a public health emergency at Union level ***declared*** by the European Commission in accordance with Article 23(1) of Regulation (EU) 2020/[…]17; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 17 [insert reference to the Regulation of the European Parliament and of the Council on serious cross-border threats to health and repealing Decision No 1082/2013/EU] OJ C […], […], p. […]. | 17 [insert reference to the Regulation of the European Parliament and of the Council on serious cross-border threats to health and repealing Decision No 1082/2013/EU] OJ C […], […], p. […]. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>260</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point c a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(ca)*** ***'supply' means total volume of stock of an individual medicinal product or medical device that is made available on the national market by a marketing authorisation holder or a manufacturer either distributors, or any other actor in the distribution chain respectively;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>261</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point c a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(ca)*** ***'supply' means total volume of stock of an individual medicinal product or medical device that is placed on the national market by a marketing authorisation holder, a manufacturer, a distributor, or any other actor in the distribution chain respectively;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>262</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point c a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(ca)*** ***'supply' means total volume of stock of an individual medicinal product or medical device that is made available on the national market by a marketing authorisation holder, a manufacturer, a distributors, or any other actor in the distribution chain respectively;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>263</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point c a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(ca)*** ***‘veterinary medicinal product’ means a veterinary medicinal product as defined in paragraph 1(b) of Article 1 of Directive 2004/28/EC of the European Parliament and of the Council;*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>264</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point c b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(cb)*** ***'demand' means total volume of an individual medicinal product or medical device that is requested in the national market in response to a clinical need, including the necessary buffer stock at wholesale level;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>265</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point c b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(cb)*** ***'demand' means total volume of an individual medicinal product or medical device that is requested in the national market in response to treatments need;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>266</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device; | (d) ‘shortage’ means that supply of a medicinal product for human ***or veterinary*** use or a medical device does not meet demand***, i.e. patient needs plus appropriate buffer stocks,*** for that medicinal product or medical device***, no matter the cause***; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>267</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device; | (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device ***for patient and healthcare actors' needs***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>268</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device; | (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device ***for patient and healthcare actors' needs***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>269</NumAm>

<RepeatBlock-By><Members>Cyrus Engerer</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device; | (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand***, that is patient demand together with appropriate buffer stocks,*** for that medicinal product or medical device; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>270</NumAm>

<RepeatBlock-By><Members>Pernille Weiss</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device; | (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet ***patients'*** demand for that medicinal product or medical device ***at national level for a period of more than two weeks***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>271</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet ***demand*** for that medicinal product or medical device; | (d) ‘shortage’ means that supply of a medicinal product for human ***or veterinary*** use or a medical device does not meet ***patient need*** for that medicinal product or medical device ***at national level no matter the cause***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>272</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet ***demand for that medicinal product or medical device***; | (d) 'shortage’ means that supply of a medicinal product for human use or a medical device does not meet ***patient and healthcare actors’ needs;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>273</NumAm>

<RepeatBlock-By><Members>Petar Vitanov</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device; | (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet ***patient*** demand ***plus the appropriate buffer stocks*** for that medicinal product or medical device; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>274</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device; | (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet ***the anticipated***demand for that medicinal product or medical device***, no matter the cause***; |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Shortages must be anticipated and coughed at an early stage to prevent negative impact on the health of patients. Shortages of medicinal products and medical devices have several causes and all of them need to be covered by the definition of ‘shortage’, including the withdrawal of products from the market for commercial reasons

</Amend>

<Amend>Amendment <NumAm>275</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet ***demand for that medicinal product or medical device***; | (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet ***the needs of patients or healthcare professionals***; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>276</NumAm>

<RepeatBlock-By><Members>Carlo Calenda</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet ***demand*** for that medicinal product or medical device; | d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet ***patients’ needs*** for that medicinal product or medical device ***at*** ***national level***; |

Or. <Original>{IT}it</Original>

</Amend>

<Amend>Amendment <NumAm>277</NumAm>

<RepeatBlock-By><Members>Sara Cerdas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device; | (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device***, regardless the cause***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>278</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device; | (d) ‘shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device***, no matter the cause***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>279</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) ***‘***shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device; | (d) shortage’ means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device***, no matter the cause***; |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Shortages of medicinal products and medical devices have several causes and all of them need to be covered by the definition of ‘shortage’, including the parallel trade or the withdrawal of products from the market for commercial reasons. The shortages caused by commercial withdrawals are very frequent and can have a disproportionate impact on patients’ care and public health. Shortages can be extremely long and difficult to solve.

</Amend>

<Amend>Amendment <NumAm>280</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(da)*** ***'supply' means total volume of stock of an individual medicinal product or medical device that is made available on the national market by a marketing authorisation holder, a manufacturer, a distributors, or any other actor in the distribution chain respectively;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>281</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point d b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(db)*** ***'demand' means total volume of an individual medicinal product or medical device that is requested in the national market in response to treatments need;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>282</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point e</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (e) ‘developer’ means any legal or natural person seeking to generate scientific data with regard to the quality, safety and efficacy of a medicinal product as part of that product’s development; | (e) ‘developer’ ***means any*** legal or natural person ***holding intellectual property rights for a medicinal product and who, as part of that product’s development, is seeking*** to generate scientific data with regard to the ***product’s quality***, safety and efficacy of a medicinal product as part of ***that product’s*** development; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>283</NumAm>

<RepeatBlock-By><Members>Pernille Weiss</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point e</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (e) ‘developer’ means any legal or natural person seeking to generate scientific data with regard to the quality, safety and efficacy of ***a*** medicinal product as part of ***that*** product’s development; | (e) ‘developer’ means any legal or natural person ***holding intellectual property rights for a medicinal product who is*** seeking to generate scientific data with regard to the quality, safety and efficacy of ***that*** medicinal product as part of ***the*** product’s development; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>284</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point e</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (e) ‘developer’ means any legal or natural person seeking to generate scientific data with regard to the quality, safety and efficacy ***of a medicinal product as part of that product’s development***; | (e) ‘developer’ means any legal or natural person ***holding intellectual property rights for a medicinal product and who, as part of that product’s development, is*** seeking to generate scientific data with regard to the ***product's*** quality, safety and efficacy; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>285</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (f) ‘major event’ means an event which is likely to pose a serious risk to public health in relation to medicinal products in more than one Member State. Such an event concerns a deadly threat or otherwise serious threat to health of biological, chemical, environmental or other origin or incident that can affect the supply or quality, safety, and efficacy of medicinal products. Such an event may lead to shortages of medicinal products in more than one Member State and necessitates urgent coordination at Union level in order to ensure a high level of human health protection. | (f) ‘major event’ means an event which is likely to pose a serious risk to public health in relation to medicinal products in more than one Member State. Such an event concerns a deadly threat or otherwise serious threat to health of biological, chemical, environmental or other origin or incident that can affect the ***demand and / or*** supply***,*** or quality, safety, and efficacy of medicinal products. Such an event may lead to shortages of ***critical*** medicinal products in more than one Member State and necessitates urgent coordination at Union level in order to ensure a high level of human health protection. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>286</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (f) ‘major event’ means an event which is likely to pose a serious risk to public health in relation to medicinal products in more than one Member State. Such an event concerns a deadly threat or otherwise serious threat to health of biological, chemical, environmental or other origin or incident that can affect the supply or quality, safety, and efficacy of medicinal products. Such an event may lead to shortages of medicinal products in more than one Member State and necessitates urgent coordination at Union level in order to ensure a high level of human health protection. | (f) ‘major event’ means an event which is likely to pose a serious risk to public health in relation to ***human and veterinary*** medicinal products in more than one Member State. Such an event concerns a deadly threat or otherwise serious threat to health of biological, chemical, environmental or other origin or incident that can affect the supply or quality, safety, and efficacy of medicinal products. Such an event may lead to shortages of medicinal products in more than one Member State and necessitates urgent coordination at Union level in order to ensure a high level of human health protection. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>287</NumAm>

<RepeatBlock-By><Members>Pernille Weiss</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (f) ‘major event’ means an event which is likely to pose a serious risk to public health in relation to medicinal products in more than one Member State. Such an event concerns a deadly threat or otherwise serious threat to health of biological, chemical, environmental or other origin or incident that can affect the supply or quality, safety, and efficacy of medicinal products. Such an event may lead to shortages of medicinal products in more than one Member State and necessitates urgent coordination at Union level in order to ensure a high level of human health protection. | (f) ‘major event’ means an event which is likely to pose a serious risk to public health in relation to medicinal products in more than one Member State. Such an event concerns a deadly threat or otherwise serious threat to health of biological, chemical, environmental or other origin or incident that can affect the supply or ***demand,*** quality, safety, and efficacy of medicinal products. Such an event may lead to shortages of ***critical*** medicinal products in more than one Member State and necessitates urgent coordination at Union level in order to ensure a high level of human health protection. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>288</NumAm>

<RepeatBlock-By><Members>Carlo Calenda</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| f) ‘major event’ means an event which is likely to pose a serious risk to public health in relation to medicinal products in more than one Member State. Such an event concerns a deadly threat or otherwise serious threat to health of biological, chemical, environmental or other origin or incident that can affect the supply or quality, safety, and efficacy of medicinal products. Such an event may lead to shortages of medicinal products in more than one Member State and necessitates urgent coordination at Union level in order to ensure a high level of human health protection. | f) ‘major event’ means an event which is likely to pose a serious risk to public health in relation to medicinal products in more than one Member State. Such an event concerns a deadly threat or otherwise serious threat to health of biological, chemical, environmental or other origin or incident that can affect the ***demand and/or*** supply or quality, safety, and efficacy of medicinal products. Such an event may lead to shortages of medicinal products in more than one Member State and necessitates urgent coordination at Union level in order to ensure a high level of human health protection. |

Or. <Original>{IT}it</Original>

</Amend>

<Amend>Amendment <NumAm>289</NumAm>

<RepeatBlock-By><Members>Traian Băsescu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (f) ‘major event’ means an event which is likely to pose a serious risk to public health in relation to medicinal products in more ***than one*** Member State. Such an event concerns a deadly threat or otherwise serious threat to health of biological, chemical, environmental or other origin or incident that can affect the supply or quality, safety, and efficacy of medicinal products. Such an event may lead to shortages of medicinal products in more than one Member State and necessitates urgent coordination at Union level in order to ensure a high level of human health protection. | (f) ‘major event’ means an event which is likely to pose a serious risk to public health in relation to medicinal products in ***one or*** more Member State. Such an event concerns a deadly threat or otherwise serious threat to health of biological, chemical, environmental or other origin or incident that can affect the supply or quality, safety, and efficacy of medicinal products. Such an event may lead to shortages of medicinal products in more than one Member State and necessitates urgent coordination at Union level in order to ensure a high level of human health protection. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>290</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fa)*** ***‘demand’ relates to the request for a medicinal product or a medical device by a healthcare professional or patient in response to a clinical need. For demand to be satisfactorily met, the medicinal product will need to be acquired in time and sufficient quantity to allow continuity of best care of patients, while following real, adequate prescription needs.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>291</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fa)*** ***‘critical medicinal product’ means any medicinal product for human and veterinary use within the meaning of Article 1(2) of Directive 2001/83/EC of the European Parliament and of the Council, or a constituent thereof, that is considered necessary for the management of a public health emergency and until such time as the emergency is resolved.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>292</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fa)*** ***‘major non-communicable disease’ means a chronic disease which tends to be of long duration and is the result of a combination of genetic, physiological, environmental and behavioural factors, such as a cardiovascular disease, cancer, respiratory disease, diabetes or mental illness, and which affects a significant number of people in the Union.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>293</NumAm>

<RepeatBlock-By><Members>Sara Cerdas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fa)*** ***‘demand’ relates to the request for a medicinal product or a medical device by a healthcare professional or patient in response to a clinical need. For demand to be satisfactorily met, the medicinal product will need to be acquired in time and sufficient quantity to allow continuity of best care of patients.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>294</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fa)*** ***‘demand’ relates to the request for a medicinal product or a medical device by a healthcare professional or patient in response to a clinical need. For demand to be satisfactorily met, the medicinal product will need to be acquired in time and sufficient quantity to allow continuity of best care of patients.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>295</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fa)*** ***‘demand’ relates to the request for a medicinal product or a medical device by a healthcare professional or patient in response to a clinical need. For demand to be satisfactorily met, the medical product will need to be acquired in time and sufficient quantity to allow continuity of best care of patients.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

‘Demand’ needs to be defined in the regulation as it determines the scope of shortages, which are at the core of the text. We recommend using as a basis the inclusive definition proposed in the EMA/HMA Guidance on the detection and notification of shortages of medicinal products for marketing authorisation holders. It acknowledges that healthcare professionals are the main prescribers of medicines and medical devices, while the ultimate objective is to guarantee the continuity of best care of patients.

</Amend>

<Amend>Amendment <NumAm>296</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fa)*** ***'demand' means total volume of an individual medicinal product or medical device that is requested in the national market in response to a clinical need*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>297</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fa)*** ***‘Health in all policies’ means health in all policies as defined in Regulation (EU) .../... EU 4 Health [OJ: ...]*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>298</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fb)*** ***‘supply’ refers to the total volume of stock of an individual medicinal product or a medical device that is placed on the market by the Marketing Authorisation Holder or the producer, including situations in which a product is withdrawn from the market for commercial reasons.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

‘Supply’ needs to be defined in the regulation as it determines the scope of shortages, which are at the core of the text. We recommend using as a basis the definition proposed in the EMA/HMA Guidance on the detection and notification of shortages of medicinal products for MHAs8, making clear that it should also cover situations in which the MAH withdraws a product from the market for commercial reasons.

</Amend>

<Amend>Amendment <NumAm>299</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fb)*** ***‘supply’ refers to the total volume of stock of an individual medicinal product or a medical device that is placed on the market by the Marketing Authorisation Holder or the producer, including situations in which a product is withdrawn from the market for commercial reasons.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>300</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fb)*** ***‘One Health approach’ means One health approach as defined in Regulation(EU) .../... EU 4 Health [OJ: ...]*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>301</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f c (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fc)*** ***‘zoonosis’ means an infectious disease that has jumped from a non-human animal to humans through zoonotic spill-over;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>302</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f d (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fd)*** ***‘zoonotic spill-over’ is the spread of a non-human disease to humans resulting in zoonosis;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>303</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f e (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fe)*** ***'veterinary medicinal product' means a medicinal product as defined in point (1) of Article 4 of Regulation (EU) 2019/6 of the European Parliament and the Council;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>304</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f f (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(ff)*** ***'supply' means total volume of stock of a medicinal product, a medical device, or a medical application, that is placed on the market by a marketing authorisation holder or a manufacturer;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>305</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 – point f g (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fg)*** ***‘supply chain’ is a steps-based network of activities, information and resources between a manufacturer company and its suppliers willing to produce and distribute a specific product to the final buyer;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>306</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 – paragraph 1 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***'supply' means total volume of stock of an individual medicinal product or medical device that is made available on the national market by a marketing authorisation holder or a manufacturer either distributors, or any other actor in the distribution chain respectively;*** |
|  | ***'demand' means total volume of an individual medicinal product or medical device that is requested in the national market in response to a clinical need;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>307</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 2 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | Article 2 a |
|  | The setting of a European Union of Health digitalized and interoperable early-warning system |
|  | ***1. In order to better manage health crisis, a European Union of Health digitalized and interoperable early-warning system to monitor and report all medicines shortage is hereby established, through an infrastructure which is in place and functional also under normal circumstances.*** |
|  | ***2. Through such a harmonized, digitalized and interoperable system, the reporting shall be based on collecting data at the national level, with data collected on common definitions and procedures, covering both Centralised and National Marketing Authorisations. The Agency shall receive, when relevant, aggregated data from national databases to monitor any potential cross-border shortages.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>308</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. The Executive Steering Group on Shortages and Safety of Medicinal Products (‘the Medicines Steering Group’) is hereby established as part of the Agency. It shall meet either in person or remotely, in preparation for or during a public health emergency or following a request for assistance referred to in Article 4(3). The Agency shall provide its secretariat. | 1. The Executive Steering Group on Shortages and Safety of ***Human and Veterinary*** Medicinal Products (‘the Medicines Steering Group’) is hereby established as part of the Agency. It shall meet either in person or remotely, in preparation for or during a public health emergency or following a request for assistance referred to in Article 4(3). The Agency shall provide its secretariat. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>309</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. The Executive Steering Group on Shortages and Safety of Medicinal Products (‘the Medicines Steering Group’) is hereby established as part of the Agency. It shall meet either in person or remotely, in preparation for or during a public health emergency or following a request for assistance referred to in Article 4(3). The Agency shall provide its secretariat. | 1. The Executive Steering Group on Shortages and Safety of Medicinal Products (‘the Medicines Steering Group’) is hereby established as part of the Agency. It shall meet ***as often as needed,*** either in person or remotely, in preparation for or during a public health emergency or following a request for assistance referred to in Article 4(3). The Agency shall provide its secretariat. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>310</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 1 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***1 a.*** ***The Medicines Steering Group will be established for a fixed term and will cease its activities when the health emergency or the imminent major event has been declared to end;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>311</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. The Medicines Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. | 2. The Medicines Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. ***Those Member States with devolved competences in health may appoint a representative from a regional competent authority who will represent the whole Member State.*** Members may be accompanied by experts in specific scientific or technical fields. ***The Steering Group shall also include a representative of the Patients’ and Consumers’ Working Party as well as a representative of the Healthcare Professionals’ Working Party as observers.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>312</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. The Medicines Steering Group shall be composed of a representative of the Agency, a representative of the Commission ***and*** one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. | 2. The Medicines Steering Group shall be composed of a representative of the Agency, a representative of the Commission***,*** one senior representative per Member State***, a representative of the Patients' and Consumers' Working Party (PCWP) and a representative of the Healthcare Professionals' Working Party (HCPWP)***. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. ***The list of members of the Steering Group shall be made public on the EMA web-portal.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Patients, consumers and HCPs need to be part of the Steering Group as shortages primarily impact patients’ health and care. Their experience as end-users or healthcare professionals/providers is needed to identify medicines considered as critical for public health and/or patients’ best care in crisis situations, and to provide adequate recommendations and guidelines to prevent or mitigate shortages. It would also help improve the transparency and communication on the Steering Group activities, as the two representatives would report to the EMA PCWP and HCPWP.

</Amend>

<Amend>Amendment <NumAm>313</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. The Medicines Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. | 2. The Medicines Steering Group shall be composed of a representative of the Agency, a representative of the Commission***, a representative of the Patients' organizations, a representative of the Healthcare Professionals' organizations*** and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. ***The list of the members of the Steering Group shall be transparent and made public on the EMA web-portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>314</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. The Medicines Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. | 2. The Medicines Steering Group shall be composed of a representative of the Agency, a representative of the Commission***,*** and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. ***The Steering Group shall also include a representative of the Patients’ and Consumers’ Working Party and a representative of the Healthcare Professionals’ Working Party.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The Regulation must allow patients to contribute their expertise to decision-making processes regarding the development of new medicines and the availability of critical products. This will help ensure that new pharmaceutical products meet the needs and expectations of end users. Likewise, it will contribute to improving the management of shortages by including the views of those most affected by supply disruptions.

</Amend>

<Amend>Amendment <NumAm>315</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. The Medicines Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. | 2. The Medicines Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. ***The Steering Group shall also include a representative the Patients’ and Consumers’ Working Party and a representative of the Healthcare Professionals’ Working Party.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>316</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. The Medicines Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. | 2. The Medicines Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State***, as well as one alternate for unforeseen circumstances***. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>317</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. The Medicines Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. | 2. The Medicines Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one ***authorised*** senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>318</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 2 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***2 a.*** ***Members of the Medicines Steering Group must have no financial or other interests that could affect their impartiality. They shall act in the public interest and in an independent manner and make an annual declaration of their financial interests. All indirect interests which could relate to the industry shall be entered in a register held by the Agency and be accessible to the public, upon request.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>319</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medicinal product interest groups ***and*** marketing authorisation holders to attend its meetings. | 3. The Medicines Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medicinal product interest groups***,*** marketing authorisation holders ***or any other entity in the relevant pharmaceutical supply chain***, ***healthcare professionals and patients’ associations,*** to attend its meetings ***to ensure transparent and effective dialogue between all stakeholders in the supply chain and the relevant authorities***. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>320</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders to attend its meetings. | 3. The Medicines Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders to attend its meetings. ***The Chair shall ensure that a broad spectrum of opinions is taken into account. The chair shall ensure that the stakeholders in the medicines supply chain can give an informed opinion about the situation in the various Member States concerned;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>321</NumAm>

<RepeatBlock-By><Members>Sara Cerdas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall be chaired by the Agency. The Chair ***may*** invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders to attend its meetings. | 3. The Medicines Steering Group shall be chaired by the Agency. ***All members of the Medicines Steering Group may propose to*** the Chair ***to*** invite third parties, including representatives of medicinal product interest groups***, representatives of healthcare professionals, patients and consumers,*** and marketing authorisation holders to attend its meetings ***when their contribution may inform the discussions of the Steering Group***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>322</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall be chaired by the Agency. The Chair ***may*** invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders to attend its meetings. | 3. The Medicines Steering Group shall be chaired by the Agency. ***All members of the Medicines Steering Group may propose to*** the Chair ***to*** invite third parties, including representatives of medicinal product interest groups***, in particular healthcare professionals, patients, consumers*** and marketing authorisation holders to attend its meetings ***when their contribution may inform the discussions of the Steering Group***. |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

All members of the Steering Group should be allowed to propose inviting third parties which have information, experience or expertise that could help the discussions and decisions of the SG. Healthcare professionals, patients and consumers have a first-hand experience and invaluable insight into medicine shortages, which may however differ according to their position, country, profession, disease area. The invitation of single organisations based on their specific expertise is thus complementary to the participation of representatives of PCWP and HCPWP as members of the SG.

</Amend>

<Amend>Amendment <NumAm>323</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall be chaired by the Agency. The Chair ***may*** invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders to attend its meetings. | 3. The Medicines Steering Group shall be chaired by the Agency. ***On a regular basis,*** the Chair ***shall*** invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders to attend its meetings. ***In the event of an actual or imminent major event, the Chair shall invite relevant entities from the pharmaceutical supply chain to attend its meetings.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>324</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medicinal product interest groups ***and*** marketing authorisation holders to attend its meetings. | 3. The Medicines Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medicinal product interest groups***,*** marketing authorisation holders***, representatives of healthcare professionals, and of patients*** to attend its meetings***, when their contribution may inform the discussions of the Steering Group***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>325</NumAm>

<RepeatBlock-By><Members>Adam Jarubas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall be chaired by the Agency. The Chair ***may*** invite third parties, including representatives of medicinal product interest groups ***and*** marketing authorisation holders to attend its meetings. | 3. The Medicines Steering Group shall be chaired by the Agency. The Chair ***shall*** invite third parties, including representatives of medicinal product interest groups***,*** marketing authorisation holders ***and other representatives of the pharmaceutical supply chain*** to attend its meetings ***and actively participate in the dialog with the authorities***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>326</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders to attend its meetings. | 3. The Medicines Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders***, representatives of healthcare professionals, patients and consumers*** to attend its meetings. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>327</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders to attend its meetings. | 3. The Medicines Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders***, representatives of patients, consumers and healthcare professionals*** to attend its meetings. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>328</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders to attend its meetings. | 3. The Medicines Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders***, representatives of patients, consumers and healthcare professionals*** to attend its meetings. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>329</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders to attend its meetings. | 3. The Medicines Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders***, and other stakeholders in the medicines supply chain,*** to attend its meetings. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>330</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall be chaired by the Agency. The Chair ***may*** invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders to attend its meetings. | 3. The Medicines Steering Group shall be chaired by the Agency. The Chair ***shall*** invite third parties, including representatives of medicinal product interest groups and marketing authorisation holders to attend its meetings. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>331</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 3 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***3a.*** ***The Medicines Steering Group shall regularly invite representatives of interest groups in the field of medicinal products and marketing authorisation holders, as well as other stakeholders in the pharmaceutical industry to exchange regularly on the situation of medicine production in Europe and worldwide. On the basis of these exchanges, the Medicines Steering Group shall draw up strategic recommendations which it shall address to the Member States during the public health emergency period.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>332</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. The Medicines Steering Group shall establish its rules of procedure including procedures relating to the working party referred to the paragraph 5 and on the adoption of lists, sets of information, and recommendations. The rules of procedure shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. | 4. The Medicines Steering Group shall establish its rules of procedure including procedures relating to the working party referred to the paragraph 5 and on the adoption of lists, sets of information, and recommendations. The rules of procedure shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. ***The agenda and minutes of the Steering Group as well as the rules of procedure and recommendations shall be made available to the public via the EMA web-portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>333</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. The Medicines Steering Group shall establish its rules of procedure including procedures relating to the working party referred to the paragraph 5 and on the adoption of lists, sets of information, and recommendations. The rules of procedure shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. | 4. The Medicines Steering Group shall establish its rules of procedure including procedures relating to the working party referred to the paragraph 5 and on the adoption of lists, sets of information, and recommendations. The rules of procedure shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. ***Agendas and minutes of the Steering Group as well as the rules of procedure and recommendations shall be made available to the public via the EMA web-portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>334</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska, Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. The Medicines Steering Group shall establish its rules of procedure including procedures relating to the working party referred to the paragraph 5 and on the adoption of lists, sets of information, and recommendations. The rules of procedure shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. | 4. The Medicines Steering Group shall establish its rules of procedure including procedures relating to the working party referred to the paragraph 5 and on the adoption of lists, sets of information, and recommendations. The rules of procedure shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. ***The agenda, minutes and recommendations of the Medicines Steering Group shall be made available to the public through the Agency's online portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>335</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. The Medicines Steering Group shall establish its rules of procedure including procedures relating to the working party referred to the paragraph 5 and on the adoption of lists, sets of information, and recommendations. The rules of procedure shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. | 4. The Medicines Steering Group shall establish its rules of procedure including ***the clarified mention of its competences,*** procedures relating to the working party referred to the paragraph 5 and on the adoption of lists, sets of information, and recommendations. The rules of procedure shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>336</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Medicines Steering Group shall be supported in its work by a working party comprised of single points of contact related to shortages from national competent authorities for medicinal products established in accordance with Article 9(1). | 5. The Medicines Steering Group shall be supported in its work by a working party comprised of single points of contact related to shortages from national***, and where applicable regional,*** competent authorities for medicinal products established in accordance with Article 9(1). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>337</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 5 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***5 a.*** ***The Medicines Steering Group shall be supported in its work by a working party comprised of industry single points of contact related to shortages (iSPOC) and a two way communication line need to be established between the Medicines Steering Group and the iSPOC.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>338</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 5 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***5 a.*** ***The Medicines Steering Group shall be supported in its work by a working party comprised of industry single points of contact related to shortages (iSPOC) and a two way communication line need to be established between the Medicines Steering Group and the iSPOC.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>339</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 6</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 6. The Medicines Steering Group shall be responsible for fulfilling the tasks referred to in Article ***4(4)*** and Articles 5 to 8. | 6. The Medicines Steering Group shall be responsible for fulfilling the tasks referred to in Article ***4(3), 4 (4)*** and Articles 5 to 8. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>340</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***6a.*** ***All members of the Medicines Steering Group shall comply with the usual rules in force in the Union on conflicts of interest, in accordance with Article 107 of Regulation (EU) 2017/745 of the European Parliament and of the Council.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>341</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***6 a.*** ***The Medicines Steering Group together with the industry (via the industry single points of contacts - iSPOCs) shall determine the list of critical products and any future actions taken for the molecules included on the critical product list.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>342</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***6 a.*** ***The members of the Medicines Steering Group must have no financial or other interests that could affect their impartiality. The list of members shall be published on the EMA’s website.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>343</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***6 a.*** ***The members of the Medicines Steering Group must have no financial or other interests that could affect their impartiality. The list of members shall be published on the EMA’s website.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Unlike in the section that describes the functioning of the Emergency Task Force, there is no reference in the proposed Regulation about the need to ensure the impartiality of the members of the Steering Groups. This should be addressed.

</Amend>

<Amend>Amendment <NumAm>344</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión, Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 3 – paragraph 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***6 a.*** ***The Medicines Steering Group shall exercise its competencies in full compliance with the principles of proportionality and subsidiarity;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>345</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 - title</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| Monitoring of events and preparedness for major events and public health emergencies | Monitoring of events and preparedness for ***temporary*** major events and public health emergencies |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>346</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. The Agency shall continuously monitor any event that ***is likely*** to lead to a major event or a public health emergency. | 1. The Agency shall continuously monitor any event that ***has the potential*** to lead to a major event or a public health emergency. ***In this regard, the Agency shall cooperate closely with the European Centre for Disease Prevention and Control (ECDC) and other Union agencies, where relevant.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>347</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. The Agency shall continuously monitor any event that is likely to lead to a major event or a public health emergency. | 1. The Agency shall continuously monitor any event that is likely to lead to a major event or a public health emergency ***and it shall be capable of establishing the necessary preventive mechanisms that are necessary***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>348</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. The Agency shall continuously monitor any event that is likely to lead to a major event or a public health emergency. | 1. The Agency shall continuously monitor any event that is likely to lead to a major event or a public health emergency ***in coordination with the relevant national or regional authorities***. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>349</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. The Agency shall continuously monitor any event that is likely to lead to a major event or a public health emergency. | 1. The Agency shall continuously monitor any event that is likely to lead to a major event or a public health emergency ***in coordination with the national and regional competent authorities***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>350</NumAm>

<RepeatBlock-By><Members>Stanislav Polčák</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. The Agency shall continuously monitor any event that is likely to lead to a major event or a public health emergency. | 1. The Agency shall continuously monitor any event ***in the Union or in third countries*** that is likely to lead to a major event or a public health emergency. |

Or. <Original>{CS}cs</Original>

</Amend>

<Amend>Amendment <NumAm>351</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. The Agency shall continuously monitor any event that is likely to lead to a major event or a public health emergency. | 1. The Agency***, in coordination with the ECDC,*** shall continuously monitor any event that is likely to lead to a major event or a public health emergency. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>352</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), ***report to the Agency on*** any event, including a shortage of a medicinal product in a given Member State, that is likely to lead to a major event or a public health emergency. Where a national competent authority ***informs the Agency*** of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing ***authorisation*** holder pursuant to Article 23a of Directive 2001/83/EC. Based on a report of an event from a national competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). | 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), ***upload in the harmonised pan-European interoperable and digitalized shortages reporting and notification system,*** any event, including a shortage of a medicinal product in a given Member State, that is likely to lead to a major event or a public health emergency. Where a national competent authority ***uploads the information*** of a shortage of a medicinal product in a given Member State ***on the pan-European harmonized system***, it shall provide the Agency with any information received from the marketing ***authorization*** holder pursuant to Article 23a of Directive 2001/83/EC***. The information uploaded in the pan-European system are directly accessible for the Agency and national competent authorities and while avoiding duplications of reporting, it shall support a two-way communication between authorities and industry to provide the transparency needed to take actions to prevent and mitigate cross border shortages***. Based on a report of an event from a national competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>353</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), report to the Agency on any event, including a shortage of a medicinal product in a given Member State, that is likely to lead to a major event or a public health emergency. Where a national competent authority informs the Agency of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing authorisation holder pursuant to Article 23a of Directive 2001/83/EC. Based on a report of an event from a national competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). | 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), report to the Agency on any event, including a shortage of a ***human or veterinary*** medicinal product in a given Member State, that is likely to lead to a major event or a public health emergency ***in other Member States***. Where a national competent authority informs the Agency of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing authorisation holder pursuant to Article 23a of Directive 2001/83/EC***, as well as any relevant additional information provided by stakeholders and actors in the pharmaceutical industry, with due regard for confidentiality and privacy, as provided for in Regulation (EU) 2016/769 of the European Parliament and of the Council (General Data Protection Regulation – GDPR)***. Based on a report of an event from a national competent authority and in order to understand ***and, in particular, anticipate*** the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>354</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), report to the Agency on any event, including a shortage of a medicinal product in a given Member State, that is likely to lead to a major event or a public health emergency. Where a national competent authority informs the Agency of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing authorisation holder pursuant to Article 23a of Directive 2001/83/EC. Based on a report of an event from a national competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). | 2. To facilitate the monitoring task referred to in paragraph 1, the national***, and where applicable regional,*** competent authorities, through the single points of contact referred to in Article 3(5) ***or the digital interoperable database referred to in Article 1(b) and Article 12(g)***, shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), report to the Agency on any event, including a shortage of a medicinal product in a given Member State, that is likely to lead to a major event or a public health emergency. Where a national***, and where applicable regional,*** competent authority informs the Agency of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing authorisation holder pursuant to Article 23a of Directive 2001/83/EC. Based on a report of an event from a national ***or regional*** competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national ***and where applicable regional,*** competent authorities, through the working party referred to in Article 3(5). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>355</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), report to the Agency on any event, including a shortage of a medicinal product in a given Member State, that is likely to lead to a major event or a public health emergency. Where a national competent authority informs the Agency of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing authorisation holder pursuant to Article 23a of Directive 2001/83/EC. Based on a report of an event from a national competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). | 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), report to the Agency***, in due time, in an interoperable and digitalized platform for reporting and notifying shortages,*** on any event, including a shortage of a medicinal product in a given Member State, that is likely to lead to a major event or a public health emergency. Where a national competent authority informs the Agency of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing authorisation holder pursuant to Article 23a of Directive 2001/83/EC. Based on a report of an event from a national competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>356</NumAm>

<RepeatBlock-By><Members>Carlo Calenda</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), report to the Agency on any ***event, including a*** shortage of a medicinal product in a given Member State, that is likely to ***lead*** to a major event or a public health emergency. Where a national competent authority informs the Agency of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing authorisation holder pursuant to Article 23a of Directive 2001/83/EC. Based on a report of an event from a national competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). | 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), report to the Agency on any ***potential*** shortage of a medicinal product in a given Member State, that is likely to ***jeopardise a timely and appropriate response*** to a major event or a public health emergency. Where a national competent authority informs the Agency of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing authorisation holder pursuant to Article 23a of Directive 2001/83/EC. Based on a report of an event from a national competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). |

Or. <Original>{IT}it</Original>

</Amend>

<Amend>Amendment <NumAm>357</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), report to the Agency on any event, including a shortage of a medicinal product in a given Member State, that is likely to lead to a major event or a public health emergency. Where a national competent authority informs the Agency of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing authorisation holder pursuant to Article 23a of Directive 2001/83/EC. Based ***on a*** report of an event from a national competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). | 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), report to the Agency on any ***potential*** event, including a shortage of a ***critical*** medicinal product in a given Member State, that is likely to lead to ***following*** a major event or a public health emergency. Where a national competent authority informs the Agency of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing authorisation holder pursuant to Article 23a of Directive 2001/83/EC. Based ***on a*** report of an event from a national competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>358</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), report to the Agency on any event, including a shortage of a medicinal product in a given Member State, that is likely to lead to a major event or a public health emergency. Where a national competent authority informs the Agency of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing authorisation holder pursuant to Article 23a of Directive 2001/83/EC. Based on a report of an event from a national competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). | 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), report ***without delay*** to the Agency on any event, including a shortage of a medicinal product in a given Member State, that is likely to lead to a major event or a public health emergency. Where a national competent authority informs the Agency of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing authorisation holder pursuant to Article 23a of Directive 2001/83/EC. Based on a report of an event from a national competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>359</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), report to the Agency on any event, including a shortage of a medicinal product in a given Member State, that ***is likely*** to lead to a major event or a public health emergency. Where a national competent authority informs the Agency of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing authorisation holder pursuant to Article 23a of Directive 2001/83/EC. Based on a report of an event from a national competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). | 2. To facilitate the monitoring task referred to in paragraph 1, the national competent authorities, through the single points of contact referred to in Article 3(5), shall, based on the reporting criteria specified by the Agency pursuant to Article 9(1)(b), report to the Agency on any event, including a shortage of a medicinal product in a given Member State, that ***has the potential*** to lead to a major event or a public health emergency. Where a national competent authority informs the Agency of a shortage of a medicinal product in a given Member State, it shall provide the Agency with any information received from the marketing authorisation holder pursuant to Article 23a of Directive 2001/83/EC. Based on a report of an event from a national competent authority and in order to understand the impact of the event in other Member States, the Agency may request information from the national competent authorities, through the working party referred to in Article 3(5). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>360</NumAm>

<RepeatBlock-By><Members>Stanislav Polčák</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. Where the Agency considers that an actual or imminent major event needs to be addressed, it shall inform the Commission and the Member States thereof. The Commission, on its own initiative or following a request from one or more Member States, or the Executive Director of the Agency may request the assistance of the Medicines Steering Group to address the major event. | 3. Where the Agency considers that an actual or imminent major event needs to be addressed, it shall inform the Commission and the Member States thereof. The Commission, on its own initiative or following a request from one or more Member States, or the Executive Director of the Agency may request the assistance of the Medicines Steering Group to address the major event. ***Where requested to do so by at least two Member States or the Executive Director of the Agency, the Commission shall request the assistance of the Steering Group.*** |

Or. <Original>{CS}cs</Original>

</Amend>

<Amend>Amendment <NumAm>361</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. Where the Agency considers that an actual or imminent major event needs to be addressed, it shall inform the Commission and the Member States thereof. The Commission***, on its own initiative or following a request from one or more Member States, or the Executive Director of the Agency may*** request the assistance of the Medicines Steering Group to address the major event. | 3. Where the Agency considers that an actual or imminent major event needs to be addressed, it shall inform the Commission and the Member States thereof. The Commission ***shall then*** request the assistance of the Medicines Steering Group to address the major event. |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The proposed Regulation gives the option to the Commission to request the assistance of a Medicines Steering Group composed by Member State representatives, as soon as a major event that can put at risk the safety or availability of pharmaceutical products is identified. Considering the vital role that such a body can play in the management of major events, most notably by fostering coordination and joint action mong Member States, it is crucial that the Steering Group is convened as soon as a major event is identified.

</Amend>

<Amend>Amendment <NumAm>362</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. Where the Agency considers that an actual or imminent major event needs to be addressed, it shall inform the Commission and the Member States thereof. The Commission***, on its own initiative or following a request from one or more Member States, or the Executive Director of the Agency may*** request the assistance of the Medicines Steering Group to address the major event. | 3. Where the Agency considers that an actual or imminent major event needs to be addressed, it shall inform the Commission and the Member States thereof. The Commission***shall then*** request the assistance of the Medicines Steering Group to address the major event. |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The proposed Regulation gives the option to the Commission to request the assistance of a Medicines Steering Group composed by Member State representatives, as soon as a major event that can put at risk the safety or availability of pharmaceutical products is identified. Considering the vital role that such a body can play in the management of major events, most notably by fostering coordination and joint action mong Member States, it is crucial that the Steering Group is convened as soon as a major event is identified.

</Amend>

<Amend>Amendment <NumAm>363</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. Where the Agency considers that an actual or imminent major event needs to be addressed, it shall inform the Commission and the Member States thereof. The Commission***, on its own initiative or following a request from one or more Member States, or the Executive Director of the Agency may*** request the assistance of the Medicines Steering Group to address the major event. | 3. Where the Agency considers that an actual or imminent major event needs to be addressed, it shall inform the Commission and the Member States thereof. The Commission ***shall then*** request the assistance of the Medicines Steering Group to address the major event. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>364</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. Where the Agency considers that an actual or imminent major event needs to be addressed, it shall inform the Commission and the Member States thereof. The Commission, ***on its own initiative or following a request from one or more Member States,*** or the Executive Director of the Agency ***may*** request the assistance of the Medicines Steering Group to address the major event. | 3. Where the Agency considers that an actual or imminent major event needs to be addressed, it shall inform the Commission and the Member States thereof. The Commission, or the Executive Director of the Agency ***shall*** request the assistance of the Medicines Steering Group to address the major event. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>365</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 4 – paragraph 5 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) where the major event or public health emergency may affect the safety, quality, and efficacy of medicinal products, Article 5 shall apply; | (a) where the major event or public health emergency may affect the ***production, manufacturing,*** safety, quality, ***distribution*** and efficacy of medicinal products, ***devices and applications*** Article ***5 shall*** apply; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>366</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 5 – title</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| Evaluation of information and the provision of advice on action in relation to the safety, quality, and efficacy of medicinal products related to public health emergencies and major events | Evaluation of information and the provision of advice on action in relation to the ***production, manufacturing,*** safety, quality, ***distribution*** and efficacy of medicinal products***, devices and applications*** related to public health emergencies and major events |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>367</NumAm>

<RepeatBlock-By><Members>Stanislav Polčák</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 5 – title</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| Evaluation of information and the provision of advice on action in relation to the safety, quality, and efficacy of medicinal products related to public health emergencies and major events | *(Does not affect English version.)* |

Or. <Original>{CS}cs</Original>

</Amend>

<Amend>Amendment <NumAm>368</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 5 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| Following the recognition of a public health emergency or a request for assistance referred to in Article 4(3), the Medicines Steering Group shall evaluate the information related to the major event or the public health emergency and consider the need for urgent and coordinated action with regard to the safety, quality, and efficacy of ***the*** medicinal products concerned. | Following the recognition of a public health emergency or a request for assistance referred to in Article 4(3), the Medicines Steering Group shall evaluate the information related to the major event or the public health emergency and consider the need for urgent and coordinated action with regard to the ***production, manufacturing,*** safety, quality, ***distribution*** and efficacy of medicinal products***, devices and applications*** concerned. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>369</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 5 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| Following the recognition of a public health emergency or a request for assistance referred to in Article 4(3), the Medicines Steering Group shall evaluate the information related to the major event or the public health emergency and consider the need for urgent and coordinated action with regard to the safety, quality, and efficacy of the medicinal products concerned. | Following the ***express*** recognition of a public health emergency or a request for assistance referred to in Article 4(3), the Medicines Steering Group shall evaluate the information related to the major event or the public health emergency and consider the need for urgent and coordinated action with regard to the safety, quality, and efficacy of the medicinal products concerned. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>370</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 5 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Medicines Steering Group shall provide advice to the Commission and Member States on any appropriate action it believes should be taken at Union level on the medicinal products concerned in accordance with the provisions of Directive 2001/83/EC or Regulation (EC) No 726/200418. | The Medicines Steering Group shall provide advice ***and recommendations*** to the Commission and Member States on any appropriate action it believes should be taken at Union level on the medicinal products concerned in accordance with the provisions of Directive 2001/83/EC or Regulation (EC) No 726/200418. |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 18 Regulation (EC) No 726/2004 | 18 Regulation (EC) No 726/2004 |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>371</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. Following a request for assistance referred to in Article 4(3) and after consultation of its working party, the Medicines Steering Group shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the major event (‘the major event critical medicines list’). The list shall be updated whenever necessary until the major event has been sufficiently addressed. | 1. Following a request for assistance referred to in Article 4(3) and after consultation of its working party, the Medicines Steering Group***, after consulting the marketing authorisation holders and representatives of stakeholders in the sector,*** shall adopt a list of ***human and veterinary*** medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the major event (‘the major event critical medicines list’). The list shall be updated whenever necessary until the major event has been sufficiently addressed***, and shall cease to apply at the end of the major event***. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>372</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Nils Torvalds, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. Following a request for assistance referred to in Article 4(3) and after consultation of its working party, the Medicines Steering Group shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the major event (‘the major event critical medicines list ’). The list shall be updated whenever necessary until the major event has been sufficiently addressed. | 1. Following a request for assistance referred to in Article 4(3) and after consultation of its working party, the Medicines Steering Group shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the major event (‘the major event critical medicines list ’). The list shall be updated whenever necessary until the major event has been sufficiently addressed ***and it is confirmed that the assistance of the Medicines Steering group is no longer needed as per Article 4(4)***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>373</NumAm>

<RepeatBlock-By><Members>Adam Jarubas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. Following a request for assistance referred to in Article 4(3) and after consultation of its working party, ***the*** Medicines Steering Group shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the major event (‘the major event critical medicines list ’). The list shall be updated whenever necessary until the major event has been sufficiently addressed. | 1. Following a request for assistance referred to in Article 4(3) and after consultation of its working party, ***medicinal product interest groups and supply chain stakeholders, in time adequate to the major event,*** Medicines Steering Group shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the major event (‘the major event critical medicines list ’). The list shall be updated whenever necessary until the major event has been sufficiently addressed. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>374</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. Following a request for assistance referred to in Article 4(3) and after consultation of its working party, the Medicines Steering Group shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the major event (‘the major event critical medicines list ’). The list shall be updated whenever necessary until the major event has been sufficiently addressed. | 1. Following a request for assistance referred to in Article 4(3) and after consultation of its working party, the Medicines Steering Group***, in consultation with marketing authorisation holders,*** shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the major event (‘the major event critical medicines list ’). The list shall be updated whenever necessary until the major event has been sufficiently addressed. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>375</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. Following a request for assistance referred to in Article 4(3) and after consultation of its working party, the Medicines Steering Group shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the major event (‘the major event critical medicines list’). The list shall be updated whenever necessary until the major event has been sufficiently addressed. | 1. Following a request for assistance referred to in Article 4(3) and after consultation of its working party, the Medicines Steering Group***, in coordination with stakeholders in the sector,*** shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the major event (‘the major event critical medicines list’). The list shall be updated whenever necessary until the major event has been sufficiently addressed. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>376</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. Following a request for assistance referred to in Article 4(3) and after consultation of its working party, the Medicines Steering Group shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the major event (‘the major event critical medicines list ’). The list shall be updated whenever necessary until the major event has been sufficiently addressed. | 1. Following a request for assistance referred to in Article 4(3) and after consultation of its working party, the Medicines Steering Group***, in consultation with marketing authorisation holders,*** shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the major event (‘the major event critical medicines list ’). The list shall be updated whenever necessary until the major event has been sufficiently addressed. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>377</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. Immediately following the recognition of a public health emergency and after consultation of its working party, the Medicines Steering Group shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the public health emergency (‘the public health emergency critical medicines list’). The list shall be updated whenever necessary until the termination of the recognition of the public health emergency. | 2. Immediately following the recognition of a public health emergency and after consultation of its working party, the Medicines Steering Group shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the public health emergency (‘the public health emergency critical medicines list’). The ***World Health Organization Model List of Essential Medicines for adults and for children shall be used as the base for its identification of critical medicinal products at Union level. The Agency shall make the public health emergency critical medicines list within 12 months after the entry into force of this Regulation. The*** list shall be updated whenever necessary until the termination of the recognition of the public health emergency ***as well as with the Commission and the European Centre for Disease Prevention and Control***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>378</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. Immediately following the recognition of a public health emergency and after consultation of its working party, the Medicines Steering Group shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the public health emergency (‘the public health emergency critical medicines list’). The list shall be updated whenever necessary until the termination of the recognition of the public health emergency. | 2. Immediately following the recognition of a public health emergency and after consultation of its working party, the Medicines Steering Group shall adopt a list of ***human and veterinary*** medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the public health emergency (‘the public health emergency critical medicines list’). The list shall be updated whenever necessary until the termination of the recognition of the public health emergency***, and shall cease to apply at the end of the public health emergency***. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>379</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Nils Torvalds, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. Immediately following the recognition of a public health emergency and after consultation of its working party, the Medicines Steering Group shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the public health emergency (‘the public health emergency critical medicines list’). The list shall be updated whenever necessary until the termination of the recognition of the public health emergency. | 2. Immediately following the recognition of a public health emergency and after consultation of its working party***, the industry and representatives of health professionals***, the Medicines Steering Group shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the public health emergency (‘the public health emergency critical medicines list’). The list shall be updated whenever necessary until the termination of the recognition of the public health emergency. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>380</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. Immediately following the recognition of a public health emergency and after consultation of its working party, the Medicines Steering Group shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the public health emergency (‘the public health emergency critical medicines list’). The list shall be updated whenever necessary until the termination of the recognition of the public health emergency. | 2. Immediately following the recognition of a public health emergency and after consultation of its working party, the Medicines Steering Group***, in coordination with stakeholders in the sector,*** shall adopt a list of medicinal products authorised in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 which it considers as critical during the public health emergency (‘the public health emergency critical medicines list’). The list shall be updated whenever necessary until the termination of the recognition of the public health emergency. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>381</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 2 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***2 a.*** ***In case of an eventual zoonotic spill-over, the Medicines Steering Group shall work with the other relevant bodies of the Agency in order to counter it as soon as possible.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>382</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall adopt a set of information necessary to monitor the supply and demand of medicinal products included on the lists referred to in paragraphs 1 and 2 (‘the critical medicines lists’) and inform its working party thereof. | 3. The Medicines Steering Group shall adopt a set of information ***and actions*** necessary to monitor the supply and demand of medicinal products included on the lists referred to in paragraphs 1 and 2 (‘the critical medicines lists’) and inform its working party thereof. ***The Medicines Steering Group shall report the Agency and the Commission in due time on the monitoring and shall notify immediately on any major event or shortage in the supply.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>383</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall adopt a set of information necessary to monitor the supply and demand of medicinal products included on the lists referred to in paragraphs 1 and 2 (‘the critical medicines lists’) and inform its working party thereof. | 3. The Medicines Steering Group shall adopt a set of information necessary to monitor the supply and demand of medicinal products included on the lists referred to in paragraphs 1 and 2 (‘the critical medicines lists’) and inform its working party thereof. ***Union or national entities that are engaged in stockpiling of medicinal products shall be informed accordingly.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

As the Commission plans to issue a legislative proposal for a new EU agency HERA which should engage, inter alia, in stockpiling, it is appropriate to address future developments in this regulation.

</Amend>

<Amend>Amendment <NumAm>384</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medicines Steering Group shall adopt a set of information necessary to monitor the supply and demand of medicinal products included on the lists referred to in paragraphs 1 and 2 (‘the critical medicines lists’) and inform its working party thereof. | 3. The Medicines Steering Group shall adopt a set of information necessary to monitor the supply and demand of ***human and veterinary*** medicinal products included on the lists referred to in paragraphs 1 and 2 (‘the critical medicines lists’) and inform its working party thereof. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>385</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. The Agency shall immediately publish the critical medicines lists and any updates to those lists on its web-portal referred to in Article 26 of Regulation (EC) No 726/2004. | 4. The Agency shall immediately publish the critical medicines lists and any updates to those lists on its web-portal referred to in Article 26 of Regulation (EC) No 726/2004. ***This list shall be published in a clear and accessible way so that Member States, actors in the pharmaceutical supply chain and all stakeholders can easily access this information and, where appropriate, can easily report possible changes or publication problems.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>386</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. ***The Agency shall immediately publish*** the critical medicines lists and any updates to those lists ***on its*** web-portal referred to in Article 26 of Regulation (EC) No 726/2004. | 4. ***Access to*** the critical medicines lists and any updates to those lists ***shall be granted to Member State representatives and the European Commission on a confidential basis, via the Agency’s*** web-portal referred to in Article 26 of Regulation (EC) No 726/2004. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>387</NumAm>

<RepeatBlock-By><Members>Pernille Weiss</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. ***The Agency*** shall ***immediately publish*** the critical medicines lists and any updates to those lists ***on its*** web-portal referred to in Article 26 of Regulation (EC) No 726/2004. | 4. ***Member State representatives and the European Commission*** shall ***on a confidential basis be granted access to*** the critical medicines lists and any updates to those lists ***via the*** web-portal referred to in Article 26 of Regulation (EC) No 726/2004. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>388</NumAm>

<RepeatBlock-By><Members>Carlo Calenda</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. The Agency shall ***immediately publish*** the critical medicines lists and any updates to those lists ***on its web-portal referred to in Article 26 of Regulation (EC) No 726/2004***. | 4. The Agency shall ***make available*** the critical medicines lists and any updates to those lists ***to the representatives of the Member States and the Commission***. |

Or. <Original>{IT}it</Original>

</Amend>

<Amend>Amendment <NumAm>389</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 4 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***4 a.*** ***The Agency, under its own assessment, shall establish an open, digital and interoperable database with information on expected and actual shortages of critical medical products, devices and applications. The database shall contain information on but not limited to:*** |
|  | ***a. Trade name and international non-proprietary name;*** |
|  | ***b. Indication;*** |
|  | ***c. Reason for the shortage;*** |
|  | ***d. Start and end dates;*** |
|  | ***e. Member States and/or regions affected, especially cross-border regions;*** |
|  | ***f. Possible consequences to non-communicable diseases or conditions, such as mental health and possible medical solutions and other measures;*** |
|  | ***g. Information for healthcare professionals and patients, including information on alternative treatments.*** |
|  | ***This database shall be accessible to the public. The Agency shall include the national, and where applicable regional, registries on medicine shortages on its web-portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>390</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 4 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***4 a.*** ***The Agency shall establish a publicly accessible database with information on expected and actual shortages of critical medicines. Reference to national shortage registries shall also be linked on the web portal. The database shall contain information on, but not limited to:*** |
|  | ***(a) Trade name and international non-proprietary name;*** |
|  | ***(b) Indication;*** |
|  | ***(c) Reason for the shortage;*** |
|  | ***(d) Start and end dates;*** |
|  | ***(e) Member States affected;*** |
|  | ***(f) Information for healthcare professionals and patients, including information on alternative treatments.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>391</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 4 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***4 a.*** ***The Agency shall establish a database with information on expected and actual shortages of critical medicines. The database shall contain information on but not limited to:*** |
|  | ***(a) Trade name and international non-proprietary name;*** |
|  | ***(b) Indication;*** |
|  | ***(c) Reason for the shortage;*** |
|  | ***(d) Start and end dates;*** |
|  | ***(e) Member States affected;*** |
|  | ***(f) Information for healthcare professionals and patients, including information on alternative treatments.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The Regulation should require that the EMA sets up a public database to inform patients, consumers and healthcare professionals about the expected or actual shortage of medicines that are critical to address a major event or public health emergency. This is essential to consider potential alternatives and minimise as much as possible the impact on care. The database should also contain information on those critical medical devices that are on shortage.

</Amend>

<Amend>Amendment <NumAm>392</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 4 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***4 a.*** ***The Agency shall establish a database with information on expected and actual shortages of critical medicines. The database shall contain information on but not limited to:*** |
|  | ***(a) Trade name and international non-proprietary name;*** |
|  | ***(b) Indication;*** |
|  | ***(c) Reason for the shortage;*** |
|  | ***(d) Start and end dates;*** |
|  | ***(e) Member States affected;*** |
|  | ***(f) Information for healthcare professionals and patients, including information on alternative treatments.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>393</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 4 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***4a.*** ***The Agency, in cooperation with the Commission and the national competent authorities of the Member States, shall work with representatives of the European medicinal product industry to ensure that medicinal products included on the critical medicines list made available in one Member State are equally available in all Member States, in one form or another, and in particular in smaller Member States.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>394</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 4 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***4 a.*** ***The Medicines Steering Group together with the industry (via the industry single points of contacts - iSPOCs) will determine the list of critical products and any future actions taken for the molecules included on the critical product list.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>395</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 4 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***4 b.*** ***The database shall be accessible to the public.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>396</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 4 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***4 b.*** ***The database shall be accessible to the public.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>397</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 4 c (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***4 c.*** ***The Agency shall list on its web-portal the national registries on medicine shortages.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>398</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 6 – paragraph 4 c (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***4 c.*** ***The Agency shall list on its web-portal the national registries on medicine shortages.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>399</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Jan Huitema</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 7 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| On the basis of the critical medicines lists and the information and data provided in accordance with Articles 10 and 11, the Medicines Steering Group shall monitor supply and demand of medicinal products included on those lists with a view to identifying any potential or actual shortages of those medicinal products. As part of that monitoring, the Medicines Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]19 and, in the case of a public health emergency, the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation. | On the basis of the ***single European*** critical medicines lists and the information and data provided in accordance with Articles 10 and 11***, , and the database established in accordance with Article 12a once fully operational***, the Medicines Steering Group shall monitor supply and demand of medicinal products included on those lists with a view to identifying any potential or actual shortages of those medicinal products. As part of that monitoring, the Medicines Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]19 and, in the case of a public health emergency, the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation***, as well as with the European Centre for Disease Prevention and Control***. ***The Medicines Steering Group shall also guarantee an open communication and close cooperation with the industry, relevant entities of the pharmaceutical supply chain, and representatives of healthcare professionals, patients and consumers with a view to enable early notification or identification of potential or actual shortages of critical medicines.*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 19 [insert reference to adopted text referred to in footnote 4] | 19 [insert reference to adopted text referred to in footnote 4] |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>400</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 7 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| On the basis of the critical medicines lists and the information and data provided in accordance with Articles 10 and 11, the Medicines Steering Group shall monitor supply and demand of medicinal products included on those lists with a view to identifying any potential or actual shortages of those medicinal products. As part of that monitoring, the Medicines Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]19 and, in the case of a public health emergency, the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation. | On the basis of the critical medicines lists and the information and data provided in accordance with Articles 10 and 11 ***of this Regulation***, the Medicines Steering Group shall ***meet regularly throughout the major event or public health emergency with the working group of designated national contact points for medicines shortages within the national competent authorities for medicines and with representatives of the medicines production and distribution sectors in order to*** monitor supply and demand of medicinal products included on those lists with a view to identifying any potential or actual shortages of those medicinal products ***and to adapt the list as well as possible throughout the major event or emergency***. As part of that monitoring, the Medicines Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]19 and, in the case of a public health emergency, the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation. |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 19 [insert reference to adopted text referred to in footnote 4] | 19 [insert reference to adopted text referred to in footnote 4] |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>401</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 7 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| On the basis of the critical medicines lists and the information and data provided in accordance with Articles 10 and 11, the Medicines Steering Group shall monitor supply and demand of medicinal products included on those lists with a view to identifying any potential or actual shortages of those medicinal products. As part of that monitoring, the Medicines Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]19 and, in the case of a public health emergency, the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation. | On the basis of the critical medicines lists***, the establishment of a two way communication line with industry via the industry single point of contacts (iSPOC)*** and the information and data provided in accordance with Articles 10 and 11, the Medicines Steering Group shall monitor supply and demand***, with demand being based on actual patient need at the Member State level, as per Article 2(f),*** of medicinal products included on those lists with a view to identifying any potential or actual shortages of those medicinal products. As part of that monitoring, the Medicines Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]19 and, in the case of a public health emergency, the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation. |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 19 [insert reference to adopted text referred to in footnote 4] | 19 [insert reference to adopted text referred to in footnote 4] |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>402</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 7 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| On the basis of the critical medicines lists and the information and data provided in accordance with Articles 10 and 11, the Medicines Steering Group shall monitor supply and demand of medicinal products included on those lists with a view to identifying any potential or actual shortages of those medicinal products. As part of that monitoring, the Medicines Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]19 and, in the case of a public health emergency, the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation. | On the basis of the critical medicines lists and the information and data provided in accordance with Articles 10 and 11, the Medicines Steering Group shall monitor supply and demand of medicinal products included on those lists with a view to identifying any potential or actual shortages of those medicinal products. As part of that monitoring, the Medicines Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]19 and, in the case of a public health emergency, the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation. ***The Medicines Steering Group shall provide the aggregated data and demand forecasts from the digital interoperable platform referred to in Article1(b) and Article 12(g).*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 19 [insert reference to adopted text referred to in footnote 4] | 19 [insert reference to adopted text referred to in footnote 4] |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>403</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 7 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| On the basis of the critical medicines lists and the information and data provided in accordance with Articles 10 and 11, the Medicines Steering Group shall monitor supply and demand of medicinal products included on those lists with a view to identifying any potential or actual shortages of those medicinal products. As part of that monitoring, the Medicines Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]19 and, in the case of a public health emergency, the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation. | On the basis of the critical medicines lists***, the establishment of a two way communication line with industry via the industry single point of contacts (iSPOC)***and the information and data provided in accordance with Articles 10 and 11, the Medicines Steering Group shall monitor supply and demand of medicinal products included on those lists with a view to identifying any potential or actual shortages of those medicinal products. As part of that monitoring, the Medicines Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]19 and, in the case of a public health emergency, the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation. |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |  |
| 19 [insert reference to adopted text referred to in footnote 4] |  |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>404</NumAm>

<RepeatBlock-By><Members>Carlo Calenda</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 7 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| On the basis of the critical medicines lists and the information and data provided in accordance with Articles 10 and 11, the Medicines Steering Group ***shall monitor supply and demand of medicinal products*** included on those lists with a view to identifying any potential or actual shortages of those medicinal products. As part of that monitoring, the Medicines Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]19 and, in the case of a public health emergency, the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation. | On the basis of the critical medicines lists and the information and data provided in accordance with Articles 10 and 11, the Medicines Steering Group***, based on patients’ actual and potential needs,*** included on those lists with a view to identifying any potential or actual shortages of those medicinal products. As part of that monitoring, the Medicines Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]19 and, in the case of a public health emergency, the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation. |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 19 [insert reference to adopted text referred to in footnote 4] | 19 [insert reference to adopted text referred to in footnote 4] |

Or. <Original>{IT}it</Original>

</Amend>

<Amend>Amendment <NumAm>405</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 7 – paragraph 1 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***There should also be regular structured dialogue with industry, entities involved in the pharmaceutical supply chain, healthcare professionals and patients’ associations so that any potential or actual shortages of those medicinal products in a public health emergency and/or major event can be managed as effectively as possible.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>406</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 7 – paragraph 1 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***The Medicines Steering Group shall monitor supply and demand of medicinal products included on those across the entire value-chain, from resources to patient;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>407</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 7 – paragraph 1 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***The Single Point of Contact Network (SPOC) shall be extended to become a reliable monitoring system for shortages of medicines and other medical counter.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The fast-track monitoring system that has been put in place by the EU Executive Steering Group is a welcome initiative. Given that its scope is limited to medicines used for treating COVID-19, the single point of contact network (SPOC) should be adequately resourced to ensure it is an effective communication tool on other drug supplies affected by the response to the pandemic. The SPOC system, currently being piloted by the European Medicines Agency and the Heads of Medicines Agencies (HMA), should become an established monitoring system thereafter.

</Amend>

<Amend>Amendment <NumAm>408</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 7 – paragraph 1 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***As shortage of medicines outside of the critical lists established in a public health emergency or a major event are outside of the scope of this Regulation and yet pose a persistent challenge that has been increasingly affecting health and well-being of EU citizens for the past decades, this Regulation should be a first step towards improving the EU response to this long-lasting issue. The Commission shall subsequently propose the expansion of this framework to ensure that the issue of shortages is broadly and permanently tackled in the upcoming revision of Regulation (EC) 726/2004 and Directive 2001/83/EC.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>409</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. For the duration of a public health emergency or following a request for assistance referred to in Article 4(3) and until its closure, the Medicines Steering Group shall regularly report the results of its monitoring to the Commission and the sub-network referred to in Article 9(2), and, in particular, signal any potential or actual shortages of medicinal products included on the critical medicines lists. | 1. For the duration of a public health emergency or following a request for assistance referred to in Article 4(3) and until its closure, the Medicines Steering Group shall regularly report the results of its monitoring to the Commission***, the pharmaceutical industry*** and the sub-network referred to in Article 9(2), and, in particular, signal any potential or actual shortages of medicinal products included on the critical medicines lists. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>410</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. For the duration of a public health emergency or following a request for assistance referred to in Article 4(3) and until its closure, the Medicines Steering Group shall regularly report the results of its monitoring to the Commission and the sub-network referred to in Article 9(2), and, in particular, signal any potential or actual shortages of medicinal products included on the critical medicines lists. | 1. For the duration of a public health emergency or following a request for assistance referred to in Article 4(3) and until its closure, the Medicines Steering Group shall regularly report the results of its monitoring to the Commission***, national public health authorities*** and the sub-network referred to in Article 9(2), and, in particular, signal any potential or actual shortages of medicinal products included on the critical medicines lists. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>411</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. For the duration of a public health emergency or following a request for assistance referred to in Article 4(3) and until its closure, the Medicines Steering Group shall regularly report the results of its monitoring to the Commission and the sub-network referred to in Article 9(2), and, in particular, signal any potential or actual shortages of medicinal products included on the critical medicines lists. | 1. For the duration of a public health emergency or following a request for assistance referred to in Article 4(3) and until its closure, the Medicines Steering Group shall regularly report the results of its monitoring to the Commission***, Member States, the pharmaceutical industry*** and the sub-network referred to in Article 9(2), and, in particular, signal any potential or actual shortages of medicinal products included on the critical medicines lists. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>412</NumAm>

<RepeatBlock-By><Members>Stanislav Polčák</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. For the duration of a public health emergency or following a request for assistance referred to in Article 4(3) and until ***its closure***, the Medicines Steering Group shall regularly report the results of its monitoring to the Commission and the sub-network referred to in Article 9(2), and, in particular, signal any potential or actual shortages of medicinal products included on the critical medicines lists. | 1. For the duration of a public health emergency or following a request for assistance referred to in Article 4(3) and until ***it is confirmed that its assistance is no longer needed under Article 4(4)***, the Medicines Steering Group shall regularly report the results of its monitoring to the Commission and the sub-network referred to in Article 9(2), and, in particular, signal any potential or actual shortages of medicinal products included on the critical medicines lists. |

Or. <Original>{CS}cs</Original>

</Amend>

<Amend>Amendment <NumAm>413</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska, Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. For the duration of a public health emergency or following a request for assistance referred to in Article 4(3) and until its closure, the Medicines Steering Group shall ***regularly*** report the results of its monitoring to the Commission and the sub-network referred to in Article 9(2), and, in particular, signal any potential or actual shortages of medicinal products included on the critical medicines lists. | 1. For the duration of a public health emergency or following a request for assistance referred to in Article 4(3) and until its closure, the Medicines Steering Group shall report ***on a systematic, structured, and timely basis*** the results of its monitoring to the Commission and the sub-network referred to in Article 9(2), and, in particular, signal any potential or actual shortages of medicinal products included on the critical medicines lists. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>414</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. For the duration of a public health emergency or following a request for assistance referred to in Article 4(3) and until its closure, the Medicines Steering Group shall regularly report the results of its monitoring to the Commission and the sub-network referred to in Article 9(2), and, in particular, signal any potential or actual shortages of medicinal products included on the critical medicines lists. | 1. For the duration of a public health emergency or following a request for assistance referred to in Article 4(3) and until its closure, the Medicines Steering Group shall regularly report the results of its monitoring to the Commission***, the pharmaceutical industry*** and the sub-network referred to in Article 9(2), and, in particular, signal any potential or actual shortages of medicinal products included on the critical medicines lists. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>415</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 1 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***1 a.*** ***Reports of any potential or actual shortages of medicinal products included on the critical medicines lists shall also be made available to industry and other entities of the pharmaceutical supply chain, where relevant.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>416</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. Where requested by the Commission or the sub-network referred to in Article 9(2), the Medicines Steering Group shall provide aggregated data and forecasts of demand to substantiate its findings. In that regard, the Medicines Steering Group shall liaise with the European Centre for Disease Prevention and Control to obtain epidemiological data to help forecast medicinal product needs, and with the Executive Steering Group on Shortages of Medical Devices referred to in Article 19 where medicinal products included on the critical medicines lists are administered with a medical device. | 2. Where requested by the Commission or the sub-network referred to in Article 9(2), the Medicines Steering Group shall provide aggregated data and forecasts of demand to substantiate its findings. In that regard, the Medicines Steering Group shall liaise with the European Centre for Disease Prevention and Control to obtain epidemiological data to help forecast medicinal product needs, and with the Executive Steering Group on Shortages of Medical Devices referred to in Article 19 where medicinal products included on the critical medicines lists are administered with a medical device. ***The aggregated data and forecasts of demand shall also be made available to industry and other entities of the pharmaceutical supply chain, where relevant, with the view to better prevent or mitigate potential or actual shortages.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>417</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. Where requested by the Commission or the sub-network referred to in Article 9(2), the Medicines Steering Group shall provide aggregated data and forecasts of demand to substantiate its findings. In that regard, the Medicines Steering Group shall liaise with the European Centre for Disease Prevention and Control to obtain epidemiological data to help forecast medicinal product needs, and with the Executive Steering Group on Shortages of Medical Devices referred to in Article 19 where medicinal products included on the critical medicines lists are administered with a medical device. | 2. Where requested by the Commission or the sub-network referred to in Article 9(2), the Medicines Steering Group shall provide aggregated data and forecasts of demand to substantiate its findings. In that regard, the Medicines Steering Group shall liaise with the European Centre for Disease Prevention and Control to obtain epidemiological data to help forecast medicinal product needs, and with the Executive Steering Group on Shortages of Medical Devices referred to in Article 19 where medicinal products included on the critical medicines lists are administered with a medical device. ***It shall share its findings and conclusions with Union and national entities engaged with stockpiling of medicinal products and medical devices.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>418</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. Where requested by the Commission or the sub-network referred to in Article 9(2), the Medicines Steering Group shall provide aggregated data and forecasts of demand to substantiate its findings. In that regard, the Medicines Steering Group shall liaise with the European Centre for Disease Prevention and Control to obtain epidemiological data to help forecast medicinal product needs, and with the Executive Steering Group on Shortages of Medical Devices referred to in Article 19 where medicinal products included on the critical medicines lists are administered with a medical device. | 2. Where requested by the Commission or the sub-network referred to in Article 9(2), the Medicines Steering Group shall provide aggregated data and forecasts of demand to substantiate its findings. In that regard, the Medicines Steering Group ***shall use data from its interoperable and digitalized platform for reporting and notifying shortages and*** shall liaise with the European Centre for Disease Prevention and Control to obtain epidemiological data to help forecast medicinal product needs, and with the Executive Steering Group on Shortages of Medical Devices referred to in Article 19 where medicinal products included on the critical medicines lists are administered with a medical device. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>419</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. Where requested by the Commission or the sub-network referred to in Article 9(2), the Medicines Steering Group shall provide aggregated data and forecasts of demand to substantiate its findings. In that regard, the Medicines Steering Group shall liaise with the European Centre for Disease Prevention and Control to obtain epidemiological data to help forecast medicinal product needs, and with the Executive Steering Group on Shortages of Medical Devices referred to in Article 19 where medicinal products included on the critical medicines lists are administered with a medical device. | 2. Where requested by the Commission, ***one or more national public health authorities*** or the sub-network referred to in Article 9(2), the Medicines Steering Group shall provide aggregated data and forecasts of demand to substantiate its findings. In that regard, the Medicines Steering Group shall liaise with the European Centre for Disease Prevention and Control to obtain epidemiological data to help forecast medicinal product needs, and with the Executive Steering Group on Shortages of Medical Devices referred to in Article 19 where medicinal products included on the critical medicines lists are administered with a medical device. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>420</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska, Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. As part of that reporting, the Medicines Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, as relevant, with the Health Security Committee and, in the case of a public health emergency, the Advisory Committee on public health emergencies. | 3. As part of that reporting, the Medicines Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities***, including healthcare professionals and patient organisations,*** to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, as relevant, with the Health Security Committee and, in the case of a public health emergency, the Advisory Committee on public health emergencies. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>421</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. As part of that reporting, the Medicines Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, as relevant, with the Health Security Committee and, in the case of a public health emergency, the Advisory Committee on public health emergencies. | 3. As part of that reporting, the Medicines Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities***, including healthcare professionals, consumers and patients,*** to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, as relevant, with the Health Security Committee and, in the case of a public health emergency, the Advisory Committee on public health emergencies. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>422</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. As part of that reporting, the Medicines Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, as relevant, with the Health Security Committee and, in the case of a public health emergency, the Advisory Committee on public health emergencies. | 3. As part of that reporting, the Medicines Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities***, including healthcare professionals or patients,*** to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, as relevant, with the Health Security Committee and, in the case of a public health emergency, the Advisory Committee on public health emergencies. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>423</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. As part of that reporting, the Medicines Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, as relevant, with the Health Security Committee and, in the case of a public health emergency, the Advisory Committee on public health emergencies. | 3. As part of that reporting, the Medicines Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities***, including healthcare professionals and patients,*** to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, as relevant, with the Health Security Committee and, in the case of a public health emergency, the Advisory Committee on public health emergencies. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>424</NumAm>

<RepeatBlock-By><Members>Sara Cerdas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. As part of that reporting, the Medicines Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, as relevant, with the Health Security Committee and, in the case of a public health emergency, the Advisory Committee on public health emergencies. | 3. As part of that reporting, the Medicines Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities***, including healthcare professionals and patients,*** to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, as relevant, with the Health Security Committee and, in the case of a public health emergency, the Advisory Committee on public health emergencies. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>425</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. As part of that reporting, the Medicines Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, as relevant, with the Health Security Committee and, in the case of a public health emergency, the Advisory Committee on public health emergencies. | 3. As part of that reporting, the Medicines Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities***, including healthcare professionals and patients,*** to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, as relevant, with the Health Security Committee and, in the case of a public health emergency, the Advisory Committee on public health emergencies. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>426</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. As part of that reporting, the Medicines Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, as relevant, with the Health Security Committee and, in the case of a public health emergency, the Advisory Committee on public health emergencies. | 3. As part of that reporting, the Medicines Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities***, including healthcare professionals and patients,*** to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, as relevant, with the Health Security Committee and, in the case of a public health emergency, the Advisory Committee on public health emergencies. |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Concrete mitigation measures for potential and actual shortages should be shared directly with healthcare professionals and patients, using for example the network that EMA has established via its Healthcare Professional Working Party (HCPWP) and the Patients' and Consumers' Working Party (PCWP). By sharing recommendations on measures directly with healthcare professionals and patient organisations it can be ensured that these are taken into account as soon as the measures become known

</Amend>

<Amend>Amendment <NumAm>427</NumAm>

<RepeatBlock-By><Members>Pernille Weiss</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. The Medicines Steering Group may, on its own initiative or upon request from the Commission, provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities to ensure preparedness to deal with potential or actual shortages of medicinal products caused by public health emergencies or major events. | 4. The Medicines Steering Group may, on its own initiative or upon request from the Commission, provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities to ensure preparedness to deal with potential or actual shortages of medicinal products caused by public health emergencies or major events. ***These recommendations may include measures to minimize unnecessary administrative burdens or facilitate flexible supply chains.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>428</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. The Medicines Steering Group may, on its own initiative or upon request from the Commission, provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities to ensure preparedness to deal with potential or actual shortages of medicinal products caused by public health emergencies or major events. | 4. The Medicines Steering Group may, on its own initiative or upon request from the Commission, provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities***, including healthcare professionals,*** to ensure preparedness to deal with potential or actual shortages of medicinal products caused by public health emergencies or major events. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>429</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. The Medicines Steering Group may, on its own initiative or upon request from the Commission, provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities to ensure preparedness to deal with potential or actual shortages of medicinal products caused by public health emergencies or major events. | 4. The Medicines Steering Group may, on its own initiative or upon request from the Commission, provide recommendations on measures, which may be taken by the Commission, Member States, marketing authorisation holders and other entities to ensure preparedness to deal with potential or actual shortages of ***human and veterinary*** medicinal products caused by public health emergencies or major events. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>430</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 4 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***4 a.*** ***Without prejudice to Article 30, reports and recommendations of the Medicines Steering Group will be made available to the public to their greatest extent.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>431</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska, Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Medicines Steering Group may upon request from the Commission ***coordinate*** measures, where relevant, between the national competent authorities, the marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages in the context of a major event or public health emergency. | 5. The Medicines Steering Group may upon request from the Commission ***coordinated*** measures, where relevant, between the national competent authorities, the marketing authorisation holders and other entities***, including healthcare professionals and patient organisations,*** to prevent or mitigate potential or actual shortages in the context of a major event or public health emergency. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>432</NumAm>

<RepeatBlock-By><Members>Sara Cerdas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Medicines Steering Group may upon request from the Commission coordinate measures, where relevant, between the national competent authorities, the marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages in the context of a major event or public health emergency. | 5. The Medicines Steering Group may upon request from the Commission coordinate measures, where relevant, between the national competent authorities, the marketing authorisation holders and other entities***, including healthcare professionals and patients,*** to prevent or mitigate potential or actual shortages in the context of a major event or public health emergency. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>433</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Medicines Steering Group may upon request from the Commission coordinate measures, where relevant, between the national competent authorities, the marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages in the context of a major event or public health emergency. | 5. The Medicines Steering Group may upon request from the Commission coordinate measures, where relevant, between the national competent authorities, the marketing authorisation holders and other entities***, including healthcare professionals,*** to prevent or mitigate potential or actual shortages in the context of a major event or public health emergency. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>434</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Nils Torvalds, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Medicines Steering Group may upon request from the Commission coordinate measures, where relevant, between the national competent authorities, the marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages in the context of a major event or public health emergency. | 5. The Medicines Steering Group may upon request from the Commission coordinate measures, where relevant, between the national competent authorities, the marketing authorisation holders and other entities***, including healthcare professionals,*** to prevent or mitigate potential or actual shortages in the context of a major event or public health emergency. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>435</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Medicines Steering Group may upon request from the Commission coordinate measures, where relevant, between the national competent authorities, the marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages in the context of a major event or public health emergency. | 5. The Medicines Steering Group may upon request from the Commission coordinate measures, where relevant, between the national competent authorities, the marketing authorisation holders and other entities***, including healthcare professionals,*** to prevent or mitigate potential or actual shortages in the context of a major event or public health emergency. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>436</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Medicines Steering Group may upon request from the Commission coordinate measures, where relevant, between the national competent authorities, the marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages in the context of a major event or public health emergency. | 5. The Medicines Steering Group may upon request from the Commission coordinate measures, where relevant, between the national***, and where applicable regional,*** competent authorities, the marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages in the context of a major event or public health emergency. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>437</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Medicines Steering Group may upon request from the Commission coordinate measures, where relevant, between the national competent authorities, the marketing authorisation holders and other entities to prevent or mitigate potential or actual shortages in the context of a major event or public health emergency. | 5. The Medicines Steering Group may upon request from the Commission coordinate measures, where relevant, between the national competent authorities, the marketing authorisation holders and other entities***, including healthcare professionals,*** to prevent or mitigate potential or actual shortages in the context of a major event or public health emergency. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>438</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 5 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***5 a.*** ***In case any of the aforementioned stakeholders does not give information to the Agency in the time lapse established by the Agency, the Commission shall assist the Agency in obtaining such information, with the prospect of an eventual sanction, which should also be duly informed to the public. This sanction shall be established in an implementing regulation.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>439</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin, Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 5 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***5a.*** ***The measures recommended by the Steering Group to the Commission, Member States, marketing authorisation holders and other stakeholders should include a relaxing of rules to deal with potential shortages.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>440</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 8 – paragraph 5 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***5 b.*** ***The Agency, together with the Commission, shall also present recommendations to the Commission to counterbalance smear campaigns and disinformation on medicines, medical products, devices or applications, in order to ensure proper information to the public.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>441</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. In order to prepare for fulfilling the tasks referred to in Articles 4 to 8, the Agency shall: | 1. In order to prepare for fulfilling the tasks referred to in Articles 4 to 8 ***and after having consulted representatives from national competent authorities and from marketing authorisation holder representatives, as well as other stakeholders in the medicines supply chain***, the Agency shall: |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>442</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin, Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. In order to prepare for fulfilling the tasks referred to in Articles 4 to 8, the Agency shall: | 1. In order to prepare for fulfilling the tasks referred to in Articles 4 to 8, ***and after consulting representatives of national authorities and marketing authorisation holders, as well as other stakeholders in the pharmaceutical sector,*** the Agency shall: |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>443</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) specify the procedures for establishing the critical medicines lists; | (a) specify the procedures for establishing the critical medicines lists***, , ensuring adequate consultation with healthcare professionals, consumers, patients a high level of transparency in decision-making***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>444</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) specify the procedures for establishing the critical medicines lists; | (a) specify the procedures for establishing the critical medicines lists***, ensuring adequate consultation with patients, consumers and healthcare professionals and a high level of transparency***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>445</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) specify the procedures for establishing the critical medicines lists; | (a) specify the procedures for establishing the critical medicines lists***, ensuring adequate consultation with consumers, patients and healthcare professionals and a high level of transparency***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>446</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) specify the procedures for establishing the critical medicines lists; | (a) specify the procedures for establishing the critical medicines lists***, ensuring adequate consultation with consumers, patients and healthcare professionals and a high level of transparency***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>447</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) specify the procedures for establishing the critical medicines lists; | (a) specify the procedures for establishing the critical medicines lists ***and the minimum stock levels required to ensure continuity of medical care***; |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>448</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) specify the procedures for establishing the critical medicines lists; | (a) specify the procedures ***and criteria*** for establishing the critical medicines lists; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>449</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) specify the procedures for establishing the critical medicines lists; | (a) specify the procedures for establishing ***and reviewing*** the critical medicines lists; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>450</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) specify the methods of and criteria for the monitoring, data collection and reporting provided for in Articles 4, 7 and 8; | (b) specify the methods of and criteria for the monitoring, data collection and reporting ***through the European Union of Health digitalized and interoperable early-warning system of shortage of medicines, established in Article 2bis(new), and***provided for in Articles 4, 7 and 8; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>451</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) develop streamlined electronic monitoring and reporting systems; | (c) develop streamlined electronic monitoring and reporting systems ***by implementing and building on existing regulatory infrastructure (EU telematics[1]). This system shall be interoperable with the national shortages reporting to prevent any duplication of the reporting process***; ***the system shall establish a two-way digital communication between the Agency and the national competent authorities, as well as a two way communication between the Agency and marketing authorisation holders. In case of public health emergency, aggregated information shall be collected by the Agency from national competent authority shortages reporting systems in a harmonised and consolidated way, based on national harmonised data fields and definitions across Member States. The Agency can request additional information directly from the marketing authorisation holders via the industry single point of contact (iSPOC), if this information has not been provided yet to the Member States through the system;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>452</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) develop streamlined electronic monitoring and reporting systems; | (c) develop streamlined electronic monitoring and reporting systems; ***by implementing and building on existing regulatory infrastructure (EU telematics[1]). This system shall be interoperable with the national shortages reporting to prevent any duplication of the reporting process; the system should establish a two-way digital communication between the Agency and the national competent authorities, as well as a two way communication between the Agency and marketing authorisation holders. In case of public health emergency, aggregated information should be collected by the Agency from national competent authority shortages reporting systems in a harmonised and consolidated way, based on harmonised data fields across Member States. The Agency can request additional information directly from the marketing authorisation holders via the industry single point of contact (iSPOC), if this information has not been provided yet to the Member States.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>453</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) develop streamlined electronic monitoring and reporting systems; | (c) develop streamlined electronic monitoring and reporting systems***,*** ***by implementing and building on existing regulatory infrastructure (EU telematics). This system shall be interoperable with the national shortages reporting to prevent any duplication of the reporting process***; ***the system should establish a two-way digital communication between the Agency and the national competent authorities, as well as a two way communication between the Agency and marketing authorisation holders. In case of public health emergency, aggregated information should be collected by the Agency from national competent authority shortages reporting systems in a harmonised and consolidated way, based on harmonised data fields across Member States. The Agency can request additional information directly from the marketing authorisation holders via the industry single point of contact (iSPOC), if this information has not been provided yet to the Member States.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>454</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) develop streamlined electronic monitoring and reporting systems; | (c) develop streamlined electronic monitoring and reporting systems;***by implementing and building on existing regulatory infrastructure (EU telematics). This system shall be interoperable with the national shortages reporting to prevent any duplication of the reporting process; the system should establish a two-way digital communication between the Agency and the national competent authorities, as well as a two way communication between the Agency and marketing authorisation holders. In case of public health emergency, aggregated information should be collected by the Agency from national competent authority shortages reporting systems in a harmonised and consolidated way, based on harmonised data fields across Member States. The Agency can request additional information directly from the marketing authorisation holders via the industry single point of contact (iSPOC), if this information has not been provided yet to the Member States.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>455</NumAm>

<RepeatBlock-By><Members>Adam Jarubas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) develop streamlined electronic monitoring and reporting systems; | (c) develop streamlined electronic monitoring and reporting systems***, building upon EU telematics regulatory infrastructure, SPOR, into national shortage reporting interoperable system, based on national harmonised data fields and definitions across Member States, preventing reporting duplication, using international standards (ISO IDMP) and supporting mutual cooperation of the Agency and national competent authorities and via iSPOC with marketing authorisation holders***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>456</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) develop ***streamlined electronic*** monitoring ***and*** reporting ***systems***; | (c) develop ***an interoperable and digitalized platform for*** monitoring***,*** reporting ***and notifying***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>457</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) establish and maintain membership of the working party referred to in Article 3(5) comprised of single points of contacts from national competent authorities for medicinal products; | (d) establish and maintain membership of the working party referred to in Article 3(5) comprised of single points of contacts from national***, and where applicable regional,*** competent authorities for medicinal products; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>458</NumAm>

<RepeatBlock-By><Members>Adam Jarubas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point e</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (e) establish and maintain a list of single points of contact from marketing authorisation holders for all medicinal products for human use authorised in the Union, through the database provided for in Article 57(1)(l) of Regulation 726/2004; | (e) establish and maintain a list of single points of contact from marketing authorisation holders for all medicinal products for human use authorised in the Union, through the database provided for in Article 57(1)(l) of Regulation 726/2004 ***after updating it by including the industry single point of contacts (iSPOC)maintaining compliance with ISO IDMP***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>459</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point e</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (e) ***establish and maintain a list of single points of contact from marketing authorisation holders for all medicinal products for human use authorised in the Union, through the database provided for in*** Article 57(1)(l) of Regulation 726/2004; | (e) ***update the*** Article 57(1)(l) of Regulation 726/2004 ***Data base by including the industry single point of contacts (iSPOC), this database should be digital, regularly updated, and compliant with the standards of the International Organization for Standardization (ISO) for the identification of medicinal products (IDMP)2***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>460</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point e</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (e) ***establish and maintain a list of single points of contact from marketing authorisation holders for all medicinal products for human use authorised in the Union, through the database provided for in*** Article 57(1)(l) of Regulation 726/2004; | (e) ***update the*** Article 57(1)(l) of Regulation 726/2004***Data base by including the industry single point of contacts (iSPOC), this database should be digital, regularly updated, and compliant with the standards of the International Organization for Standardization (ISO) for the identification of medicinal products (IDMP)***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>461</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point e</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (e) ***establish and maintain a list of single points of contact from marketing authorisation holders for all medicinal products for human use authorised in the Union, through the database provided for in*** Article 57(1)(l) of Regulation 726/2004; | (e) ***update the*** Article57(1)(l) of Regulation 726/2004 ***database by including the industry single point of contact (iSPOC)***; ***this database should be digital, regularly updated, and compliant with the International Organization for Standardization (ISO) for the identification of medicinal products (IDMP)*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>462</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point f a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fa)*** ***update the format and content of the Article 57 database to include the industry Single Point of contact (iSPOC) names as reported by industry. Industry should be able to digitally update the iSPOC names in the article 57 database if needed and compliant with the standards of the International Organization for Standardization (ISO) for the identification of medicinal products (IDMP);*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>463</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point f a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fa)*** ***The Agency shall publish information referred to in paragraph (1) (a), (b), (f) on its web-portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>464</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point f a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fa)*** ***publish information referred to in paragraph (1) (a), (b) and (f) on its web-portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>465</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 – point f b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fb)*** ***Include the use of including use of the European Medicines Verification System data for shortages in an epidemiological crisis by enabling national regulators to assess the availability of products versus what has been consumed or parallel exported in their market;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>466</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 1 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***1 a.*** ***The Agency shall publish the information referred to in paragraph 1 (a), (b), (f) on its web portal without delay.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>467</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 2 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) establish and maintain for the duration of the public health emergency or major event, a sub-network of single points of contact from marketing authorisation holders based on the medicinal products included on the critical medicines lists; | (a) establish and maintain for the duration of the public health emergency or major event, a sub-network of single points of contact from marketing authorisation holders ***who can be different from the contacts established under Article 9(1) point (e), and of representatives of other relevant supply chain stakeholders involved in the distribution and supply of medicinal products to the public,*** based on the medicinal products included on the critical medicines lists; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>468</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 2 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) request information from the points of contact included in the sub-network referred to in point (a) and set a deadline for its submission; | (b) request information***, including on the supply of the list of critical medicinal products,*** from the points of contact included in the sub-network referred to in point (a) and set a deadline for its submission ***in the platform***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>469</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 2 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) request information from the single points of contact from Member States’ national competent authorities based on the set of information agreed on by the Medicines Steering Group and set a deadline for its submission. | (c) request information***, including on the supply of the list of critical medicinal products,*** from the single points of contact from Member States’ national competent authorities based on the set of information agreed on by the Medicines Steering Group and set a deadline for its submission ***in the platform***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>470</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 2 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) request information from the single points of contact from Member States’ national competent authorities based on the set of information agreed on by the Medicines Steering Group and set a deadline for its submission. | (c) request information from the single points of contact from Member States’ national***, and where applicable regional,*** competent authorities based on the set of information agreed on by the Medicines Steering Group and set a deadline for its submission. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>471</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The information referred to in point (b) of paragraph 2 shall include ***at least:*** | 3. The information referred to in point (b) of paragraph 2 ***(as determined in Article 9(1) (c) and Article 11 (a)*** shall ***not*** include ***any information available to the Agency via collection of information submitted by industry to the national competent authority shortages systems in a harmonised and consolidated way by means of common data fields for each Member State. The system at the Agency shall be interoperable with the national shortages reporting to prevent any duplication of the reporting process by industry via Industry Single Points of Contact (iSPOC).*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>472</NumAm>

<RepeatBlock-By><Members>Pernille Weiss</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The information referred to in point (b) of paragraph 2 shall include ***at least***: | 3. ***The scope of*** the information referred to in point (b) of paragraph 2 shall ***be discussed with representatives of the relevant marketing authorisation holders, including to avoid overlaps with information already submitted following Directive 2001/83/EC. Requested information may*** include: |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>473</NumAm>

<RepeatBlock-By><Members>Adam Jarubas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The information referred to in point (b) of paragraph 2 shall include at least: | 3. The information referred to in point (b) of paragraph 2***, without duplicating information available to the Agency via collection of information submitted by industry to the national competent authority shortages systems,*** shall include at least: |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>474</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (d) details of the potential or actual shortage such as actual or estimated start and end dates and suspected or known cause; | (d) details of the potential or actual shortage such as actual or estimated start and end dates and suspected or known cause ***as well as information on potential bottlenecks in the supply chain***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>475</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point d a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(da)*** ***information on active substance manufacturing sites, where relevant;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>476</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point e</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| ***(e)*** ***sales and market share data;*** | ***deleted*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>477</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point e</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (e) sales and market share data; | (e) sales***, available stock, where relevant,*** and market share data; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>478</NumAm>

<RepeatBlock-By><Members>Pernille Weiss</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point f</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (f) details of available alternative medicinal products; | (f) details of available alternative medicinal products ***where known by the marketing authorisation holder***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>479</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point g</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (g) mitigation plans including production and supply capacity; | (g) ***prevention and*** mitigation plans including ***but not limited to information on*** production and supply capacity***, production sites of finished pharmaceutical products and active pharmaceutical ingredients and raw materials, potential alternative production sites, minimum stock levels***;***[PA1] such plans shall contain preventative measures that help ensure the continued supply of critical medicines, such as diversification of supply chains;*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

To prevent and mitigate shortages, and to organize alternative supply more information on the supply chain is needed, including where medicinal products are produced, the origin of raw materials, as well as possible alternative suppliers of raw materials, API and alternative places of production of finished products if needed.

</Amend>

<Amend>Amendment <NumAm>480</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point g</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (g) mitigation plans including production and supply capacity; | (g) ***prevention and*** mitigation plans including ***information on*** production and supply capacity; ***production sites of the finished pharmaceutical product and of active pharmaceutical ingredients, potential alternative production sites, minimum stock levels, etc.;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>481</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point g</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (g) mitigation plans including production and supply capacity; | (g) ***prevention and*** mitigation plans including ***information on*** production and supply capacity; ***production sites of the finished pharmaceutical product and of active pharmaceutical ingredients, potential alternative production sites, minimum stock levels, etc;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>482</NumAm>

<RepeatBlock-By><Members>Sara Cerdas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point g</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (g) mitigation plans including production and supply capacity; | (g) ***prevention and*** mitigation plans including ***information on*** production and supply capacity; ***production sites of the finished pharmaceutical product and of active pharmaceutical ingredients, potential alternative production sites, minimum stock levels, etc.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>483</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point g</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (g) mitigation plans including production and supply capacity; | (g) mitigation plans including production and supply capacity; ***these plans shall contain preventative measures that help ensure the continued supply of critical medicines, such as diversification of supply chains;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>484</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point g</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (g) mitigation plans including production and supply capacity; | (g) mitigation plans ***containing preventative measures that help ensure the continued supply of critical medicines, such as diversification of supply chains, as well as*** including production and supply capacity; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>485</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Nils Torvalds, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point g</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (g) mitigation plans including production and supply capacity; | (g) mitigation plans***,*** including production and supply capacity***, with a view to guarantee continued supply and prevent shortages of medicinal products included on the critical medicines lists***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>486</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point g</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (g) mitigation plans including production and supply capacity; | (g) ***prevention and*** mitigation plans including production and supply capacity; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>487</NumAm>

<RepeatBlock-By><Members>Pernille Weiss</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point g</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (g) mitigation plans ***including production and supply capacity***; | (g) mitigation plans; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>488</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point g a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(ga)*** ***update the format and content of the Article 57 database to include the industry Single Point of contact (iSPOC) names as reported by industry. Industry should be able to digitally update the iSPOC names in the Article 57 database if needed and compliant with the standards of the International Organization for Standardization (ISO) for the identification of medicinal products (IDMP)3;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>489</NumAm>

<RepeatBlock-By><Members>Sara Cerdas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point h</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| ***(h)*** ***information from the wholesale distributors and legal person entitled to supply the medicinal product to the public.*** | ***deleted*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>490</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Jan Huitema</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point h</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| ***(h)*** ***information from the wholesale distributors and legal person entitled to supply the medicinal product to the public.*** | ***deleted*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Information of a sensitive commercial nature, to be collected by national competent authorities rather.

</Amend>

<Amend>Amendment <NumAm>491</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 – point h</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (h) information from the wholesale distributors and legal person entitled to supply the medicinal product to the public. | (h) information ***on stock levels*** from the wholesale distributors and legal person entitled to supply the medicinal product to the public***, via their representatives who are part of the sub-network referred to in point (a) of paragraph 2***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>492</NumAm>

<RepeatBlock-By><Members>Sirpa Pietikäinen</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***3 a.*** ***Following the recognition of a public health emergency or a request for assistance referred to in Article 4 (3), the Agency shall establish:*** |
|  | ***(a) a minimum stock level for wholesale distributors and other legal entities entitled to supply the public with medicinal products included on the critical medicines lists;*** |
|  | ***(b) an emergency preparedness plan to fast track an increase in the production capacity so that it is sufficient to fulfil Union needs for the medicinal products included on the critical medicines lists.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>493</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***3 a.*** ***The information referred to in point (c) of paragraph 2 shall include at least details of (a) available alternative medicinal products; (b) information from the wholesale distributors and legal person entitled to supply the medicinal product to the public.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>494</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***3 a.*** ***The information referred to in point (c) of paragraph 2 shall include at least details of (a) available alternative medicinal products; (b) information from the wholesale distributors and legal person entitled to supply the medicinal product to the public.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>495</NumAm>

<RepeatBlock-By><Members>Sirpa Pietikäinen</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 9 – paragraph 3 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***3 b.*** ***In normal circumstances the Agency shall establish a minimum stock level for wholesale distributors and other legal entities entitled to supply the public with medicinal products.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>496</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – title</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| Obligations on marketing authorisation holders | Obligations on marketing authorisation holders ***and other actors in the supply chain*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>497</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, marketing authorisation holders for medicinal products included on the critical medicines lists shall submit ***the*** information referred to in Article 9(3) by the deadline set by the Agency. They shall submit ***the*** information through the points of contact designated in accordance with Article 9(2) and using the reporting methods and system established pursuant to Article 9(1). They shall provide updates where necessary. | 1. In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, marketing authorisation holders for medicinal products included on the critical medicines lists shall submit ***upload the additional*** information referred to in Article 9(3) ***in the harmonised pan-European interoperable and digitalized shortages reporting and notification system*** by the ***a reasonable*** deadline set by the Agency ***in concertation with industry***. They shall submit ***upload the additional*** information ***in the harmonised pan-European interoperable and digitalized shortages reporting and notification system*** through the points of contact designated in accordance with Article 9(2) and using the reporting methods and system established pursuant to Article 9(1). They shall provide updates where necessary. ***Once uploaded, the information is accessible to the Agency and national competent authorities, ensuring transparency and avoiding duplications of reporting at different levels and enabling the two-way communication with industry and entities of the pharmaceutical supply chain .*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>498</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, marketing authorisation holders for medicinal products included on the critical medicines lists shall submit the information referred to in Article 9(3) by the deadline set by the Agency***. They shall submit*** the information ***through the points of contact designated in accordance with Article 9(2) and using*** the reporting ***methods and system*** established ***pursuant to*** Article 9(1)***. They shall provide updates where necessary***. | 1. In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, marketing authorisation holders for medicinal products included on the critical medicines lists shall submit the information referred to in Article 9(3) by the deadline set by the Agency***, if*** the information ***is not available via the interoperable system connected with*** the ***national shortages*** reporting ***systems*** established ***in*** Article 9(1) ***(c)***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>499</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, marketing authorisation holders for medicinal products included on the critical medicines lists shall submit the information referred to in Article 9(3) by the deadline set by the Agency***. They shall submit*** the information ***through the points of contact designated in accordance with Article 9(2) and using*** the reporting ***methods and system*** established ***pursuant to*** Article ***9(1). They shall provide updates where necessary***. | 1. In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, marketing authorisation holders for medicinal products included on the critical medicines lists shall submit the information referred to in Article 9(3) by the deadline set by the Agency***, if*** the information ***is not available via the interoperable system connected with*** the ***national shortages*** reporting ***systems*** established ***in*** Article ***9 (1) (c)***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>500</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin, Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, marketing authorisation holders for medicinal products included on the critical medicines lists shall submit the information referred to in Article 9(3) by the deadline set by the Agency. They shall submit the information through the points of contact designated in accordance with Article 9(2) and using the reporting methods and system established pursuant to Article 9(1). They shall provide updates where necessary. | 1. In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, marketing authorisation holders for medicinal products included on the critical medicines lists***, and all distributors legally authorised to supply medicines to the public,*** shall submit the information referred to in Article 9(3) by the deadline set by the Agency. They shall submit the information through the points of contact designated in accordance with Article 9(2) and using the reporting methods and system established pursuant to Article 9(1). They shall provide updates where necessary. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>501</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. Marketing authorisation holders of medicinal products authorised in the Union shall, within ***6*** months from the date of application of this Regulation, provide the information required pursuant to Article 9(1)(e) in the form of an electronic submission in the database referred to in Article 57(1)(l) of Regulation (EC) No 726/2004. Those marketing authorisation holders shall update their submission wherever necessary. | 2. Marketing authorisation holders of medicinal products authorised in the Union shall, within ***12-24*** months from the date of application of this Regulation, provide the information required pursuant to Article 9(1)(e) in the form of an electronic submission in the database referred to in Article 57(1)(l) of Regulation (EC) No 726/2004 ***and compliant with the standards of the International Organization for Standardization (ISO) for the identification of medicinal products (IDMP)***. Those marketing authorisation holders shall update their submission wherever necessary. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>502</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. Marketing authorisation holders of medicinal products authorised in the Union shall, within 6 months from the date of application of this Regulation, provide the information required pursuant to Article 9(1)(e) in the form of an electronic submission in the database referred to in Article 57(1)(l) of Regulation (EC) No 726/2004. Those marketing authorisation holders shall update their submission wherever necessary. | 2. Marketing authorisation holders of medicinal products authorised in the Union shall, within 6 months from the date of application of this Regulation, provide the information required pursuant to Article 9(1)(e) in the form of an electronic submission in the database referred to in Article 57(1)(l) of Regulation (EC)No 726/2004 ***and compliant with ISO IDMP standards for the identification of human medicines***. Those marketing authorisation holders shall update their submission wherever necessary. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>503</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| ***3.*** ***Marketing authorisation holders shall justify the absence of any requested information and any delays in providing it by the deadline set by the Agency.*** | ***deleted*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

It is unclear how exactly this information will be used by the Medicines Steering Group when issuing recommendations. Moreover, medical device manufacturers and notified bodies may not always be willing to provide the Agency with the requested information, particularly in view of confidentiality provisions and the absence of any punitive sanctions, as disclosure could undermine the economic interest or competitive position of the owner of the information.

</Amend>

<Amend>Amendment <NumAm>504</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. Marketing authorisation holders shall ***justify the absence of any requested information and any delays in providing it by the deadline set by the Agency***. | 3. ***Marketing authorisation holders of medicinal products authorised in the Union shall, within 6 months from the date of application of this Regulation, provide the information required pursuant to Article 9(1)(e) in the form of an electronic submission in the database referred to in Article 57(1)(l) of Regulation (EC)No 726/2004 and compliant with ISO IDMP standards for the identification of human medicines. Those*** marketing authorisation holders shall ***update their submission wherever necessary***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>505</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. Marketing authorisation holders shall justify the absence of any requested information and any delays in providing it by the deadline set by the Agency. | 3. Marketing authorisation holders shall justify the absence of any requested information and any delays in providing it by the deadline set by the Agency. ***Marketing authorisation holders failing to comply with their reporting obligations shall be subject to proportionate sanctions set by the Commission in a delegated act.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>506</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. Marketing authorisation holders shall justify the absence of any requested information and any delays in providing it by the deadline set by the Agency. | 3. Marketing authorisation holders shall justify the absence of any requested information and any delays in providing it by the deadline set by the Agency ***after consultation and agreement with industry on a case by case scenario***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>507</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. Marketing authorisation holders shall justify the absence of any requested information and any delays in providing it by the deadline set by the Agency. | 3. Marketing authorisation holders shall justify the absence of any requested information and any delays in providing it by the deadline set by the Agency ***after consultation and agreement with industry on a case by case scenario***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>508</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. Where marketing authorisation holders for medicinal products included on the critical medicines lists indicate that the submitted information contains information of a commercially confidential nature, they shall identify the relevant parts and clarify the reasons for such an indication. The Agency shall assess the merits of each request and protect commercially confidential information against unjustified disclosure. | 4. Where marketing authorisation holders for medicinal products included on the critical medicines lists indicate that the submitted information contains information of a commercially confidential nature, they shall identify the relevant parts and clarify the reasons for such an indication. The Agency shall assess the merits of each request and protect commercially confidential information against unjustified disclosure***, in accordance with Article 30 of this Regulation***. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>509</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. Where marketing authorisation holders for medicinal products included on the critical medicines lists indicate that the submitted information contains information of a commercially confidential nature, they shall identify the relevant parts and clarify the reasons for such an indication. The Agency shall assess the merits of each request and protect commercially confidential information against unjustified disclosure. | 4. Where marketing authorisation holders for medicinal products included on the critical medicines lists indicate that the submitted information contains information of a commercially confidential nature, they shall identify the relevant parts and clarify the reasons for such an indication. ***It should be determined upfront what information is commercially confident, based on this*** the Agency shall assess the merits of each request and protect commercially confidential information against unjustified disclosure. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>510</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. Where marketing authorisation holders for medicinal products included on the critical medicines lists indicate that the submitted information contains information of a commercially confidential nature, they shall identify the relevant parts and clarify the reasons for such an indication. The Agency shall assess the merits of each request and protect commercially confidential information against unjustified disclosure. | 4. Where marketing authorisation holders for medicinal products included on the critical medicines lists indicate that the submitted information ***requested by the Agency and the national competent authorities*** contains information of a commercially confidential nature, they shall identify the relevant parts and clarify the reasons for such an indication. The Agency shall assess the merits of each request and protect commercially confidential information against unjustified disclosure. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>511</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. Where marketing authorisation holders for medicinal products included on the critical medicines lists are in possession of any additional information, which provides evidence of a potential or actual shortage they shall immediately provide such information to the Agency. | 5. Where marketing authorisation holders for medicinal products included on the critical medicines lists are in possession of any additional information, which provides evidence of a potential or actual shortage they shall immediately provide such information to the Agency. ***National, or where applicable regional, competent authorities shall facilitate patient and consumer reporting of medicine shortages through the digital interoperable database referred to in Article 1(b) and Article 12(g). Aggregated data from these reports shall be shared by the sub-network of single points of contact from national, or where applicable regional, competent authorities referred to in Article 3(5) with the Steering Group to inform recommendations on medicine shortage management.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>512</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. Where marketing authorisation holders for medicinal products included on the critical medicines lists are in possession of any additional information, which provides evidence of a potential or actual shortage they shall immediately provide such information to the Agency. | 5. Where marketing authorisation holders for medicinal products included on the critical medicines lists are in possession of any additional information, which provides evidence of a potential or actual shortage they shall immediately provide such information to the Agency. ***In the absence of notification of essential information, the Agency, the Commission and Member States should enact sanctions, e.g. financial penalties, extending compulsory license or removing intellectual property rights to allow that other actors can minimise the shortage.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Sanctions should be foreseen in case of non-respect of provision of essential information. The sanctions and/or removal of intellectual property rights aim to enable the production of essential health products by other producers.

</Amend>

<Amend>Amendment <NumAm>513</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. Where marketing authorisation holders for medicinal products included on the critical medicines lists are in possession of any additional information, which provides evidence of a potential or actual shortage they shall immediately provide such information to the Agency. | 5. Where marketing authorisation holders for medicinal products included on the critical medicines lists ***and /or other relevant entities of the pharmaceutical supply chain,*** are in possession of any additional information, which provides evidence of a potential or actual shortage they shall immediately provide such information to the Agency. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>514</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 6 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) provide any comments they have to the Agency; | (a) provide any comments they have to the Agency***, in accordance with Article 30 of this Regulation***; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>515</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 6 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) inform the Medicines Steering Group of any measures taken and report on the results of those measures, including information on the resolution of the potential or actual shortage. | (c) inform the Medicines Steering Group of any measures taken and report on the ***monitoring and*** results of those measures, including information on the resolution of the potential or actual shortage. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>516</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***6 a.*** ***In order to supplement the shortage prevention and mitigation plans of critical products, the Agency and national competent authorities may request additional information from wholesale distributors and other relevant actors regarding any logistical challenges incurred by the wholesale supply chain.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>517</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***6 a.*** ***6 a. The Commission and Member States shall lay down rules on sanctions for non-compliance with the obligations established under this Article. These sanctions shall be dissuasive.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>518</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***6 a.*** ***The Commission and Member States shall lay down rules on sanctions for non-compliance with the obligations established under this Article. These sanctions shall be dissuasive.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The Regulation should require that the European Commission and Member States lay down rules on sanctions for non-compliance by companies with their obligations.

</Amend>

<Amend>Amendment <NumAm>519</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 10 – paragraph 6 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***6 b.*** ***The Commission shall exercise its power to lay down rules on sanctions for non-compliance with the obligations established under this Article in a delegated act.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>520</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 1 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, Member States shall, by the deadline set by the Agency***:*** | 1. In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, Member States shall, by the deadline set by the Agency***, where relevant, following the creation of a harmonized pan-European interoperable and digital National Competent Authorities (NCAs) shortages reporting system based on common data fields (a) submit the set of information requested by the Agency in Chapter 2 Article 9 (4) including available and estimated data on volume of demand, through its designated point of contact and using the reporting methods and system established pursuant to Article 9(1);*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>521</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 1 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, Member States shall, by the deadline set by the Agency: | 1. In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, Member States shall, by the deadline set by the Agency***, submit the following, if not already available in the harmonised pan-European interoperable and digitalized shortages reporting and notification system*** : |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>522</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 1 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, Member States shall, by the deadline set by the Agency: | 1. In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, Member States ***or any national competent authority*** shall, by the deadline set by the Agency: |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>523</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) submit the set of information requested by the Agency including available and estimated data on volume of demand, through its designated point of contact and using the reporting methods and system established pursuant to Article 9(1); | (a) ***In order to facilitate the monitoring referred to in Article 7 and following a request from the Agency, Member States shall, by the deadline set by the Agency, where relevant, following the creation of a harmonized pan-European interoperable and digital National Competent Authorities (NCAs) shortages reporting system based on common data fields (a)*** submit the set of information requested by the Agency ***in Chapter 2 Article 9 (4)*** including available and estimated data on volume of demand, through its designated point of contact and using the reporting methods and system established pursuant to Article 9(1); |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>524</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) submit the set of information requested by the Agency including available and estimated data on volume of demand, through its designated point of contact and using the reporting methods and system established pursuant to Article 9(1); | (a) submit the set of ***additional*** information requested by the Agency ***in Chapter 2 Article 9 (3)*** including available and estimated data on volume of demand, through its designated point of contact and using the reporting methods and system established pursuant to Article 9(1); |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>525</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) submit the set of information requested by the Agency including ***available and*** estimated data on volume of demand, through its designated point of contact and using the reporting methods and system established pursuant to Article 9(1); | (a) submit the set of ***available***information ***to Member States*** requested by the Agency including estimated data on volume of demand, through its designated point of contact and using the reporting methods and system established pursuant to Article 9(1); |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>526</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) submit the set of information requested by the Agency including available and estimated data on volume of demand, through its designated point of contact and using the reporting methods ***and*** system established pursuant to Article 9(1); | (a) submit the set of information requested by the Agency including available and estimated data on volume of demand, through its designated point of contact and using the reporting methods***,*** system ***and platform*** established pursuant to Article 9(1); |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>527</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| ***2.*** ***Where necessary to fulfil their reporting obligations set out in paragraph 1, Member States, with the support of the Agency, shall gather information and data on stock levels from wholesale distributors and other legal entities entitled to supply the public with medicinal products included on the critical medicines lists.*** | ***deleted*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The obligation on manufacturers, authorised representatives and importers to provide inventory reporting is already required under EUDAMED, and it is unnecessary to include this under an additional system. Furthermore, it is questionable whether the competent authority, at the request of the Agency, will be able to contact all manufacturers, authorised representatives, importers and distributors in a timely and relevant manner in acquiring this information.

</Amend>

<Amend>Amendment <NumAm>528</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. Where necessary to fulfil their reporting obligations set out in paragraph 1, Member States, with the support of the Agency, shall gather information and data on stock levels from wholesale distributors and other legal entities entitled to supply the public with medicinal products included on the critical medicines lists***.*** | 2. Where necessary to fulfil their reporting obligations set out in paragraph 1, Member States, with the support of the Agency, shall gather information and data on stock levels from ***wholesale*** distributors and other legal entities entitled to supply the public with medicinal products included on the critical medicines lists***, when not yet available or accessible in the harmonised pan-European interoperable and digitalized shortages reporting and notification system*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>529</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. Where necessary to fulfil their reporting obligations set out in paragraph 1, Member States, with the support of the Agency, shall gather information and data on stock levels from wholesale distributors and other legal entities entitled to supply the public with medicinal products included on the critical medicines lists. | 2. Where necessary to fulfil their reporting obligations set out in paragraph 1, Member States, with the support of the Agency, shall gather information and data on stock levels from ***marketing authorisation holders,*** wholesale distributors***, community and hospital pharmacies,*** and other legal entities entitled to supply the public with medicinal products included on the critical medicines lists. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>530</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 2 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***2a.*** ***Where necessary to fulfil their reporting obligations set out in paragraph 1, Member States, with the support of the Agency, shall gather information and data on unmet demands from wholesale distributors, community and hospital pharmacies, and other legal entities entitled to supply the public with medicinal products included on the critical medicines lists.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>531</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. Where Member States are in possession of any additional information on volume of sales and volumes of prescriptions, including data based on Article 23a of Directive 2001/83/EC, which provides evidence of a potential or actual shortage of a medicinal product included on the critical medicines lists, they shall immediately provide such information to the Medicines Steering Group through their designated points of contact. | 3. Where Member States are in possession of any additional information on volume of sales and volumes of prescriptions, including data based on Article 23a of Directive 2001/83/EC, which provides evidence of a potential or actual shortage of a medicinal product included on the critical medicines lists, they shall immediately provide such information to the Medicines Steering Group through their designated points of contact ***via the harmonised pan-European interoperable and digitalized shortages reporting and notification system***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>532</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 4 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) ***take into account*** any recommendations and guidelines and comply with any measures taken at Union-level pursuant to Article 12; | (a) ***acknowledge*** any recommendations and guidelines and comply with any measures taken at Union-level pursuant to Article 12; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>533</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 4 – subparagraph 1 (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***Member States shall facilitate patient and consumer reporting of medicine shortages through the provision of alternative reporting formats in addition to web-based formats. Aggregated data from these reports shall be shared by the sub-network of single points of contact from national competent authorities referred to in Article 3 (5) with the Steering Group to inform recommendations on medicine shortage management.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>534</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 4 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***4 a.*** ***National medicines agencies in Member States shall facilitate patient and consumer reporting of medicine shortages through the provision of alternative reporting formats in addition to web-based formats. Aggregated data from these reports shall be shared by the sub-network of single points of contact from national competent authorities referred to in Article 3 (5) with the Medicines Steering Group to inform recommendations on medicine shortage impact and management.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Medicine shortages can lead to disease worsening, side effects from alternative treatments and even hospitalisation. Consumers/patients might also face extra costs due to alternative medicines being more expensive or not reimbursed. To better understand the implications of medicine shortages, and minimise their impact, public authorities should collect and process information about medicine users’ experience with shortages.

</Amend>

<Amend>Amendment <NumAm>535</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 11 – paragraph 4 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***4 a.*** ***Member States shall facilitate patient and consumer reporting of medicine shortages through the provision of alternative reporting formats in addition to web-based formats. Aggregated data from these reports shall be shared by the sub-network of single points of contact from national competent authorities referred to in Article 3 (5) with the Steering Group to inform recommendations on medicine shortage management.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Drug shortages can lead to disease worsening, side effects from alternative treatments and even hospitalisation. Consumers might also face extra costs due to alternative medicines being more expensive or not reimbursed. To better understand the implications of drug shortages, and minimise their impact on consumers, public authorities should collect and process information about medicine users’ experience with shortages.

</Amend>

<Amend>Amendment <NumAm>536</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Commission shall take into account the information from and recommendations of the Medicines Steering Group and shall: | The Commission shall take into account the ***aggregated data from the harmonised pan-European interoperable and digitalized shortages reporting and notification system, as well as*** information from and recommendations of the Medicines Steering Group and shall: |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>537</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point a a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(aa)*** ***The European Commission shall facilitate the coordination between manufacturers and other relevant stakeholders to address demand surges adapting with relevant European legislation including competition, internal market and pharmaceutical regulation.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>538</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities; | (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities***, including healthcare professionals, to support them in their work and in the communication with patients***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>539</NumAm>

<RepeatBlock-By><Members>Sara Cerdas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities; | (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities***, including healthcare professionals to support them in their work and in the communication with patients***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>540</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities; | (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities***, including healthcare professionals to support them in their work and in the communication with patients***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>541</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities; | (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities***, including healthcare professionals to support them in their work and in the communication with patients***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>542</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska, Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities; | (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities***, including healthcare professionals, in order to support their work and communication with patients***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>543</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities; | (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities ***where this is proportionate, justified and necessary***; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>544</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities; | (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities ***including from the pharmaceutical supply chain***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>545</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities; | (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities***, including healthcare professionals***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>546</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities***;*** | (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities ***of the pharmaceuticals supply chain*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>547</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) consider the need for guidelines addressed to Member States, marketing authorisation holders, and other entities; | (b) consider the need for guidelines ***and recommendations*** addressed to Member States, marketing authorisation holders, and other entities; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>548</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) inform the Medicines Steering Group of any measures taken and report on the results; | (c) inform the Medicines Steering Group ***and industry (via the trade associations)*** of any measures taken and report on the results; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>549</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) inform the Medicines Steering Group of any measures taken and report on the results; | (c) inform the Medicines Steering Group ***and industry*** of any measures taken and report on the results; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>550</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point f a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fa)*** ***assist the Agency in building the digital and interoperable database referred to in Article 1(b) and Article12(g), with the following main tasks:*** |
|  | ***i. facilitate the prevention, monitoring and reporting of shortages of medicinal products, devices and applications,*** |
|  | ***ii. track and follow medicinal products, devices and applications throughout the supply chain,*** |
|  | ***iii. determine the volume of stock, the capabilities of all stakeholders linked in the supply chain or chains, the actual, current and foreseeable level of demand obtain,*** |
|  | ***iv. record and share information about innovative medicinal products, devices, applications or developments that are still not harmonised throughout the Union, such as plasma-derived products.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>551</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 – point f b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(fb)*** ***sanction those marketing authorisation holders, manufacturers or Member States that do not comply with the demands of information by the Agency;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>552</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 – paragraph 1 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***The Commission shall provide answers to (priority) written questions from Members of the European Parliament within the deadline;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>553</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 12 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | Article 12 a |
|  | European medicines supply database |
|  | ***1. The Agency shall, in collaboration with the Commission and Member States, set up, maintain and manage the European medicines supply database (EUMSD) for the following purposes:*** |
|  | ***(a) to enable the monitoring of supply and demand of medicinal products at Union and Member State level;*** |
|  | ***(b) to enable the monitoring and reporting of shortages of medicinal products at Union and Member State level;*** |
|  | ***(c) to enable marketing authorisation holders and wholesale distributors to comply with the information obligations laid down in Article 10;*** |
|  | ***(d) to enable the Commission, the national competent authorities and the Agency to carry out their tasks relating to this Regulation on a well-informed basis and to enhance the cooperation between them.*** |
|  | ***The EUMSD, which shall be functional not only during public health emergencies and major events but also under normal circumstances, shall function as an interoperable and harmonised Union database, based on the data reported through the national electronic platforms established pursuant to paragraph 2. The database shall allow the national competent authorities and the Agency to simultaneously access and share the information provided in the database.*** |
|  | ***2. Each Member State shall develop an electronic platform for real-time monitoring of the supply of medicinal products, capable of determining the volume of supply existing at any given moment, and detecting, predicting and preventing shortages of medicinal products. Those platforms, which shall be managed by the national competent authorities, shall be fully operational at Member State level by... [30 months after the date of entry into force of this Regulation].*** |
|  | ***Data on supply and demand shall be reported at Member State level by the following entities:*** |
|  | ***(a) marketing authorisation holders*** |
|  | ***(b) wholesale distributors*** |
|  | ***(c) community and hospital pharmacies*** |
|  | ***3. In addition to paragraph 2, the electronic platforms shall provide the national competent authorities with real-time access to unmet demands from wholesale distributors, community pharmacies and hospital pharmacies at national level. Those platforms shall also allow marketing authorisation holders to report any medicinal products supply problems, including manufacturing problems.*** |
|  | ***4. Member State platforms shall be interoperable and shall replicate their information in the EUMSD managed by the Agency, thus preventing any duplication of the reporting process by the single points of contact established in Article 9(2).*** |
|  | ***5. The data generated by the Member State platforms and consequently by the EUMSD shall make it possible to identify any supply problems along the supply chain and, through the application of big data techniques and, where appropriate, artificial intelligence, shall be able to forecast supply problems in advance.*** |
|  | ***6. The data submitted shall be compliant with the International Organization for Standardization for the identification of medicinal products standards for the identification and description of medicinal products for human use and be based on the four domains of master data in pharmaceutical regulatory processes: substance, product, organisation and referential data.*** |
|  | ***7. The Agency shall, in collaboration with the Commission and Member States , draw up the functional specifications for the database, together with a plan for the implementation of the EUMSD and the Member State platforms by... [6 months after the entry into force of this Regulation] . That plan shall seek to ensure that the EUMSD is fully functional by ...[48 months after the date of entry into force of this Regulation] .*** |
|  | ***8. Where a national competent authority indicates that the submitted information contains information of a commercially confidential nature, it shall identify the relevant parts and clarify the reasons for such an indication. The Agency shall assess the merits of each request and protect commercially confidential information against unjustified disclosure.*** |
|  | ***9. Considering the commercially sensitive data provided in the EUMSD, access to the database shall be limited to the Commission, the Agency, national competent authorities reporting the data to the database and the Medicines Steering Group.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

While supporting the Rapporteur's proposal for a streamlined and single platform to monitor, detect, predict and prevent shortages of medicinal products so as to be immediately operational in preparation for or during a health crisis, the tracking and tracing system appears too costly, burdensome for pharmacies, hospitals and self-dispensing doctors. We therefore propose to amend his proposal to rely on volumes of stocks throughout the supply chain rather than a tracking-and-tracing system of individual medicinal products.

</Amend>

<Amend>Amendment <NumAm>554</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 13 – paragraph -1 (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***-1*** ***The Agency shall establish an early warning system to inform relevant stakeholders, including doctors and community and hospital pharmacists of any supply problems and potential or actual shortages of medicines included on the critical medicines list.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>555</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 13 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means, in conjunction with national competent authorities, inform the public and interest groups with regard to the work of the Medicines Steering Group. | The Agency shall, via its web-portal and other appropriate means, in conjunction with national competent authorities, inform the public and interest groups ***in a timely manner*** with regard to the work of the Medicines Steering Group***, and ensure adequate consultation with the Patients’ and Consumers’ Working Party (PCWP) and the Healthcare Professionals’ Working Party (HCPWP)***. ***The list of the members of the Medicines Steering Group, the rules of procedure, agendas and minutes of the meetings and recommendations shall be published on the Agency’s web-portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>556</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 13 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means, in conjunction with national competent authorities, inform the public and interest groups with regard to the work of the Medicines Steering Group. | The Agency shall, via its web-portal and other appropriate means, in conjunction with national***, or where applicable regional,*** competent authorities, inform the public and interest groups with regard to the work of the Medicines Steering Group***, ensuring the sharing of information by the Patients’ and Consumers’ Working Party as well as a representative of the Healthcare Professionals’ Working Party as observers***. ***The Agency shall assess the transparency of the undertakings of the Medicines Steering Group, taking into account principles of transparency and accountability.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>557</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 13 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means, in conjunction with national competent authorities, inform the public and interest groups with regard to the work of the Medicines Steering Group. | The Agency shall, via its web-portal and other appropriate means, in conjunction with national competent authorities, inform the public and interest groups with regard to the work of the Medicines Steering Group***, and ensure adequate consultation with the Patients’ and Consumers’ Working Party and the Healthcare Professionals’ Working Party***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>558</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 13 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means, in conjunction with national competent authorities, inform the public and interest groups with regard to the work of the Medicines Steering Group***.*** | The Agency shall, via its web-portal and other appropriate means, in conjunction with national competent authorities, inform the public and interest groups with regard to the work of the Medicines Steering Group***, and ensure adequate consultation with the Patients’ and Consumers’ Working Party and the Healthcare Professionals’ Working Party*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>559</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 13 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means, in conjunction with national competent authorities, inform the public and interest groups with regard to the work of the Medicines Steering Group. | The Agency shall, via its web-portal and other appropriate means, in conjunction with national competent authorities, inform ***without delay*** the public and interest groups with regard to the work of the Medicines Steering Group***, and respond to disinformation as appropriate***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>560</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. The Emergency Task Force is hereby established as part of the Agency***.*** It shall be convened during public health emergencies, either in person or remotely. The Agency shall provide its secretariat. | 1. The Emergency Task Force is hereby established as ***a permanent structure as*** part of the Agency It shall be convened during public health emergencies, either in person or remotely. The Agency shall provide its secretariat. ***The Emergency Task Force shall work with scientific committees, working parties and scientific advisory groups of the Agency in the area of pandemic preparedness and response. It shall cooperate with Union bodies and agencies, the World Health Organization, third countries, and international scientific organisations on scientific and technical issues related to pandemic preparedness. The Agency, in collaboration with the Member States, shall, in parallel, proactively foster expertise building to avoid a shortage of expertise due to a public health emergency, in areas which are unrelated to the public health emergency.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>561</NumAm>

<RepeatBlock-By><Members>Carlo Calenda</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. The Emergency Task Force is hereby established as part of the Agency. It shall be convened during public health emergencies, either in person or remotely. The Agency shall provide its secretariat. | 1. The ***permanent*** Emergency Task Force is hereby established as part of the Agency. It shall be convened during public health emergencies, either in person or remotely. The Agency shall provide its secretariat. ***The Emergency Task Force shall cooperate with EU bodies and agencies, the World Health Organization, third countries and international scientific organisations in preparing timely and appropriate responses to health emergencies. The Agency, working together with the Member States, shall undertake to develop the protocols and expertise necessary for a timely and appropriate response to health crises, including for sectors other than the health sector, in order to improve crisis response capacity.*** |

Or. <Original>{IT}it</Original>

</Amend>

<Amend>Amendment <NumAm>562</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. The Emergency Task Force is hereby established as part of the Agency. It shall be convened during public health emergencies, either in person or remotely. The Agency shall provide its secretariat. | 1. The Emergency Task Force is hereby established as part of the Agency. It shall be convened ***as often as needed*** during public health emergencies, either in person or remotely. The Agency shall provide its secretariat. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>563</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. The Emergency Task Force is hereby established as part of the Agency. It shall be convened during public health emergencies, either in person or remotely. The Agency shall provide its secretariat. | 1. The Emergency Task Force is hereby established as part of the Agency. It shall be convened ***in preparation for and*** during public health emergencies, either in person or remotely. The Agency shall provide its secretariat. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>564</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. The Emergency Task Force is hereby established as part of the Agency. It shall be convened during public health emergencies, either in person or remotely. The Agency shall provide its secretariat. | 1. The Emergency Task Force is hereby established as part of the Agency. It shall be convened ***only*** during public health emergencies, either in person or remotely. The Agency shall provide its secretariat. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>565</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 2 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) providing scientific advice and reviewing the available scientific data on medicinal products with the potential to address the public health emergency, including requesting data from developers and engaging with them in preliminary discussions; | (a) providing scientific advice and reviewing the available scientific data on ***human and veterinary*** medicinal products with the potential to address the public health emergency, including requesting data from developers and engaging with them in preliminary discussions; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>566</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 2 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) reviewing clinical trial protocols and providing advice to developers on clinical trials to be conducted in the Union for medicinal products intended to treat, prevent, or diagnose the disease causing the public health emergency, in accordance with Article 15; | (b) reviewing clinical trial protocols and providing advice to developers on clinical trials to be conducted in the Union***, in particular on large multicentre clinical trials,*** for medicinal products intended to treat, prevent, or diagnose the disease causing the public health emergency, in accordance with Article 15; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>567</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 2 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) reviewing clinical trial protocols and providing advice to developers on clinical trials to be conducted in the Union for medicinal products intended to treat, prevent, or diagnose the disease causing the public health emergency, in accordance with Article 15; | (b) reviewing clinical trial protocols and providing advice to developers on clinical trials to be conducted in the Union***, in particular on large multi-centre trials,*** for medicinal products intended to treat, prevent, or diagnose the disease causing the public health emergency, in accordance with Article 15; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>568</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 2 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) reviewing clinical trial protocols and providing advice to developers on clinical trials to be conducted in the Union for medicinal products intended to treat, prevent, or diagnose the disease causing the public health emergency, in accordance with Article 15; | (b) reviewing clinical trial protocols and providing advice to developers on clinical trials to be conducted in the Union***, in particular on large multicentre clinical trials,*** for medicinal products intended to treat, prevent, or diagnose the disease causing the public health emergency, in accordance with Article 15; |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

During the COVID-19 pandemic, there has been a large mobilisation of resources to fund clinical trials for the development of vaccines and treatments. However, there has not been sufficient coordination among the various initiatives leading most likely to redundancies and delays. To avoid that, the Regulation should explicitly require in Article 14 that the Task Force that will be set up to promote the development of medicines that can help address public health emergencies supports coordinated multicentre trials.

</Amend>

<Amend>Amendment <NumAm>569</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 2 – point e</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (e) providing scientific recommendations with regard to the use of any medicinal product, which may have the potential to address public health emergencies, in accordance with Article 16; | (e) providing scientific recommendations with regard to the use of any medicinal product***, and in particular alternative medicinal products***, which may have the potential to address public health emergencies, in accordance with Article 16; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>570</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 2 – point e</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (e) providing scientific recommendations with regard to the use of any medicinal product, which may have the potential to address public health emergencies, in accordance with Article 16; | (e) providing scientific recommendations with regard to the use of any ***human or veterinary*** medicinal product, which may have the potential to address public health emergencies, in accordance with Article 16; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>571</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 2 – point e a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(ea)*** ***collecting information from national competent authorities and defining a pan-European list of alternative products for use to address public health emergencies. Such list shall be accessible for relevant healthcare stakeholders;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>572</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 2 – point f</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (f) cooperating with Union bodies and agencies, the World Health Organization, third countries, and international scientific organisations on scientific and technical issues relating to the public health emergency and to medicinal products which may have the potential to address public health emergencies, as necessary. | (f) cooperating with ***national and regional competent authorities,*** Union bodies and agencies, the World Health Organization, third countries, and international scientific organisations on scientific and technical issues relating to the public health emergency and to medicinal products which may have the potential to address public health emergencies, as necessary. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>573</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Emergency Task Force shall be composed of representatives of the scientific committees, working parties, and staff members of the Agency, the coordination group established in accordance with Article 27 of Directive 2001/83/EC, and the Clinical Trials Coordination and Advisory Group established in accordance with Article 85 of Regulation (EU) 536/2014.21 External experts may be appointed and representatives of other Union bodies and agencies be invited on an ad hoc basis, as necessary. It shall be chaired by the Agency. | 3. The Emergency Task Force shall be composed of representatives of the scientific committees, working parties***, including a representative of the Patients’ and Consumers’ Working Party and a representative of the Healthcare Professionals’ Working Party***, and staff members of the Agency, the coordination group established in accordance with Article 27 of Directive 2001/83/EC, and the Clinical Trials Coordination and Advisory Group established in accordance with Article 85 of Regulation (EU) 536/2014 .21 External experts may be appointed and representatives of other Union bodies and agencies be invited on an ad hoc basis, as necessary. It shall be chaired by the Agency. |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 21 Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC, OJ L 158, 27.5.2014, p. 1 | 21 Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC, OJ L 158, 27.5.2014, p. 1 |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>574</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Emergency Task Force shall be composed of representatives of the scientific committees, working parties, and staff members of the Agency, the coordination group established in accordance with Article 27 of Directive 2001/83/EC, and the Clinical Trials Coordination and Advisory Group established in accordance with Article 85 of Regulation (EU) 536/2014.21 External experts may be appointed and representatives of other Union bodies and agencies be invited on an ad hoc basis, as necessary. It shall be chaired by the Agency. | 3. The Emergency Task Force shall be composed of representatives of the scientific committees, working parties***, including a representative of the Patients’ and Consumers’ Working Party and a representative of the Healthcare Professionals’ Working Party***, and staff members of the Agency, the coordination group established in accordance with Article 27 of Directive 2001/83/EC, and the Clinical Trials Coordination and Advisory Group established in accordance with Article 85 of Regulation (EU) 536/2014.21 External experts may be appointed and representatives of other Union bodies and agencies be invited on an ad hoc basis, as necessary. It shall be chaired by the Agency. |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 21 Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC, OJ L 158, 27.5.2014, p. 1 | 21 Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC, OJ L 158, 27.5.2014, p. 1 |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>575</NumAm>

<RepeatBlock-By><Members>Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Emergency Task Force shall be composed of representatives of the scientific committees, working parties, and staff members of the Agency, the coordination group established in accordance with Article 27 of Directive 2001/83/EC, and the Clinical Trials Coordination and Advisory Group established ***in accordance with Article 85 of Regulation (EU) 536/2014***.21 External experts may be appointed and representatives of other Union bodies and agencies be invited on an ad hoc basis, as necessary. It shall be chaired by the Agency. | 3. The Emergency Task Force shall be composed of representatives ***of the Member States,*** of the scientific committees, working parties, and staff members of the Agency, the coordination group established in accordance with Article 27 of Directive 2001/83/EC, and the Clinical Trials Coordination and Advisory Group established ***under Heads of Medicines Agencies. Each Member State may appoint one representative***. ***A Member State may delegate its tasks in the Emergency Task Force to another Member State.*** External experts may be appointed and representatives of other Union bodies and agencies be invited on an ad hoc basis, as necessary. It shall be chaired by the Agency. |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |  |
| 21 Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC, OJ L 158, 27.5.2014, p. 1 |  |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>576</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Emergency Task Force shall be composed of representatives of the scientific committees, working parties, and staff members of the Agency, the coordination group established in accordance with Article 27 of Directive 2001/83/EC, and the Clinical Trials Coordination and Advisory Group established in accordance with Article 85 of Regulation (EU) 536/2014.21 External experts may be appointed and representatives of other Union bodies and agencies be invited on an ad hoc basis, as necessary. It shall be chaired by the Agency. | 3. The Emergency Task Force shall be composed of representatives of the scientific committees, working parties***, namely representatives of the Patients’ and Consumers’ Working Party and the Healthcare Professionals’ Working Party***, and staff members of the Agency, the coordination group established in accordance with Article 27 of Directive 2001/83/EC, and the Clinical Trials Coordination and Advisory Group established in accordance with Article 85 of Regulation (EU) 536/2014.21 External experts may be appointed and representatives of other Union bodies and agencies be invited on an ad hoc basis, as necessary. It shall be chaired by the Agency. |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 21 Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC, OJ L 158, 27.5.2014, p. 1 | 21 Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC, OJ L 158, 27.5.2014, p. 1 |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>577</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 3 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***3 a.*** ***The Emergency Task Force shall be empowered to coordinate and exchange information and best practices with the health authorities of the Member States and the pharmaceutical industry in order to generate new synergies.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>578</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Chair ***may*** invite representatives of Member States, members of scientific committees of the Agency and working parties, and third parties, including representatives of medicinal product interest groups, marketing authorisation holders, developers of medicinal products, clinical trial sponsors, representatives of clinical trial networks, and interest groups representing patients and healthcare professionals ***to attend its meetings***. | 5. The Chair ***shall*** invite, ***to Emergency Task Force meetings throughout the public health emergency,*** representatives of Member States, members of scientific committees of the Agency and working parties, and third parties, including representatives of medicinal product interest groups, marketing authorisation holders, developers of medicinal products, clinical trial sponsors, representatives of clinical trial networks, and interest groups representing patients and healthcare professionals***, in order to provide the Emergency Task Force with the broadest and most detailed view of the situation at all times throughout the public health emergency***. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>579</NumAm>

<RepeatBlock-By><Members>Sara Cerdas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Chair may invite representatives of Member States, members of scientific committees of the Agency and working parties, and third parties, including representatives of medicinal product interest groups, marketing authorisation holders, developers of medicinal products, clinical trial sponsors, representatives of clinical trial networks, and interest groups representing patients and healthcare professionals to attend its meetings. | 5. The Chair may invite representatives of Member States, members of scientific committees of the Agency and working parties, and third parties, including representatives of medicinal product interest groups, marketing authorisation holders, developers of medicinal products, clinical trial sponsors, representatives of clinical trial networks, ***independent clinical trial experts and researchers,*** and interest groups representing patients and healthcare professionals to attend its meetings. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>580</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Chair may invite representatives of Member States, members of scientific committees of the Agency and working parties, and third parties, including representatives of medicinal product interest groups, marketing authorisation holders, developers of medicinal products, clinical trial sponsors, representatives of clinical trial networks, and interest groups representing patients and healthcare professionals to attend its meetings. | 5. The Chair may invite representatives of Member States, members of scientific committees of the Agency and working parties, and third parties, including representatives of medicinal product interest groups, marketing authorisation holders, developers of medicinal products, clinical trial sponsors, representatives of clinical trial networks, ***independent clinical trials experts and researchers,*** and interest groups representing patients and healthcare professionals to attend its meetings. |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The Covid-19 pandemic has shown that independent clinical trials experts had been among the first to point out the weaknesses in clinical trial protocols. The EMA emergency Task Force should have the possibility to take the advice of independent clinical trials experts.

</Amend>

<Amend>Amendment <NumAm>581</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Nils Torvalds, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Chair may invite representatives of Member States, members of scientific committees of the Agency and working parties, and third parties, including representatives of medicinal product interest groups, marketing authorisation holders, developers of medicinal products, clinical trial sponsors, representatives of clinical trial networks, and interest groups representing patients and healthcare professionals to attend its meetings. | 5. The Chair may invite representatives of Member States, members of scientific committees of the Agency and working parties, and third parties, including representatives of medicinal product interest groups, marketing authorisation holders, developers of medicinal products, clinical trial sponsors, representatives of clinical trial networks, ***independent clinical trial experts and researchers,*** and interest groups representing patients and healthcare professionals to attend its meetings. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>582</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Chair may invite representatives of Member States, members of scientific committees of the Agency and working parties, and third parties, including representatives of medicinal product interest groups, marketing authorisation holders, developers of medicinal products, clinical trial sponsors, representatives of clinical trial networks, and interest groups representing patients and healthcare professionals to attend its meetings. | 5. The Chair may invite representatives of Member States, members of scientific committees of the Agency and working parties, and third parties, including representatives of medicinal product interest groups, marketing authorisation holders, developers of medicinal products, clinical trial sponsors, representatives of clinical trial networks, ***independent clinical trial experts and researchers,*** and interest groups representing patients and healthcare professionals to attend its meetings. |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The Covid-19 pandemic has shown that independent clinical trials experts had been among the first to point out the weaknesses in clinical trial protocols. The EMA emergency Task Force should have the possibility to take the advice of independent clinical trials experts.

</Amend>

<Amend>Amendment <NumAm>583</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 6</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 6. The Emergency Task Force shall establish its rules of procedure including rules on the adoption of recommendations. The rules of procedure shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. | 6. The Emergency Task Force shall establish its rules of procedure including rules on the adoption of recommendations. The rules of procedure shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. ***The rules of procedure including rules on the adoption of recommendations as well as the opinions should be made public on the Agency web-portal. The agenda and minutes of the Task Force shall be made public via the Agency web-portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>584</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 6</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 6. The Emergency Task Force shall establish its rules of procedure including rules on the adoption of recommendations. The rules of procedure shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. | 6. The Emergency Task Force shall establish its rules of procedure including rules on the adoption of recommendations. The rules of procedure shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. ***The rules of procedure including rules on the adoption of recommendations, as well as the opinions meeting minutes and agendas should be made public on the Agency web-portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>585</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 6</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 6. The Emergency Task Force shall establish its rules of procedure including rules on the adoption of recommendations. The rules of procedures shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. | 6. The Emergency Task Force shall establish its rules of procedure***, which shall include rules relating to its formation, structure and confidentiality,*** including ***potential conflicts of interest. These rules of procedure shall also include*** rules on the adoption of recommendations. The rules of procedures shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>586</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska, Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 6</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 6. The Emergency Task Force shall establish its rules of procedure including rules on the adoption of recommendations. The rules of procedure shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. | 6. The Emergency Task Force shall establish its rules of procedure including rules on the adoption of recommendations. The rules of procedure shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. ***The agenda and minutes of the Task Force shall be made public through the Agency's online portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>587</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 14 – paragraph 9 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***9a.*** ***The Agency shall use traditional and social media to issue periodic communications, agreed by all Member States, to keep the general public informed, using accessible language and providing explanations that can be understood by all;*** |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>588</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 15 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. During a public health emergency, the Emergency Task Force shall review clinical trial protocols submitted or intended to be submitted in a clinical trial application by developers of medicinal products as part of an accelerated scientific advice process. | 1. During a public health emergency, the Emergency Task Force shall review clinical trial protocols submitted or intended to be submitted in a clinical trial application by developers of medicinal products as part of an accelerated scientific advice process***, taking into account possible innovative medicinal products, devices, applications or developments that are still not harmonised throughout the Union, such as plasma-derived products***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>589</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 15 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Emergency Task Force shall establish procedures for the request and submission of the set of information and data required, ***including information on*** the Member ***State or*** States where an application for authorisation of a clinical trial is submitted or is intended to be submitted. | 3. The Emergency Task Force shall establish procedures for the request and submission of the set of information and data required, ***in cooperation with*** the Member States where an application for authorisation of a clinical trial is submitted or is intended to be submitted ***in accordance with Article 4 of the Regulation 536/2014 on clinical trials on medicinal products for human use***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>590</NumAm>

<RepeatBlock-By><Members>Stanislav Polčák</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 15 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. The Emergency Task Force shall involve representatives of the Member State or States where an application for authorisation of a clinical trial is submitted or is intended to be submitted in the preparation of the scientific advice. | 4. ***For the purposes of this Article,*** the Emergency Task Force shall involve representatives of the Member State or States where an application for authorisation of a clinical trial is submitted or is intended to be submitted in the preparation of the scientific advice. |

Or. <Original>{CS}cs</Original>

</Amend>

<Amend>Amendment <NumAm>591</NumAm>

<RepeatBlock-By><Members>Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 15 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. When authorising a clinical trial application for which scientific advice has been given, Member States shall take that advice duly into account. | 5. When authorising a clinical trial application for which scientific advice has been given, Member States shall take that advice duly into account. ***The scientific advice provided by the Emergency Task Force and endorsed by the Committee for Medicinal Products for Human Use referred to in paragraph 2 shall have no binding force on the opinion of an independent Ethics Committee issued within authorisation of a clinical trial application.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>592</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Nils Torvalds, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Jan Huitema</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 15 – paragraph 5 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***5 a.*** ***Where a clinical trial reviewed as part of an accelerated scientific advice process is authorised, the developer of the clinical trial shall:*** |
|  | ***(a) publish the study protocol at the start of the trial through the European Union clinical trials register;*** |
|  | ***(b) publish the summary of the results of the trial through the European Union clinical trials register by a deadline set by the Agency shorter than that laid down in Article 37 of Regulation (EU) No 536/2014, taking into consideration the public interest and nature of the health emergency.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The WHO has recommended that the deadline for reporting study results be shorter than the general 12 months in situations of public health emergency. See : www.who.int/medicines/ebola-treatment/data-sharing\_phe/en/

</Amend>

<Amend>Amendment <NumAm>593</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 15 – paragraph 5 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***5 b.*** ***Where a clinical trial took part in an accelerated scientific advice process and the related medicinal product receives a marketing authorisation, the Agency shall:*** |
|  | ***(a) publish the European Public Assessment Reports in full within 7 days of authorisation by the Commission;*** |
|  | ***(b) publish the clinical data submitted to the Agency in support of the application within two months of authorisation by the Commission, and after personal data have been anonymised and commercially confidential information redacted;*** |
|  | ***(c) publish the Risk Management Plan in full, and any updated version.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>594</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 16 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. Following the recognition of a public health emergency, the Emergency Task Force shall undertake a review of the available scientific data on medicinal products, which may have the potential to be used to address the public health emergency. The review shall be regularly updated during the public health emergency. | 1. Following the recognition of a public health emergency, the Emergency Task Force shall undertake a review of the available scientific data on ***human or veterinary*** medicinal products, which may have the potential to be used to address the public health emergency. The review shall be regularly updated during the public health emergency. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>595</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 16 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. In preparation of the review, the Emergency Task Force may request information and data from marketing authorisation holders and from developers and engage with them in preliminary discussions. The Emergency Task Force may also, where available, make use of observational studies of health data generated outside of clinical studies taking into account their reliability. | 2. In preparation of the review, the Emergency Task Force may request information and data from marketing authorisation holders and from developers and engage with them in preliminary discussions. The Emergency Task Force may also, where available, make use of observational studies of health data generated outside of clinical studies taking into account their reliability. ***The Emergency Task Force shall liaise with medicine agencies of third countries for additional information and data exchange.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>596</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 16 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. In preparation of the review, the Emergency Task Force ***may*** request information and data from marketing authorisation holders and from developers and engage with them in preliminary discussions. The Emergency Task Force may also, where available, make use of observational studies of health data generated outside of clinical studies taking into account their reliability. | 2. In preparation of the review, the Emergency Task Force ***shall*** request information and data from marketing authorisation holders and from developers and engage with them in preliminary discussions. The Emergency Task Force may also, where available, make use of observational studies of health data generated outside of clinical studies taking into account their reliability. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>597</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 16 – paragraph 3 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. Based on a request from one or more Member States, or the Commission, the Emergency Task Force shall provide recommendations to the Committee for Medicinal Products for Human Use for an opinion in accordance with paragraph 4 on the following: | 3. Based on a request from one or more Member States, or the Commission, the Emergency Task Force shall provide recommendations to the Committee for Medicinal Products for Human ***and Veterinary*** Use for an opinion in accordance with paragraph 4 on the following: |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>598</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 16 – paragraph 3 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) the compassionate use of medicinal products falling under the scope of Directive 2001/83/EC or Regulation (EC) No 726/2004; | (a) the compassionate use of medicinal products falling under the scope of Directive 2001/83/EC or Regulation (EC) No 726/2004 ***and the whole production and distribution chain, as well as the adapted prescription by carers in accordance with Article 83(8) of Regulation (EC) No 726/2004***; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>599</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 16 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. Following receipt of the recommendation, the Committee for Medicinal Products for Human Use shall adopt an opinion on the conditions for use, the conditions for distribution and the patients targeted. The opinion shall be updated where necessary. | 4. Following receipt of the recommendation, the Committee for Medicinal Products for Human Use shall adopt an opinion on the conditions for use, the conditions for distribution and the patients targeted. The opinion shall be updated where necessary***, and made public on the Agency's web-portal***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>600</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 16 – paragraph 6</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 6. In the preparation of its recommendations provided pursuant to paragraphs 3, the Emergency Task Force may consult the concerned Member State and request it to provide any information and data, which informed the Member State’s decision to make the medicinal product available for compassionate use. Following such a request, the Member State shall provide all of the requested information. | 6. In the preparation of its recommendations provided pursuant to paragraphs 3, the Emergency Task Force may consult the concerned Member State and request it to provide any information and data, which informed the Member State’s decision to make the medicinal product available for compassionate use. Following such a request, the Member State shall provide all of the ***best available*** requested information. |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Evidently, recommendations cannot impose binding obligations on Member States. However, in the event that a Member State considers it inappropriate to follow a recommendation, it should be obliged to state the reasons for any non-compliance in order to better understand the Member States' respective situations.

</Amend>

<Amend>Amendment <NumAm>601</NumAm>

<RepeatBlock-By><Members>Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 16 – paragraph 7</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 7. The Agency shall publish the opinions adopted pursuant to paragraph 4 including any updates on its web-portal. | 7. The Agency shall publish ***the recommendations provided pursuant to paragraph 3 and*** the opinions adopted pursuant to paragraph 4 including any updates on its web-portal. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>602</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 16 – paragraph 7</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 7. The Agency shall publish the opinions adopted pursuant to paragraph 4 including any updates on its web-portal***.*** | 7. The Agency shall publish the***recommendations provided pursuant to paragraph3 and*** opinions adopted pursuant to paragraph 4 including any updates on its web-portal |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Wording of Article 16 is not clear as regards the procedure following a potential negative opinion of ETF. If ETF does not recommend a medicinal product for rolling review, it should inform all Member States thereof and subsequent opinion of CHMP should be published in line with para 7. Wording of paragraph 4 implies that paragraph 7 refers only to “positive” recommendations. For the sake of transparency, the public should be informed also of negative outcomes of assessment by ETF and CHMP.

</Amend>

<Amend>Amendment <NumAm>603</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 16 – paragraph 7 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***7 a.*** ***Marketing authorisation holders or developers may suggest medicinal products which may have the potential to be used to address the public health emergency. The Emergency Taskforce shall take these suggestions into account and, given that the suggestion is accompanied with sufficient scientific data that the medicinal products have the potential to halt the public health emergency, give an appropriate reaction to the suggestion. The reaction shall be public.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>604</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 17 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Emergency Task Force. | The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Emergency Task Force***, and ensure adequate consultation with the Patients’ and Consumers’ Working Party and the Healthcare Professionals’ Working Party***. ***The list of the members of the Emergency Task Force, the rules of procedure, agendas and minutes of the meetings and recommendations shall be published on the Agency’s web-portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>605</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 17 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Emergency Task Force. | The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Emergency Task Force***, and ensure adequate consultation with the Patients’ and Consumers’ Working Party and the Healthcare Professionals’ Working Party***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>606</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 17 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Emergency Task Force. | The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Emergency Task Force***, and ensure adequate consultation with the Patients’ and Consumers’ Working Party and the Healthcare Professionals’ Working Party***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>607</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 17 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Emergency Task Force. | The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Emergency Task Force***, as well as its decisions, proposals and recommendations to the national and European authorities***. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>608</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 17 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Emergency Task Force. | The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform ***without delay*** the public and relevant interest groups with regard to the work of the Emergency Task Force***, and respond to disinformation as appropriate***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>609</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| To prepare for and support the work of the Emergency Task Force during public health emergencies, the Agency shall: | To prepare for and support the work ***related to the reporting and notification obligations defined in this Regulation, as well as the tasks of the Agency bodies established, including*** of the Emergency Task Force during public health emergencies, the Agency shall: |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>610</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) develop and maintain electronic tools for the submission of information and data, including electronic health data generated outside the scope of clinical studies; | (a) develop and maintain ***pan-European interoperable and digitalized*** electronic tools for the submission of information and data, including electronic health data generated outside the scope of clinical studies***, as well as for the harmonised pan-European interoperable and digitalized shortages reporting and notification system, based on ISO IDMP standards for the identification of human medicines and based on a harmonized data collection model with interoperability with SPOR data, as well as on the EUDAMED IT platform for medical devices. Those platforms shall be accessible to relevant authorities at EU and national level to ensure the transparency needed to take actions to prevent and mitigate cross border shortages, as well as to avoid duplications of reporting at different levels***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>611</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) develop and maintain electronic tools for the submission of information and data, including electronic health data generated outside the scope of clinical studies; | (a) develop and maintain ***European-designed*** electronic tools for the submission of information and data, including electronic health data generated outside the scope of clinical studies***, in strict compliance with Union law on personal data and the GDPR***; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>612</NumAm>

<RepeatBlock-By><Members>Cristian-Silviu Buşoi, Radan Kanev</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) develop and maintain electronic tools for the submission of information and data, including electronic health data generated outside the scope of clinical studies; | (a) develop and maintain electronic tools***, including an interoperable and digitalized platform,*** for the submission of information and data, including electronic health data generated outside the scope of clinical studies; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>613</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) develop and maintain electronic tools for the submission of information and data, including electronic health data generated outside the scope of clinical studies; | (a) develop and maintain electronic tools for the submission of information and data, including electronic health data generated outside the scope of ***interventional*** clinical studies; |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

develop and maintain electronic tools for the submission of information and data, including electronic health data generated outside the scope of interventional clinical studies.

</Amend>

<Amend>Amendment <NumAm>614</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Nils Torvalds, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) coordinate independent ***vaccine*** effectiveness and safety monitoring studies using relevant data held by public authorities***.*** Such coordination shall be conducted jointly with the European Centre for Disease Prevention and Control and notably through a new vaccine monitoring platform; | (b) coordinate independent ***utilisation,*** effectiveness and safety monitoring studies ***of medicinal products intended to treat, prevent or diagnose a disease*** using relevant data held by public authorities***; for vaccines,*** such coordination shall be conducted jointly with the European Centre for Disease Prevention and Control and notably through a new vaccine monitoring platform; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>615</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) as part of its regulatory tasks, make use of digital infrastructures or tools, to facilitate the rapid access to or analysis of available electronic health data generated outside the scope of clinical studies, and the exchange of such data between Member States, the Agency, and other Union bodies; | (c) as part of its regulatory tasks, make use of digital infrastructures or tools, to facilitate the rapid access to or analysis of available electronic health data generated outside the scope of clinical studies, and the exchange of such data between Member States, the Agency, and other Union bodies***, in strict compliance with Union law on personal data and the GDPR***; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>616</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) as part of its regulatory tasks, make use of digital infrastructures or tools, to facilitate the rapid access to or analysis of available electronic health data generated outside the scope of clinical studies, and the exchange of such data between Member States, the Agency, and other Union bodies; | (c) as part of its regulatory tasks, make use of digital infrastructures or tools***, as referred to in point (a)***, to facilitate the rapid access to or analysis of available electronic health data generated outside the scope of clinical studies, and the exchange of such data between Member States, the Agency, and other Union bodies; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>617</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) as part of its regulatory tasks, make use of digital infrastructures or tools, to facilitate the rapid access to or analysis of available electronic health data generated outside the scope of clinical studies, and the exchange of such data between Member States, the Agency, and other Union bodies***;*** | (c) as part of its regulatory tasks, make use of digital infrastructures or tools, to facilitate the rapid access to or analysis of available electronic health data generated outside the scope of ***interventional*** clinical studies, and the exchange of such data between ***the***Member States, the Agency, and ***the***other Union bodies***.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

There is no definition of “data generated outside the scope of clinical trials” in the Proposal, for better clarity this concept should be defined. Namely, it should be specified whether it applies only to interventional clinical trials or also to observational (non-interventional) studies where no common rules for data sharing exist.

</Amend>

<Amend>Amendment <NumAm>618</NumAm>

<RepeatBlock-By><Members>Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) as part of its regulatory tasks, make use of digital infrastructures or tools, to facilitate the rapid access to or analysis of available electronic health data generated outside the scope of clinical studies, and the exchange of such data between Member States, the Agency, and other Union bodies; | (c) as part of its regulatory tasks, make use of digital infrastructures or tools, to facilitate the rapid access to or analysis of available electronic health data generated outside the scope of ***interventional*** clinical studies, and the exchange of such data between Member States, the Agency, and other Union bodies; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>619</NumAm>

<RepeatBlock-By><Members>Adam Jarubas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point d a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(da)*** ***develop IT tools interoperable with harmonized shortages reporting systems of National Competent Authorities (NCAs) by building on the existing digital regulatory infrastructure and ongoing projects on data management and implement AI technics to among others forecast crisis development, prepare responses and proactively initiate optimisation of resources management.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>620</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point d a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(da)*** ***take urgent and appropriate measures to ensure the protection of health data from attacks against information systems. These measures should be built on combination of regular penetration testing, decentralised solutions and security by design principles.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>621</NumAm>

<RepeatBlock-By><Members>Traian Băsescu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point d a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(da)*** ***develop, implement and coordinate an online European platform where consumers, pharmacists, medical professionals and all other European citizens can report shortages of medicinal products or medical devices in any of the Member States;*** |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>622</NumAm>

<RepeatBlock-By><Members>Danilo Oscar Lancini</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point d a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(da)*** ***develop IT tools interoperable with harmonized shortages reporting systems of National Competent Authorities (NCAs) by building on the existing digital regulatory infrastructure and ongoing projects on data management.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>623</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point d a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(da)*** ***develop IT tools interoperable with harmonized shortages reporting systems of National Competent Authorities (NCAs) by building on the existing digital regulatory infrastructure and ongoing projects on data management.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>624</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point d a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(da)*** ***ensure that it has the necessary resources to secure and protect the data flow within the Agency, and in particular to resist and/or counter cyberattacks and human leaks of documentation;*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>625</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 – point d a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(da)*** ***build the digital and interoperable database as referred to in Article1(b) and Article 12(g).*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>626</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 – paragraph 1 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***ensure enhanced protection of electronic tools and disseminated data against cyberattacks, deciding in conjunction with the Member States how the data in question can be accessed (users with access, data access period, data retention period);*** |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>627</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | Article 18 a |
|  | Public information about clinical trials and marketing authorisation decisions |
|  | ***1. For the duration of a public health emergency, the sponsors of clinical trials conducted in the EU shall:*** |
|  | ***(a) publish the study protocol at the start of the trial through the EU clinical trials register;*** |
|  | ***(b) publish the summary of the results through the EU clinical trials register within a timeline set by the Agency that is shorter than the timeline laid down in Article 37 of Regulation (EU) No 536/2014.*** |
|  | ***2. The Agency shall publish:*** |
|  | ***(a) the European Public Assessment Reports as soon as possible and ideally within seven days of marketing authorisation;*** |
|  | ***(b) the full body of the Risk Management Plan and any updated versions.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Public health emergency situations require higher standards for the reporting of clinical trials. As recommended by the WHO, the deadline for reporting study results in these situations should be much shorter than the general rule of 12 months. Likewise, building on the transparency measures implemented during the COVID-19 pandemic, the EMA should provide enhanced information on marketing authorisation decisions. As such, the Regulation should require that the Agency publishes European Public Assessment Reports much quicker and Risk Management Plans in full.

</Amend>

<Amend>Amendment <NumAm>628</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 18 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | Article 18 a |
|  | new Article 19 |
|  | ***1. For the duration of a public health emergency, the sponsors of clinical trials conducted in the EU shall:*** |
|  | ***(a) publish the study protocol at the start of the trial through the EU clinical trials register;*** |
|  | ***(b) publish the summary of the results through the EU clinical trials register within a timeline set by the Agency that is shorter than the timeline laid down in Article 37 of Regulation (EU) No 536/2014.*** |
|  | ***2. The Agency shall publish:*** |
|  | ***(a) the European Public Assessment Reports as soon as possible and ideally within seven days of marketing authorisation;*** |
|  | ***(b) the full body of the Risk Management Plan and any updated versions.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>629</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. The Executive Steering Group on Medical Devices (‘the Medical Devices Steering Group’) is hereby established as part of the Agency. It shall meet either in person or remotely, in preparation for or during a public health emergency. The Agency shall provide its secretariat. | 1. The Executive Steering Group on Medical Devices (‘the Medical Devices Steering Group’) is hereby established as part of the Agency. It shall meet ***as often as needed,*** either in person or remotely, in preparation for or during a public health emergency. The Agency shall provide its secretariat. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>630</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. The Medical Devices Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. | 2. The Medical Devices Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. ***The Steering Group shall also include a representative of the Patients’ and Consumers’ Working Party as well as a representative of the Healthcare Professionals’ Working Party as observers. The Agency shall assess the transparency of the undertakings of the Executive Steering Group on Medical Devices, taking into account principles of transparency and accountability.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>631</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. The Medical Devices Steering Group shall be composed of a representative of the Agency, a representative of the Commission ***and*** one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. | 2. The Medical Devices Steering Group shall be composed of a representative of the Agency, a representative of the Commission***,*** one senior representative per Member State***, a representative of the Patients' and Consumers' Working Party (PCWP) and a representative of the Healthcare Professionals' Working Party (HCPWP)***. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. ***The list of members of the Steering Group shall be made public on the Agency web-portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>632</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. The Medical Devices Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. | 2. The Medical Devices Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. ***The Steering Group shall also include a representative the Patients’ and Consumers’ Working Party and a representative of the Healthcare Professionals’ Working Party.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>633</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. The Medical Devices Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. | 2. The Medical Devices Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. ***The Steering Group shall also include a representative the Patients’ and Consumers’ Working Party and a representative of the Healthcare Professionals’ Working Party.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>634</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. The Medical Devices Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. | 2. The Medical Devices Steering Group shall be composed of a representative of the Agency, a representative of the Commission and one senior representative per Member State***, including one alternate in case of unforeseen circumstances***. Each Member State shall appoint their representative. Members may be accompanied by experts in specific scientific or technical fields. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>635</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 2 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***2 a.*** ***Members of the Medical Devices Steering Group must have no financial or other interests that could affect their impartiality. They shall act in the public interest and in an independent manner and make an annual declaration of their financial interests. All indirect interests which could relate to the industry shall be entered in a register held by the Agency and be accessible to the public, upon request.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>636</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medical Devices Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medical device interest groups to attend its meetings. | 3. The Medical Devices Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medical device interest groups***, any other entity in the relevant pharmaceutical supply chain, healthcare professionals and patients’ associations,*** to attend its meetings ***to ensure transparent and effective dialogue between all stakeholders in the supply chain and the relevant authorities***. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>637</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medical Devices Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medical device interest groups to attend its meetings. | 3. The Medical Devices Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medical device interest groups to attend its meetings ***ensuring the sharing of information by the Patients’ and Consumers’ Working Party as well as a representative of the Healthcare Professionals’ Working Party as observers***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>638</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medical Devices Steering Group shall be chaired by the Agency. The Chair ***may*** invite third parties, including representatives of medical device interest groups to attend its meetings. | 3. The Medical Devices Steering Group shall be chaired by the Agency. ***All members of the Medicines Steering Group may propose to*** the Chair ***to*** invite third parties, including representatives of medical device interest groups***, in particular healthcare professionals, consumers and patients,*** to attend its meetings ***when their contribution may inform the discussions of the Steering Group***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>639</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medical Devices Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medical device interest groups to attend its meetings. | 3. The Medical Devices Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medical device interest groups ***and representatives of patients, consumers and healthcare professionals*** to attend its meetings. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>640</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medical Devices Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medical device interest groups to attend its meetings. | 3. The Medical Devices Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medical device interest groups ***and representatives of patients, consumers and healthcare professionals*** to attend its meetings. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>641</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Medical Devices Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medical device interest groups to attend its meetings. | 3. The Medical Devices Steering Group shall be chaired by the Agency. The Chair may invite third parties, including representatives of medical device interest groups***, representatives of patients and healthcare professionals,*** to attend its meetings. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>642</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 3 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***3a.*** ***The Medical Devices Steering Group shall regularly invite representatives of medicinal product interest groups and marketing authorisation holders, as well as other stakeholders in the pharmaceutical industry, to discuss the situation of drug production in Europe and worldwide. On the basis of these exchanges, the Medical Devices Steering Group shall draw up strategic recommendations which it shall address to the Member States during the public health emergency period.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>643</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 4. The Medical Devices Steering Group shall establish its rules of procedure including procedures relating to the working party referred to in paragraph 5, and on the adoption of lists, sets of information and recommendations. The rules of procedures shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. | 4. The Medical Devices Steering Group shall establish its rules of procedure including procedures relating to the working party referred to in paragraph 5, and on the adoption of lists, sets of information and recommendations. The rules of procedures shall enter into force after receiving a favourable opinion from the Commission and the Management Board of the Agency. ***Agendas and minutes of the Steering Group as well as the rules of procedure and recommendations should be made available to the public via the Agency web-portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>644</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Medical Devices Steering Group shall be supported in its work by a working party comprised of single points of contact from national competent authorities for medical devices established in accordance with Article 23(1). | 5. The Medical Devices Steering Group shall be supported in its work by a working party comprised of single points of contact from national***, and where applicable regional,*** competent authorities for medical devices established in accordance with Article 23(1). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>645</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Medical Devices Steering Group ***shall*** be supported in its work by a working party comprised of single points of contact from national competent authorities for medical devices established in accordance with Article 23(1). | 5. The Medical Devices Steering Group ***may*** be supported in its work by a working party comprised of single points of contact from national competent authorities for medical devices established in accordance with Article 23(1). |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The national competent authorities for medical devices supervise the safety and effectiveness of medical devices; they do not supervise and monitor medical entities and therefore are unaware of their needs for medical devices. Moreover, manufacturers, importers and distributors, do not supervise the users of such devices, as this would be an obvious conflict of interest. It is therefore unclear where the competent authorities will obtain the data on the volume of demand included in the above-mentioned inventory, and why these authorities should provide such data to the EMA.

</Amend>

<Amend>Amendment <NumAm>646</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 5 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***5 a.*** ***The Medical Devices Steering Group will establish the basis for strengthened cooperation with national health authorities and the pharmaceutical industry.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>647</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***6 a.*** ***The members of the Medicines Steering Group must have no financial or other interests that could affect their impartiality. The list of members shall be published on the Agency website.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>648</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 19 – paragraph 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***6 a.*** ***The members of the Medicines Steering Group must have no financial or other interests that could affect their impartiality. The list of members shall be published on the Agency website.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>649</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 20 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. Immediately following the recognition of a public health emergency and after consultation of its working party, the Medical Devices Steering Group shall adopt a list of medical devices which it considers as critical during the public health emergency (‘the public health emergency critical devices list’). The list shall be updated whenever necessary until the termination of the recognition of the public health emergency. | 1. Immediately following the recognition of a public health emergency and after consultation of its working party, the Medical Devices Steering Group***, after consulting marketing authorisation holders and representatives of stakeholders in the sector,*** shall adopt a list of medical devices which it considers as critical during the public health emergency (‘the public health emergency critical devices list’). The list shall be updated whenever necessary until the termination of the recognition of the public health emergency***, and shall cease to apply at the end of the public health emergency***. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>650</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 20 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. Immediately following the recognition of a public health emergency and after consultation of its working party, the Medical Devices Steering Group shall adopt a list of medical devices which it considers as critical during the public health emergency (‘the public health emergency critical devices list’). The list shall be updated whenever necessary until the termination of the recognition of the public health emergency. | 1. Immediately following the recognition of a public health emergency and after consultation of its working party, the Medical Devices Steering Group***, in coordination with stakeholders in the sector,*** shall adopt a list of medical devices which it considers as critical during the public health emergency (‘the public health emergency critical devices list’). The list shall be updated whenever necessary until the termination of the recognition of the public health emergency. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>651</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 20 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. Immediately following the recognition of a public health emergency and after consultation of its working party, the Medical Devices Steering Group shall adopt a list of medical devices which it considers as critical during the public health emergency (‘the public health emergency critical devices list’). The list shall be updated whenever necessary until the termination of the recognition of the public health emergency. | 1. Immediately following the recognition of a public health emergency and after consultation of its working party, the Medical Devices Steering Group shall adopt a list of medical devices which it considers as critical during the public health emergency (‘the public health emergency critical devices list’) ***as well as minimum necessary stock levels***. The list shall be updated whenever necessary until the termination of the recognition of the public health emergency. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>652</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 20 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. The Medical Devices Steering Group shall adopt a set of information necessary to monitor ***the supply and demand*** of medical devices included on the public health emergency critical devices list ***and inform its working party thereof***. | 2. The Medical Devices Steering Group shall adopt a set of information necessary to ***only*** monitor ***data for the long-term safety assessment*** of medical devices included on the public health emergency critical devices list. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>653</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 20 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. The Agency shall publish the public health emergency critical devices list and any updates to that list on its web-portal. | 3. The Agency shall publish the public health emergency critical devices list and any updates to that list on its web-portal. ***This list shall be published in a clear and accessible way so that Member States, actors in the pharmaceutical supply chain and all stakeholders can easily access this information and, where appropriate, can easily report possible changes or publication problems.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>654</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 20 – paragraph 3 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***3a.*** ***The Agency, in cooperation with the Commission and the national competent authorities of the Member States, shall work with representatives of the European medical device industry to ensure that medical devices included on the critical devices list made available in one Member State are equally available in all Member States, in one form or another, and in particular in smaller Member States.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>655</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 20 – paragraph 3 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***3 a.*** ***The Agency shall report about the shortage of public health emergency critical devices through the database referred to in Article 6 (4a).*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>656</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 20 – paragraph 3 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***3 a.*** ***The Agency shall report about the shortage of public health emergency critical devices through the database referred to in Article 6(5).*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>657</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 20 – paragraph 3 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***3 a.*** ***The Agency shall report about the shortage of public health emergency critical devices through the database referred to in Article 6(5).*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>658</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 21 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. On the basis of the public health emergency critical devices list and the information and data provided in accordance with Articles 24 and 25, the Medical Devices Steering Group shall monitor supply and demand of medical devices included on that list with a view to identifying any potential or actual shortages of those medical devices. As part of that monitoring, the Medical Devices Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]22 and the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation. | 1. On the basis of the public health emergency critical devices list and the information and data provided in accordance with Articles 24 and 25 ***of this Regulation***, the Medical Devices Steering Group shall ***meet regularly throughout the major event or public health emergency with the working group of designated national contact points for medicines shortages within the national competent authorities for medicines and with representatives of the medicines production and distribution sectors in order to*** monitor supply and demand of medical devices included on that list with a view to identifying any potential or actual shortages of those medical devices ***and to adapt the list as best as possible throughout the major event or emergency***. As part of that monitoring, the Medical Devices Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]***[1]*** and the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 22 [insert reference to adopted text referred to in footnote 4] | ***[1] [insérer référence au texte adopté mentionné à la note de bas de page 4]*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>659</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 21 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. On the basis of the public health emergency critical devices list and the information and data provided in accordance with Articles 24 and 25, the Medical Devices Steering Group shall ***monitor supply and demand of*** medical devices included on ***that list*** with a view to identifying any potential or actual shortages of those medical devices. As part of that monitoring, the Medical Devices Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]22 and the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation. | 1. On the basis of the public health emergency critical devices list and the information and data provided in accordance with Articles 24 and 25, the Medical Devices Steering Group shall ***update the*** medical devices included on ***the list compiled by the Medical Device Coordination Group (MDCG)*** with a view to identifying any potential or actual shortages of those medical devices. As part of that monitoring, the Medical Devices Steering Group shall liaise, where relevant, with the Health Security Committee established in Article 4 of Regulation (EU) 2020/[…]22 and the Advisory Committee on public health emergencies established pursuant to Article 24 of that Regulation. |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 22 [insert reference to adopted text referred to in footnote 4] | 22 [insert reference to adopted text referred to in footnote 4] |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

It should be noted that as a result of the ongoing COVID-19 pandemic, a list of diagnostic medical devices to be observed as critical in a public health emergency has already been developed by the MDCG, established pursuant to Article 103 of Regulation (EU) 2017/745 and Article 98 of Regulation (EU) 2017/746.

</Amend>

<Amend>Amendment <NumAm>660</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 21 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| ***2.*** ***As part of the monitoring, the Medical Devices Steering Group may also make use of data from device registries and databanks where such data is available to the Agency. In so doing, the Medical Devices Steering Group shall take into account the data generated pursuant to Article 108 of Regulation (EU) 2017/745 and Article 101 of Regulation (EU) 2017/746.*** | ***deleted*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The registers and databases do not and will not contain any data useful for the assessment of supply and demand, as they only gather data used to assess the long-term safety and performance of medical devices. Up-to-date information on medical devices, their manufacturers, authorised representatives and importers will already be included in the EUDAMED database referred to in Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnostic medical devices. The obligation of inventories should be reported by manufacturers, authorised representatives and importers should be part of EUDAMED.

</Amend>

<Amend>Amendment <NumAm>661</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 22 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. For the duration of the public health emergency, the Medical Devices Steering Group shall regularly report the results of its monitoring to the Commission and the sub-network referred to in Article 23(1)(b), and, in particular, signal any potential or actual shortages of medical devices included on the public health emergency critical devices list. | 1. For the duration of the public health emergency, the Medical Devices Steering Group shall regularly report the results of its monitoring to the Commission***, national public health authorities*** and the sub-network referred to in Article 23(1)(b), and, in particular, signal any potential or actual shortages of medical devices included on the public health emergency critical devices list. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>662</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 22 – paragraph 2</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 2. Where requested by the Commission or the sub-network referred to in Article 23(2)(b), the Medical Devices Steering Group shall provide aggregated data and forecasts of demand to support its findings. In that regard, the Steering Group shall liaise with the European Centre for Disease Prevention and Control to obtain epidemiological data to help forecast medical device needs, and with the Medicines Steering Group referred to in Article 3 where medical devices included on the public health emergency critical devices list are used to jointly with a medicinal product. | 2. Where requested by the Commission***, one or more national public health authorities*** or the sub-network referred to in Article 23(2)(b), the Medical Devices Steering Group shall provide aggregated data and forecasts of demand to support its findings. In that regard, the Steering Group shall liaise with the European Centre for Disease Prevention and Control to obtain epidemiological data to help forecast medical device needs, and with the Medicines Steering Group referred to in Article 3 where medical devices included on the public health emergency critical devices list are used jointly with a medicinal product. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>663</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 22 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| ***3.*** ***As part of the reporting referred to in paragraphs 1 and 2, the Medical Devices Steering Group may also provide recommendations on measures, which may be taken by the Commission, Member States, medical device manufacturers, notified bodies and other entities to prevent or mitigate potential or actual shortages. In that regard the Group shall liaise, where relevant, with the Health Security Committee and the Advisory Committee on public health emergencies.*** | ***deleted*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

As registers and databases only gather data used to assess the long-term safety and performance of medical devices, this provision should be deleted. Up-to-date information on medical devices, their manufacturers, authorised representatives and importers will already be included in the EUDAMED database referred to in Regulation (EU) 2017/745 and Regulation (EU) 2017/746.

</Amend>

<Amend>Amendment <NumAm>664</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 22 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| ***4.*** ***The Medical Devices Steering Group may, on its own initiative or upon request from the Commission, provide recommendations on measures which may be taken by the Commission, Member States, medical device manufacturers, notified bodies and other entities to ensure preparedness to deal with potential or actual shortages of medical devices caused by public health emergencies.*** | ***deleted*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The national competent authorities for medical devices supervise the safety and effectiveness of medical devices; they do not supervise and monitor medical entities and therefore are unaware of their needs for medical devices. Moreover, manufacturers, importers and distributors, do not supervise the users of such devices, as this would be an obvious conflict of interest. It is therefore unclear where the competent authorities will obtain the data on the volume of demand included in the above-mentioned inventory, and why these authorities should provide such data to the EMA.

</Amend>

<Amend>Amendment <NumAm>665</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 22 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Medical Devices Steering Group may, upon request from the Commission coordinate measures, where relevant, between the national competent authorities, manufacturers of medical devices, notified bodies, and other entities to prevent or mitigate potential or actual shortages in the context of a public health emergency. | 5. The Medical Devices Steering Group may, upon request from the Commission coordinate measures, where relevant, between the national***, and where applicable regional,*** competent authorities, manufacturers of medical devices, notified bodies, and other entities to prevent or mitigate potential or actual shortages in the context of a public health emergency. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>666</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 22 – paragraph 5 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***5a.*** ***The measures recommended by the Steering Group to the Commission, Member States, marketing authorisation holders and other stakeholders should include a relaxing of rules to deal with potential shortages.*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>667</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 1 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. In order to prepare for fulfilling the tasks referred to in Articles 20, 21, and 22, the Agency shall: | 1. In order to prepare for fulfilling the tasks referred to in Articles 20, 21 and 22, ***and after consulting representatives of national authorities and marketing authorisation holders, as well as other stakeholders in the pharmaceutical sector,*** the Agency shall: |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>668</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) specify the procedures for establishing the public health emergency critical devices list; | (a) specify the procedures for establishing the public health emergency critical devices list***, ensuring adequate consultation with healthcare professionals, consumers, patients and a high level of transparency indecision-making***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>669</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) specify the procedures for establishing the public health emergency critical devices list; | (a) specify the procedures for establishing the public health emergency critical devices list***, ensuring adequate consultation with consumers, patients and healthcare professionals and a high level of transparency***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>670</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) specify the procedures for establishing the public health emergency critical devices list; | (a) specify the procedures for establishing the public health emergency critical devices list***, ensuring adequate consultation with consumers, patients and healthcare professionals and a high level of transparency***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>671</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) specify the procedures for establishing the public health emergency critical devices list; | (a) specify the procedures for establishing the public health emergency critical devices list***, ensuring adequate consultation with consumers, patients and healthcare professionals and a high level of transparency***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>672</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) specify the procedures for establishing the public health emergency critical devices list; | (a) specify the procedures ***and criteria*** for establishing the public health emergency critical devices list; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>673</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) develop streamlined electronic monitoring and reporting systems; | (b) develop streamlined electronic monitoring and reporting systems***, including for existing or potential stock levels***; |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>674</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 1 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) establish and maintain membership of the working party referred to in Article 19(5) comprised of single points of contact from Member States’ national competent authorities for medical devices; | (c) establish and maintain membership of the working party referred to in Article 19(5) comprised of single points of contact from Member States’ national***, and where applicable regional,*** competent authorities for medical devices; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>675</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 1 – point d</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| ***(d)*** ***establish and maintain a list of single points of contact from medical device manufacturers, authorised representatives and notified bodies;*** | ***deleted*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

It will be extremely difficult for the Agency to manually set-up and maintain a list of contact points for medical devices manufacturers, authorised representatives and NBs as proposed in article 23.1(d) since the EMA does not hold any information with regard to these stakeholders. However, since there exists a database of medical device manufacturers i.e. EUDAMED, it would be much more efficient to include such contact details in the EUDAMED database. It is therefore proposed to remove requirement (d) from Article 23.1 and to add a reference to EUDAMED in Article 23.2.

</Amend>

<Amend>Amendment <NumAm>676</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 2 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) establish and maintain for the duration of the public health emergency, a sub-network of single points of contact from medical device manufacturers and notified bodies based on the medical devices included on the public health emergency critical devices list; | (a) establish and maintain for the duration of the public health emergency, a sub-network of single points of contact from medical device manufacturers and notified bodies based on the medical devices included on the public health emergency critical devices list ***based on single points of contact to be included for all medical device manufacturers in the database referred to in Article 33 of Regulation (EU) 2017/745 and Article 30 of Regulation (EU) 2017/746***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>677</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 2 – point c</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (c) request information from the single points of contact from Member States’ national competent authorities based on the set of information agreed on by the Medical Devices Steering Group and set a deadline for its submission. | (c) request information from the single points of contact from Member States’ national***, and where applicable regional,*** competent authorities based on the set of information agreed on by the Medical Devices Steering Group and set a deadline for its submission. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>678</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 3 – point e</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| ***(e)*** ***sales and market share data;*** | ***deleted*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>679</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 3 – point e</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (e) sales and market share data; | (e) sales***, stock, where relevant,*** and market share data; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>680</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 3 – point f</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (f) mitigation plans including production and supply capacity; | (f) ***prevention and*** mitigation plans including production and supply capacity; ***such plans shall contain preventative measures that help ensure the continued supply of critical medical devices;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>681</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Nils Torvalds, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 3 – point f</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (f) mitigation plans including production and supply capacity; | (f) mitigation plans including production and supply capacity***, with a view to guarantee continued supply and prevent shortages of medicinal products included on the critical medicines lists***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>682</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 3 – point f</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (f) mitigation plans including production and supply capacity; | (f) mitigation plans including production and supply capacity; ***these plans shall contain preventative measures that help ensure the continued supply of critical medical devices;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>683</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 3 – point f</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (f) mitigation plans including production and supply capacity; | (f) mitigation plans including production and supply capacity; ***these plans shall contain preventative measures that help ensure the continued supply of critical medical devices;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>684</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 3 – point f</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (f) mitigation plans including production and supply capacity; | (f) mitigation plans***, containing preventative measures to ensure the continued supply of critical medical devices as well as*** including production and supply capacity; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>685</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 3 – point f</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (f) mitigation plans including production and supply capacity; | (f) mitigation plans including production and supply capacity***,*** ***so as to ensure the minimum stock levels required***; |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>686</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 23 – paragraph 3 – point f</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (f) mitigation plans including production and supply capacity; | (f) ***prevention and*** mitigation plans including production and supply capacity; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>687</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 24 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. In order to facilitate the monitoring referred to in Article 21 and following a request from the Agency, medical device manufacturers of the medical devices included on the public health emergency critical devices list and, where necessary, concerned notified bodies, shall submit the information requested by the deadline set by the Agency. They shall submit the information requested through the points of contact designated in accordance with Article 23(2) and using the reporting methods and system established pursuant to Article 23(1). They shall provide updates wherever necessary. | 1. In order to facilitate the monitoring referred to in Article 21 and following a request from the Agency, medical device manufacturers of the medical devices included on the public health emergency critical devices list***, and all distributors legally authorised to supply medical devices to the public*** and, where necessary, concerned notified bodies, shall submit the information requested by the deadline set by the Agency. They shall submit the information requested through the points of contact designated in accordance with Article 23(2) and using the reporting methods and system established pursuant to Article 23(1). They shall provide updates wherever necessary. |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>688</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 24 – paragraph 4</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| ***4.*** ***Where manufacturers of medical devices included on the public health emergency critical devices list and concerned notified bodies are in possession of any additional information, which provides evidence of a potential or actual shortage, they shall immediately provide such information to the Agency.*** | ***deleted*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The marketing departments of manufacturers, either directly or through importers and distributors, monitor the needs of healthcare facilities, in addition to cooperating with procurement departments, management and outlet staff. Furthermore, their development and production departments also take account of supply chain requirements and their technological capabilities. In this regard, manufacturers are already active and prepared in times of crisis in the supply of medical devices.

</Amend>

<Amend>Amendment <NumAm>689</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 24 – paragraph 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***6 a.*** ***The Commission and Member States shall lay down rules on sanctions for non-compliance with the obligations established under this Article. These sanctions shall be dissuasive.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>690</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 24 – paragraph 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***6 a.*** ***The Commission and Member States shall lay down rules on sanctions for non-compliance with the obligations established under this Article. These sanctions shall be dissuasive.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>691</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 24 – paragraph 6 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***6 a.*** ***The Commission shall exercise its power to lay down rules on sanctions for non-compliance with the obligations established under this Article in a delegated act.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>692</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 25 – paragraph 1 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. In order to facilitate the monitoring referred to in Article 21 and following a request from the Agency, Member States shall, by the deadline set by the Agency: | 1. In order to facilitate the monitoring referred to in Article 21 and following a request from the Agency, Member States ***or any national competent authority*** shall, by the deadline set by the Agency: |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>693</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 25 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) indicate the existence of any commercially confidential information, and, clarify the reasons for such an indication; | (b) indicate the existence of any commercially confidential information, and, clarify the reasons for such an indication***, in accordance with Article 30 of this Regulation***; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>694</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 25 – paragraph 1 – point c a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(ca)*** ***regional authorities with devolved health policy competences shall also comply with Article 25 and provide this information both to the national competent authority and to the Agency.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>695</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 25 – paragraph 4 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) consider the need to provide for temporary exemptions at Member State level pursuant to Article 59(1) of Regulation (EU) 2017/745 or Article 54(1) of Regulation (EU) 2017/746 with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list; | (a) consider the need to provide for temporary exemptions at Member State level pursuant to Article 59(1) of Regulation (EU) 2017/745 or Article 54(1) of Regulation (EU) 2017/746 with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list***, while at the same time ensuring a high level of patient and product safety***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>696</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 25 – paragraph 4 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) consider the need to provide for temporary exemptions at Member State level pursuant to Article 59(1) of Regulation (EU) 2017/745 or Article 54(1) of Regulation (EU) 2017/746 with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list; | (a) consider the need to provide for temporary exemptions at Member State level pursuant to Article 59(1) of Regulation (EU) 2017/745 or Article 54(1) of Regulation (EU) 2017/746 with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list***, while at the same time ensuring both patient and product safety***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>697</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 25 – paragraph 4 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) consider the need to provide for temporary exemptions at Member State level pursuant to Article 59(1) of Regulation (EU) 2017/745 or Article 54(1) of Regulation (EU) 2017/746 with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list; | (a) consider the need to provide for temporary exemptions at Member State level pursuant to Article 59(1) of Regulation (EU) 2017/745 or Article 54(1) of Regulation (EU) 2017/746 with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list***, while at the same time ensuring both patient and product safety***; |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Temporary exemption from the conformity assessment procedure should only be considered in exceptional circumstances. Before allowing for such a derogation the considerations should take into account both the safety of patients/citizens using the device and the safety of the product. Only if both can be ensured even without a conformity assessment procedure and the benefits for safeguarding supply outweigh the risks a temporary exemption could be offered.

</Amend>

<Amend>Amendment <NumAm>698</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 25 – paragraph 4 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) consider the need to provide for temporary exemptions at Member State level pursuant to Article 59(1) of Regulation (EU) 2017/745 or Article 54(1) of Regulation (EU) 2017/746 with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list; | (a) consider the need to provide for temporary exemptions at Member State level pursuant to Article 59(1) of Regulation (EU) 2017/745 or Article 54(1) of Regulation (EU) 2017/746 with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list ***while at the same time ensuring both patient and product safety***; |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Temporary exemption from the conformity assessment procedure should only be considered in exceptional circumstances. Before allowing for such a derogation the considerations should take into account both the safety of patients/citizens using the device and the safety of the product. Only if both can be ensured even without a conformity assessment procedure and the benefits for safeguarding supply outweigh the risks a temporary exemption could be offered.

</Amend>

<Amend>Amendment <NumAm>699</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos, Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 26 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) take all necessary action within the limits of the powers conferred on it, with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list, including, where necessary, granting temporary exemptions at Union level pursuant to Article 59(3) of Regulation (EU) 2017/745 or Article 54(3) of Regulation (EU) 2017/746; | (a) take all necessary action within the limits of the powers conferred on it, with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list, including, where necessary, granting temporary exemptions at Union level pursuant to Article 59(3) of Regulation (EU) 2017/745 or Article 54(3) of Regulation (EU) 2017/746***, while at the same time ensuring a high level of patient and product safety***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>700</NumAm>

<RepeatBlock-By><Members>Sara Cerdas</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 26 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) take all necessary action within the limits of the powers conferred on it, with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list, including, where necessary, granting temporary exemptions at Union level pursuant to Article 59(3) of Regulation (EU) 2017/745 or Article 54(3) of Regulation (EU) 2017/746; | (a) take all necessary action within the limits of the powers conferred on it, with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list, including, where necessary, granting temporary exemptions at Union level pursuant to Article 59(3) of Regulation (EU) 2017/745 or Article 54(3) of Regulation (EU) 2017/746***, while at the same time ensuring both patient and product safety***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>701</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 26 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) take all necessary action within the limits of the powers conferred on it, with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list, including, where necessary, granting temporary exemptions at Union level pursuant to Article 59(3) of Regulation (EU) 2017/745 or Article 54(3) of Regulation (EU) 2017/746; | (a) take all necessary action within the limits of the powers conferred on it, with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list, including, where necessary, granting temporary exemptions at Union level pursuant to Article 59(3) of Regulation (EU) 2017/745 or Article 54(3) of Regulation (EU) 2017/746***, while at the same time ensuring both patient and product safety***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>702</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 26 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) take all necessary action within the limits of the powers conferred on it, with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list, including, where necessary, granting temporary exemptions at Union level pursuant to Article 59(3) of Regulation (EU) 2017/745 or Article 54(3) of Regulation (EU) 2017/746; | (a) take all necessary action within the limits of the powers conferred on it, with a view to mitigating potential or actual shortages of medical devices included on the public health emergency critical devices list, including, where necessary, granting temporary exemptions at Union level pursuant to Article 59(3) of Regulation (EU) 2017/745 or Article 54(3) of Regulation (EU) 2017/746 ***while at the same time ensuring both patient and product safety***; |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

Extensions of the temporary exemption from the conformity assessment procedure should only be considered in exceptional circumstances. Before allowing for such a derogation the considerations should take into account both the safety of patients/citizens using the device and the safety of the product. Only if both can be ensured even without a conformity assessment procedure and the benefits for safeguarding supply outweigh the risks a temporary exemption could be offered.

</Amend>

<Amend>Amendment <NumAm>703</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 26 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) consider the need for guidelines addressed to Member States, medical device manufacturers, notified bodies and other entities; | (b) consider the need for guidelines addressed to Member States, medical device manufacturers, notified bodies and other entities ***where this is proportionate, justified and necessary***; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>704</NumAm>

<RepeatBlock-By><Members>Joanna Kopcińska, Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 26 – paragraph 1 – point d a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***(da)*** ***work in conjunction with the European Centre for Disease Prevention and Control (ECDC) to categorise and establish different priority levels for the medicinal products identified as critical.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>705</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 27 – paragraph -1 (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***-1*** ***The Agency shall establish an early warning system to inform relevant stakeholders, including healthcare professionals of any supply problems and potential or actual shortages of medicinal products included on the critical products list.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>706</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 27 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Medical Devices Steering Group. | ***The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Medical Devices Steering Group, and ensure adequate consultation with the Patients’ and Consumers’ Working Party and the Healthcare Professionals’ Working Party***. ***The list of the members of the Medical Devices Steering Group, the rules of procedure, agendas and minutes of the meetings and recommendations shall be published on the Agency’s web-portal.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>707</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 27 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Medical Devices Steering Group. | The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Medical Devices Steering Group ***and ensure adequate consultation with the Patients’ and Consumers’ Working Party and the Healthcare Professionals’ Working Party***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>708</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 27 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Medical Devices Steering Group. | The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Medical Devices Steering Group ***and ensure adequate consultation with the Patients’ and Consumers’ Working Party and the Healthcare Professionals’ Working Party***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>709</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 27 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Medical Devices Steering Group. | The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Medical Devices Steering Group ***and its proposals and recommendations***. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>710</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 27 – paragraph 1</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform the public and relevant interest groups with regard to the work of the Medical Devices Steering Group. | The Agency shall, via its web-portal and other appropriate means and, in conjunction with national competent authorities, inform ***without delay*** the public and relevant interest groups with regard to the work of the Medical Devices Steering Group***, and respond to disinformation***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>711</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 28 – paragraph 1 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, on behalf of the Commission***, from 1 March 2022 onwards***, provide the secretariat of the expert panels designated in accordance with Implementing Decision (EU) 2019/1396 and provide the support necessary to ensure that those panels can efficiently perform their tasks as set out in Article 106(9) and (10) of Regulation (EU) 2017/745. The Agency shall: | The Agency shall, on behalf of the Commission, provide the secretariat of the expert panels designated in accordance with Implementing Decision (EU) 2019/1396 and provide the support necessary to ensure that those panels can efficiently perform their tasks as set out in Article 106(9) and (10) of Regulation (EU) 2017/745. The Agency shall: |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>712</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 28 – paragraph 1 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| The Agency shall, on behalf of the Commission***, from 1 March 2022 onwards***, provide the secretariat of the expert panels designated in accordance with Implementing Decision (EU) 2019/1396 and provide the support necessary to ensure that those panels can efficiently perform their tasks as set out in Article 106(9) and (10) of Regulation (EU) 2017/745. The Agency shall: | The Agency shall, on behalf of the Commission, provide the secretariat of the expert panels designated in accordance with Implementing Decision (EU) 2019/1396 and provide the support necessary to ensure that those panels can efficiently perform their tasks as set out in Article 106(9) and (10) of Regulation (EU) 2017/745. The Agency shall: |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

To be consistent and avoid confusion with the date of application of Chapter IV.

</Amend>

<Amend>Amendment <NumAm>713</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 28 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) provide administrative and technical support to the expert panels for the provision of scientific opinions, views and advice; | (a) provide administrative***, scientific*** and technical support to the expert panels for the provision of scientific opinions, views and advice; |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

It is appropriate to reflect also EMA’s scientific support to the expert panels, by analogy to the Agency’s support that is provided to EMA’s main scientific committees, pursuant to article 56(f) of Regulation (EC) No 726/2004.

</Amend>

<Amend>Amendment <NumAm>714</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 29 – paragraph 1 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***1 a.*** ***The purpose of this Regulation is to increase cooperation between the European Medicines Agency, the European Commission, the Member States and stakeholders. Highlights that under no circumstances this Regulation should establish a sanctions regime.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>715</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 29 – paragraph 3</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 3. In agreement with the Chairs, ***joint meetings of*** the Medicines and Medical Devices Steering Groups ***may be held***. | 3. In agreement with the Chairs, the Medicines and Medical Devices Steering Groups ***shall be maintained and deployed beyond crisis situations for the management of medicines shortage, ensuring proportionality of their actions compared to emergency situations***. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>716</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión, Joanna Kopcińska</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 29 – paragraph 3 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***3 a.*** ***The Commission shall carry out an impact assessment prior to the entry into force of this Regulation.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>717</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 29 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | Article 29 a |
|  | Transparency and publication of clinical data |
|  | ***1. For the duration of a public health emergency, the sponsors of clinical trials related to products linked to the disease in question, shall:*** |
|  | ***(a) publish the study protocol at the start of the trial through the EU clinical trials register;*** |
|  | ***(b) publish the summary of the results through the EU clinical trials register within two months after marketing authorisation.*** |
|  | ***2. The Agency shall implement exceptional measures with regard to medicinal products, including vaccines, and medical devices falling under the scope of this Regulation, strengthening transparency measures and speeding up standard publication timelines and providing more information. These measures include:*** |
|  | ***(a) Publication of the product information with details of the conditions of use at the time of marketing authorisation;*** |
|  | ***(b) Expedited publication of the full European Public Assessment Reports (EPAR), within 7days after marketing authorisation. The EPARs should include a description of received scientific advice;*** |
|  | ***(c) Expedited publication, within a period of 2 months after marketing authorisation, of clinical data submitted to the Agency in support of the applications for medicines, after personal data have been anonymised and any commercially confidential information redacted. Access shall be provided to all independent individual participant level data along with protocols and analytic codes;*** |
|  | ***(d) Publication of the full risk management plan for authorised medicines;*** |
|  | ***(e) Publication of news announcements within 1 day of the start of initial rolling reviews or the evaluation of new evidence or applications for extension of indication.*** |
|  | ***3. The Agency shall make agendas and minutes of all meetings public, as well as the recommendations, opinions and decisions from the Steering Groups and the Emergency Task Force on its web-portal.*** |
|  | ***4. The membership of the Emergency Task Force, Steering Groups and Working Parties shall be made public. Members of the Emergency Task Force, Steering Groups and experts shall not have financial or other interests in the pharmaceutical or medical device industry which could affect their impartiality. They shall act in the public interest in an independent manner and shall make an annual declaration of their financial interests. All indirect interests which could relate to the industry shall be entered in a register held by the Agency, which is accessible to the public, upon request. Members of the Emergency Task Force, Steering Groups and Working Parties, and experts who participate in meetings or working groups of the Agency shall declare, at each meeting, any specific interests which could be considered to be prejudicial to their independence with respect to the items on the agenda. These declarations shall be made available to the public.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>718</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 29 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | Article 29 a |
|  | Protection against cyber-attacks |
|  | ***The Agency shall be equipped with a high level of security controls and processes against cyber-attacks to ensure the normal functioning of the Agency at all time, and especially during public health emergencies and major events at Union level. To that end, the Agency shall actively pursue and implement best cybersecurity practices within Union institutions and bodies to prevent, detect, mitigate, and respond to cyber-attacks.*** |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

EMA is already cooperation with the Computer Emergency Response Team for the Union Institutions, bodies, and agencies. We therefore propose to broaden the Rapporteur's proposal to a higher level of requirement.

</Amend>

<Amend>Amendment <NumAm>719</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – title</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| Confidentiality | Confidentiality ***and data privacy*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>720</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – paragraph 1 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. Unless otherwise provided for in this Regulation and without prejudice to Regulation (EC) No 1049/200124 and existing national provisions and practices in the Member States on confidentiality, all parties involved in the application of this Regulation shall respect the confidentiality of information and data obtained in carrying out their tasks in order to protect the following: | 1. Unless otherwise provided for in this Regulation and without prejudice to Regulation (EC) No 1049/200124 ***and on the legal protection of persons who report breaches of Union law,*** and existing national provisions and practices in the Member States on confidentiality, all parties involved in the application of this Regulation shall respect the confidentiality of information and data obtained in carrying out their tasks in order to protect the following: |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 24 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents, OJ L 145, 31.05.2001, p. 43 | 24 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents, OJ L 145, 31.05.2001, p. 43 |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The concept of confidentiality would need to be balanced from the start in the article’s ‘chapeau’.

The Whistleblower (WB) Directive cannot be added after the reference to Regulation on Access to Docs. The MS practices on confidentiality can include flexibilities/exceptions but legal protection of WB is a distinct set of rules

</Amend>

<Amend>Amendment <NumAm>721</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – paragraph 1 – introductory part</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 1. Unless otherwise provided for in this Regulation and without prejudice to Regulation (EC) No 1049/200124 and existing national provisions and practices in the Member States on confidentiality, all parties involved in the application of this Regulation shall respect the confidentiality of information and data obtained in carrying out their tasks in order to protect the following: | 1. Unless otherwise provided for in this Regulation and without prejudice to Regulation (EC) No 1049/200124 and ***all*** existing national provisions and practices in the Member States on confidentiality, all parties involved in the application of this Regulation shall respect the confidentiality of information and data obtained in carrying out their tasks in order to protect the following: |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 24 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents, OJ L 145, 31.05.2001, p. 43 | 24 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents, OJ L 145, 31.05.2001, p. 43 |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>722</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) personal data in accordance with Article ***32***; | (a) personal data in accordance with ***the definitions contained in*** Article ***4(1) of Regulation (EU) 2016/679 (GDPR) and Article3(1) of Regulation (EU) 2018/1725 (EUDPR)***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>723</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – paragraph 1 – point a</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (a) personal data ***in accordance with*** Article***32***; | (a) personal data ***as defined in*** Article***4(1) of the GDPR***; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>724</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) commercially confidential information and trade secrets of a natural or legal person***, including*** intellectual property rights; | (b) commercially confidential information and trade secrets of a natural or legal person ***in accordance with Directive 2016/943 and without prejudice to Directive 2019/1937, as well as*** intellectual property rights***, unless there is an overriding public interest in disclosure***; |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

IP rights and commercially confidential information are not the same and need to be distinguished in the text. IP rights should not be considered as commercially confidential information.

</Amend>

<Amend>Amendment <NumAm>725</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) commercially confidential information and trade secrets of a natural or legal person, including intellectual property rights; | (b) commercially confidential information and trade secrets of a natural or legal person, including intellectual property rights***, unless there is an overriding public interest in disclosure.***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>726</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – paragraph 1 – point b</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| (b) commercially confidential information and trade secrets of a natural or legal person, including intellectual property rights; | (b) commercially confidential information and trade secrets of a natural or legal person, including intellectual property rights***, unless there is an overriding public interest in disclosure***; |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The proposed Article on confidentiality should contain stronger language on transparency, to ensure that information on medicines and medical devices that is relevant to patients, consumers and healthcare professionals is made publicly available.

</Amend>

<Amend>Amendment <NumAm>727</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Commission, the Agency, and Member States may exchange commercially confidential information and, where necessary to protect public health, personal data, with regulatory authorities of third countries with which they have concluded bilateral or multilateral confidentiality arrangements. | 5. The Commission, the Agency, and***the*** Member States may exchange commercially confidential information and, where necessary to protect public health, ***anonymised and aggregated personal and sensitive*** personal data, with regulatory authorities of ***the*** third countries with which they have concluded bilateral or multilateral confidentiality arrangements. |

Or. <Original>{EN}en</Original>

<TitreJust>Justification</TitreJust>

The need for sharing personal data of the EU citizens with the third countries is not justified, proper reflection on the Formal Comments of the European Data Protection Supervisor on the Proposal as regards lack of provision on the applicability of the EU data protection rules, should be included. When exchanged with regulatory authorities of the third countries, any personal data and especially personal sensitive data should be anonymised and aggregated.

</Amend>

<Amend>Amendment <NumAm>728</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Commission, the Agency, and Member States may exchange commercially confidential information and, where necessary to protect public health, personal data, with regulatory authorities of third countries with which they have concluded bilateral or multilateral confidentiality arrangements. | 5. The Commission, the Agency, and Member States may***, in compliance with Chapter V of the EUDPR,*** exchange commercially confidential information and, where necessary to protect public health, personal data, with regulatory authorities of third countries with which they have concluded bilateral or multilateral confidentiality arrangements. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>729</NumAm>

<RepeatBlock-By><Members>Ondřej Knotek</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – paragraph 5</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 5. The Commission, the Agency, and Member States may exchange commercially confidential information and, where necessary to protect public health, personal data, with regulatory authorities of third countries with which they have concluded bilateral or multilateral confidentiality arrangements. | 5. The Commission, the Agency, and Member States may exchange commercially confidential information and, where necessary to protect public health, ***anonymised and aggregated sensitive*** personal data, with regulatory authorities of third countries with which they have concluded bilateral or multilateral confidentiality arrangements. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>730</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – paragraph 5 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***5 a.*** ***All parties involved in the application of this Regulation shall ensure that the concept of commercially confidential information is interpreted narrowly, and information of public interest is, to the extent possible, proactively disclosed.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>731</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – paragraph 5 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***5 a.*** ***All parties involved in the application of this Regulation shall ensure that the concept of commercially confidential information is interpreted narrowly, and information of public interest is, to the extent possible, proactively disclosed.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>732</NumAm>

<RepeatBlock-By><Members>Dan-Ştefan Motreanu</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – paragraph 5 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***5 a.*** ***All parties involved in the application of this Regulation shall ensure that the concept of commercially confidential information is interpreted narrowly, and information of public interest is, to the extent possible, proactively disclosed.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>733</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 30 – paragraph 5 b (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***5 b.*** ***This Regulation shall be without prejudice to the obligations of Member States relating to their processing of personal data under Regulation (EU) No 2016/679 and Directive 2002/58/EC on privacy and electronic communications, or the obligations of the Agency and the Commission relating to their processing of personal data under Regulation (EU) No 2018/1725, when fulfilling their responsibilities.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>734</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 31 – title</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 31 Entry into Force | 31 Entry into Force ***and date of application*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>735</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 31 – title</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
| 31 Entry into Force | 31 Entry into Force ***and application*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>736</NumAm>

<RepeatBlock-By><Members>Frédérique Ries, Véronique Trillet-Lenoir, Nicolae Ştefănuță, Susana Solís Pérez, Andreas Glück, Martin Hojsík, María Soraya Rodríguez Ramos</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 31 – paragraph 1 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***Chapters IV shall apply from… [date of entry into force + 12 months].*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>737</NumAm>

<RepeatBlock-By><Members>Tilly Metz</Members>

</RepeatBlock-By>

<DocAmend>Proposal for a regulation</DocAmend>

<Article>Article 31 – paragraph 2 a (new)</Article>

|  |
| --- |
|  |
| Text proposed by the Commission | Amendment |
|  | ***Chapters I, II and III shall apply from [date of entry into force].*** |
|  | ***Chapter IV shall apply from [date of entry into force + 3 months].*** |

Or. <Original>{EN}en</Original>

</Amend></RepeatBlock-Amend>